Numbers registry
Every source-listed Step 2 threshold, with context and topic ID; verify against the current guideline when using clinically.
| Threshold | Value and context | Topic |
|---|---|---|
| 1-h postprandial target | <140 mg/dL | OB-GDM-01 |
| 17-OHP diagnostic level | often > 10,000 ng/dL salt-wasting/simple-virilizing CAH, basal | ENDO-ADR-04 |
| 17-OHP screening cutoff (basal) | > 200 ng/dL warrants ACTH stimulation test | ENDO-ADR-04 |
| 17-OHP stimulated cutoff | > 1,000 ng/dL post-ACTH stimulation confirms nonclassic CAH | ENDO-ADR-04 |
| 1mg overnight DST abnormal cutoff | > 1.8 mcg/dL 8 AM cortisol; false positives with estrogen/pregnancy or CYP3A4 inducers | ENDO-ADR-02 |
| 2-h postprandial target | <120 mg/dL | OB-GDM-01 |
| 2024 ARDS non-intubated criterion | HFNC ≥30 L/min 2024 global ARDS definition | RESP-ARDS-01 |
| 2024 ARDS SpO2/FiO2 threshold | ≤315 2024 global ARDS definition | RESP-ARDS-01 |
| 5-ARI onset | 3–6 months prostate volume reduction | RENAL-LUTS-01 |
| 5-year survival (after Whipple) | ~20% | GI-PANC-02 |
| 5-year survival (overall) | ~10% | GI-PANC-02 |
| A-a gradient normal | age/4 + 4 mmHg room air | RESP-ABG-01 |
| AAA elective repair (men) | ≥5.5 cm or growth ≥0.5 cm/6 months or symptomatic | CV-AORTA-01 |
| AAA elective repair (women/CTD) | ≥5.0 cm higher rupture risk at smaller diameter | CV-AORTA-01 |
| AAA repair threshold (men) | ≥5.5 cm or growth >0.5 cm/6mo, >1 cm/y, or symptomatic | PREV-CVM-01 |
| AAA repair threshold (women) | ≥5.0 cm AAA repair | PREV-CVM-01 |
| AAA screening | one-time ultrasound men 65–75, ever smoked | BIO-SCREEN-01 |
| AAA screening age | 65–75 men who ever smoked; one-time ultrasound (Grade B) | PREV-CVM-01 |
| AAP 2021 low-risk ANC | ≤4,000/mm³ 8–60 day pathway | MULTI-FEVER-01 |
| AAP 2021 low-risk CRP | ≤2 mg/dL 8–60 day pathway | MULTI-FEVER-01 |
| abdominal compartment syndrome threshold | >20 mmHg IAP with new organ dysfunction | EM-CRIT-03 |
| ABI arterial ulcer | ≤0.90 absent/diminished pulses | SKIN-ULCER-01 |
| ABI compression contraindicated | <0.5 avoid compression therapy | SKIN-ULCER-01 |
| ABI critical limb ischemia (CLTI) | <0.4 rest pain, nonhealing ulcer, gangrene | CV-PAD-01 |
| ABI diagnostic (PAD) | ≤0.90 ankle-brachial index | CV-PAD-01 |
| ABI noncompressible | >1.40 calcified vessel; obtain toe-brachial index | CV-PAD-01 |
| ABI noncompressible | >1.40 diabetics/CKD — obtain toe-brachial index | SKIN-ULCER-01 |
| ABRS double-sickening onset | 5–7 days | NEURO-ENT-01 |
| ABRS persistent symptoms | ≥10 days | NEURO-ENT-01 |
| abscess adjunct-antibiotic trigger | SIRS/host factors, not size after I&D add MRSA antibiotics for cellulitis, SIRS, extensive/multiple lesions, immunocompromise, age extremes, hard-to-drain/facial site, or failed I&D | SKIN-INF-01 |
| acceleration criteria (<32 wk) | ≥10 bpm ×10 sec <32 wk | OB-FHR-01 |
| acceleration criteria (≥32 wk) | ≥15 bpm ×15 sec ≥32 wk | OB-FHR-01 |
| accessory spleen prevalence | ~10% cause of post-splenectomy ITP recurrence | HEME-PLT-01 |
| accreta-hysterectomy-timing | 34 0/7–35 6/7 wk planned cesarean hysterectomy, placenta left in situ | OB-HEM-01 |
| accreta-most-common-subtype | ~75% accreta vs increta/percreta | OB-HEM-01 |
| acei-arb-effect-window | 2nd/3rd trimester fetal renal/pulmonary effects | OB-MED-01 |
| acei-arb-first-trimester-risk | small malformation risk switch regardless of trimester | OB-MED-01 |
| acetaminophen proportion of US acute liver failure | ~50% most common cause | GI-LIV-02 |
| achalasia integrated relaxation pressure | >15 mm Hg high-resolution manometry diagnostic threshold | GI-ESO-02 |
| acidosis treatment threshold | <18 mEq/L start bicarbonate therapy in CKD | RENAL-CKD-01 |
| acquired factor VIII inhibitor mixing delay | 1–2 h incubation time-dependent inhibitor vs immediate lupus anticoagulant | HEME-COAG-01 |
| ACR/EULAR RA classification score | ≥6/10 2010 criteria | MSK-RHEUM-01 |
| acromegaly OGTT cutoff | GH > 1 ng/mL failure to suppress = positive | ENDO-PIT-01 |
| ACS bladder pressure threshold | >27 cmH2O with organ dysfunction, confirms ACS | PERIOP-COMPL-01 |
| ACS severe threshold | no fixed PaO2 cutoff worsening hypoxemia despite O2, multilobar/progressive infiltrates, or falling Hgb despite simple transfusion → exchange transfusion | HEME-SICK-02 |
| ACTH-dependent | > 20 pg/mL ACTH-dependent disease → pituitary MRI | ENDO-ADR-02 |
| ACTH-independent | < 10 pg/mL ACTH-independent adrenal source | ENDO-ADR-02 |
| actinic keratosis to SCC transformation | ~1%/yr untreated | SKIN-CA-02 |
| active TB duration | 6 months (9 if cavitary + culture+ at 2mo) RIPE ×2mo then RI ×4mo | MULTI-TB-01 |
| active-phase-arrest-adequate | ≥4 h no change, >200 MVU ≥6 cm | OB-LD-02 |
| active-phase-arrest-inadequate | ≥6 h no change despite oxytocin | OB-LD-02 |
| active-phase-protraction-multipara | <1 cm over 2 h dilation rate | OB-LD-02 |
| active-phase-protraction-nullipara | <1 cm over 2 h dilation rate | OB-LD-02 |
| acute angle-closure IOP | >40 mmHg typical presenting IOP | NEURO-OPH-01 |
| acute liver failure definition | INR ≥1.5 + encephalopathy + <26 weeks illness no pre-existing liver disease | GI-LIV-02 |
| acute rejection window | weeks to months highest risk in first 3–6 months post-transplant | IMM-TXP-01 |
| acute resp acidosis compensation | HCO3 +1 per 10 mmHg PaCO2 acute | RESP-ABG-01 |
| acute resp alkalosis compensation | HCO3 −2 per 10 mmHg PaCO2 acute | RESP-ABG-01 |
| acute severe UC steroid response window | 3 d | GI-IBD-01 |
| acyclovir dose | 10 mg/kg IV q8h | NEURO-INF-01 |
| acyclovir duration | 14–21 days | NEURO-INF-01 |
| ADAMTS13 diagnostic threshold | <10% TTP | HEME-MAHA-01 |
| added calories in pregnancy | 0 / ~340 / ~450 kcal/day trimester 1 / 2 / 3 | NUTR-PREG-01 |
| adenocarcinoma progression high-grade dysplasia | ~6%/yr | GI-ESO-01 |
| adenocarcinoma progression no dysplasia | ~0.2–0.3%/yr | GI-ESO-01 |
| adenoma washout cutoff | absolute ≥60% or relative ≥40% at 15 min indeterminate adrenal lesions | ENDO-ADR-04 |
| adenomyosis junctional zone | >12 mm MRI diagnostic threshold | REPRO-ENDOM-01 |
| adenosine dose in heart transplant recipients | 3 mg reduced initial dose, denervated heart | CV-ARR-02 |
| adequate antidepressant trial before switch | 4–6 wk full SSRI/SNRI response assessment | PSY-MOOD-01 |
| adequate screening definition | 3 consecutive negative Paps or 2 consecutive negative co-tests within 10 yr, most recent within 5 yr stopping criterion | PREV-CERV-01 |
| adequate-contraction-strength | >200 MVU intrauterine pressure catheter | OB-LD-02 |
| ADHD symptom threshold adults ≥17 | ≥5 of 9 reduced threshold | PSY-PEDS-01 |
| ADHD symptom threshold children | ≥6 of 9 (inattentive or hyperactive) DSM-5 criteria | PSY-PEDS-01 |
| admission SpO2 threshold | <90% bronchiolitis | RESP-BRO-01 |
| adolescent depression screening age | 12–18 years USPSTF Grade B | PREV-MH-01 |
| adolescent hospitalization HR | <50/min awake (<45/min asleep) medical instability threshold | PSY-EAT-01 |
| adolescent surgery eligibility | ≥13 years; BMI ≥35 + comorbidity or ≥40 AAP 2023 | NUTR-OBES-01 |
| ADPKD ESRD contribution | ~5% ADPKD | RENAL-CYST-01 |
| ADPKD target BP | ≤110/75 mmHg (age 18–49, eGFR >60); <130/80 mmHg general HTN target otherwise ACE inhibitor/ARB therapy, HALT-PKD | RENAL-CYST-01 |
| adrenal crisis hydrocortisone bolus | 100 mg IV bolus, then 200 mg/24 h immediate treatment | ENDO-ADR-01 |
| adrenal incidentaloma pheo-testing exemption | ≤ 10 HU on unenhanced CT homogeneous lesion; biochemical testing for pheo unnecessary | ENDO-ADR-03 |
| adrenal tumor DHEA-S threshold | >700 µg/dL prompts adrenal CT | REPRO-PCOS-01 |
| adult bicarbonate threshold | pH <7.0 adult DKA; consider for severe acidosis | ENDO-DM-04 |
| adult chelation threshold | ≥80 µg/dL (asymptomatic) or ≥50 µg/dL (symptomatic) occupational lead exposure | EM-TOX-07 |
| Adult DKA initial fluids | 500–1,000 mL/h for 2–4 h adult; no cardiac/renal compromise; shock requires individualized boluses | MULTI-FE-01 |
| adult DKA resolution | β-OHB <0.6 mmol/L AND (pH ≥7.3 OR HCO₃ ≥18) not glucose normalization | ENDO-DM-04 |
| adult each leg TBSA | 18% rule of 9s | EM-BURN-01 |
| adult head TBSA | 9% rule of 9s | EM-BURN-01 |
| adult HHS glucose | ≥600 mg/dL diagnosis | ENDO-DM-04 |
| adult HHS osmolality | >300 effective (>320 total) mOsm/kg diagnosis | ENDO-DM-04 |
| adult hospitalization HR | <40/min medical instability threshold | PSY-EAT-01 |
| adult ITP treatment threshold | <30,000/µL newly diagnosed adults, even if asymptomatic | HEME-PLT-01 |
| adult K hold-insulin threshold | ≤3.5 mEq/L replete before insulin | ENDO-DM-04 |
| adult SBP prerequisite | ≥100 mmHg and MAP ≥75 mmHg brain death evaluation | SOC-EOL-07 |
| adult UOP target | 0.5–1 mL/kg/h burn resuscitation | EM-BURN-01 |
| AFE mortality | 20–60% | OB-EMER-01 |
| AFP level strongly suggestive of HCC | >400 ng/mL in a cirrhotic patient with a liver mass | GI-LIV-02 |
| age-adjusted D-dimer | >50 y age above which the D-dimer cutoff is age-adjusted | RESP-DYSP-01 |
| age-of-consent | 16–18 years (state-dependent) statutory rape reporting | SOC-CONF-03 |
| AHI diagnostic threshold | ≥5/hr with symptoms, or ≥15/hr regardless polysomnography criteria for OSA | RESP-OSA-01 |
| AHI diagnostic threshold | ≥5/hr with symptoms, or ≥15/hr regardless obstructive sleep apnea diagnosis | PSY-SLEEP-01 |
| AHI severity mild | 5–14/hr OSA severity classification | RESP-OSA-01 |
| AHI severity moderate | 15–29/hr OSA severity classification | RESP-OSA-01 |
| AHI severity severe | ≥30/hr OSA severity classification | RESP-OSA-01 |
| AIN triad frequency | 10–30% fever + rash + eosinophilia | RENAL-AKI-02 |
| AKI definition | Cr rise ≥0.3 mg/dL in 48h or ≥50% in 7d, or UOP <0.5 mL/kg/h ×6h KDIGO | RENAL-AKI-01 |
| albumin AG correction | +2.5 mEq/L per 1 g/dL below 4.0 hypoalbuminemia | RESP-ABG-01 |
| albumin challenge dose | 1 g/kg/day (max 100 g/day) × 2 days rule out hypovolemia before diagnosing HRS | GI-CIRR-02 |
| albumin gradient transudate | >1.2 g/dL serum − pleural albumin, reclassifies diuretic-treated CHF effusions | RESP-PLEFF-01 |
| alcohol screening frequency | no USPSTF interval (annual common practice) AUDIT-C, all adults ≥18 | PREV-MH-01 |
| alcohol withdrawal autonomic symptom onset | 6–24h after last drink tremulousness, tachycardia, hypertension | PERIOP-COMPL-01 |
| alcohol withdrawal seizure onset | 12–48h after last drink heavy pre-admission drinking history | PERIOP-COMPL-01 |
| ALL best-prognosis WBC | <50,000/µL at presentation | HEME-MALIG-01 |
| ALL favorable WBC at diagnosis | <50,000/µL favorable prognostic feature | PEDS-HEME-01 |
| allergic contact dermatitis onset after re-exposure | 24–96 h type IV hypersensitivity | SKIN-INFLAM-01 |
| allopurinol starting dose | 100 mg/day (50 mg if CKD) gout ULT | MSK-RHEUM-03 |
| allopurinol titration interval | 2–5 wk to reach target serum urate | MSK-RHEUM-03 |
| alpha | 0.05 conventional Type I error threshold | BIO-STAT-01 |
| alpha-blockade duration before pheochromocytoma resection | 7–14 days phenoxybenzamine or doxazosin preoperative preparation | PERIOP-MED-01 |
| alpha-blocker onset | 1–2 weeks symptom relief | RENAL-LUTS-01 |
| alpha-gal reaction delay | 3–6 h after red meat ingestion | IMM-ANAPH-01 |
| alteplase dose | 0.9 mg/kg (max 90 mg) 10% bolus, remainder over 60 min | NEURO-STROKE-02 |
| Alvarado score thresholds | ≤ 4 low, 5–6 moderate, 7–10 high | GI-APP-01 |
| Alzheimer disease share | 60–80% of all dementia | NEURO-DEM-01 |
| amendment response | ≤60 days request to amend record | SOC-CONF-02 |
| AML blast diagnostic threshold | ≥20% bone marrow blasts | HEME-MALIG-01 |
| amniocentesis-miscarriage-risk | ~0.1–0.3% experienced centers | OB-PRE-02 |
| amniocentesis-window | 15–20 wk karyotype + AFP | OB-PRE-02 |
| amyloid voltage mismatch | <5 mm limb leads thick walls on echo with low ECG voltage | CV-CM-01 |
| anaphylaxis criterion-2 systems | ≥2 skin, respiratory, cardiovascular, GI after likely allergen | IMM-ANAPH-01 |
| anaphylaxis epinephrine dose | 0.01 mg/kg IM (max 0.5 mg adult, 0.3 mg child) repeat every 5–15 min | CV-SHOCK-01 |
| anastomotic leak peak timing | POD 5–7 (range POD 3–14) colorectal surgery | PERIOP-COMPL-01 |
| anatomy-scan-window | 18–22 wk structural survey | OB-PRE-02 |
| ANC abnormal | >4000/µL febrile infant 22–60 days, inflammatory marker stratification | PEDS-FEV-01 |
| androgen-secreting tumor testosterone threshold | >200 ng/dL prompts pelvic ultrasound; not PCOS | REPRO-PCOS-01 |
| aneurysm-anticoag-inr | 2–3 warfarin for mural thrombus | CV-ACS-03 |
| anion gap albumin correction | +2.5 mEq/L per 1 g/dL albumin below 4 hypoalbuminemia correction | RENAL-ABG-01 |
| anion gap normal | 8–12 mEq/L AG = Na − (Cl + HCO3) | RESP-ABG-01 |
| anorexia mortality | ~5–10% highest of any psychiatric disorder | PSY-EAT-01 |
| anorexia severity by BMI | mild ≥17; moderate 16–16.99; severe 15–15.99; extreme <15 DSM-5-TR severity specifier | PSY-EAT-01 |
| antenatal-testing-onset | 32 wk high-risk pregnancy, earlier if higher risk | OB-SURV-01 |
| anterior shoulder dislocation | ~95% proportion of shoulder dislocations | MSK-JOINT-02 |
| anti-AChR antibody positivity | ~85% generalized MG | NEURO-NM-01 |
| anti-D-indication-window | ≥12 wk pregnancy loss; <12 wk reasonable to forgo Rh testing and anti-D | OB-SAB-01 |
| anti-D-standard-dose | 300 mcg additional dosing guided by KB test/flow cytometry after large fetomaternal hemorrhage | OB-PRE-02 |
| anti-MuSK positivity | ~40% of AChR-antibody-negative generalized MG | NEURO-NM-01 |
| anti-PLA2R positivity | ~70% primary membranous nephropathy | RENAL-GN-01 |
| anti-tTG IgA recheck interval | 6–12 months confirm response to gluten-free diet | GI-CEL-01 |
| antibiotic discontinuation window | 24–36h low-risk infant with negative blood/urine/CSF cultures | MULTI-FEVER-01 |
| antibiotic door time | ≤1 h febrile neutropenia | HEME-ONC-01 |
| antibiotic timeout | 48–72 h reassess necessity and duration | RESP-PNA-02 |
| antibiotic timing | within 1 hour after blood cultures are drawn | CV-SHOCK-01 |
| antibiotic timing | within 1 hour Hour-1 bundle, from sepsis recognition | MULTI-SEP-01 |
| antibiotics | ≤1 h from presentation | MSK-FRAC-05 |
| anticoagulation threshold | albumin <2.0–2.5 g/dL membranous nephropathy | RENAL-GN-01 |
| antidepressant continuation after remission | 6–12 months first MDD episode, same agent/dose; ≥3 lifetime episodes → indefinite maintenance | PSY-MOOD-01 |
| antifungal trigger | 4–7 days persistent fever despite antibiotics | HEME-ONC-01 |
| anxiety screening age | ≤64 years USPSTF Grade B, 2023 (adults); Grade B, 2022 (ages 8–18) | PREV-MH-01 |
| AOM amoxicillin dose | 80–90 mg/kg/day divided BID | NEURO-ENT-01 |
| AOM course | 10 days (<2y or severe); 7 days (2–5y); 5–7 days (≥6y) | NEURO-ENT-01 |
| apixaban/rivaroxaban hold before surgery | 1 day (low bleed risk), 2 days (high bleed risk) general non-neuraxial surgery | PERIOP-MED-01 |
| apnea test abort | SBP <100 (or MAP <75) mmHg or SpO2 <85% brain death | SOC-EOL-07 |
| apnea test PaCO2 rise | ≥60 mmHg and ≥20 mmHg above baseline positive apnea test for brain death (pH <7.30) | EM-TRAUMA-05 |
| apnea test PaCO2 rise | ≥60 mmHg and ≥20 mmHg above baseline brain death confirmation | NEURO-ICP-01 |
| apnea test PaCO2 target | ≥60 mmHg and ≥20 mmHg above baseline brain death | SOC-EOL-07 |
| apnea test pH | <7.30 brain death | SOC-EOL-07 |
| apnea test pH threshold | <7.30 arterial pH at test completion | NEURO-ICP-01 |
| Appendiceal NET size thresholds | <1 cm appendectomy; 1–2 cm appendectomy unless high-risk features; ≥2 cm or base → hemicolectomy ENETS/NANETS | GI-OTH-01 |
| APS antibody interval | ≥12 wk apart 2 positive labs required | OB-MISC-01 |
| AR surgery threshold | EF ≤55% or LVESD ≥50 mm asymptomatic severe AR | CV-VALV-01 |
| ARDS mild P/F | 201–300 on PEEP ≥5 | RESP-ARDS-01 |
| ARDS moderate P/F | 101–200 on PEEP ≥5 | RESP-ARDS-01 |
| ARDS plateau pressure target | ≤30 cmH2O reduce TV if exceeded | RESP-ARDS-01 |
| ARDS severe P/F | ≤100 on PEEP ≥5 | RESP-ARDS-01 |
| ARDS tidal volume | 6 mL/kg IBW lung-protective ventilation | RESP-ARDS-01 |
| ARR positive screen | ratio >30 with aldosterone >15 ng/dL primary hyperaldosteronism screen | CV-HTN-02 |
| ARR screen positive | > 20 with suppressed renin; assay-dependent | ENDO-ADR-04 |
| arrival-to-ECG | within 10 min suspected ACS; obtain and review ECG | CV-ACS-01 |
| ART timing, CD4 <50 | within 2 weeks HIV-TB coinfection, not TB meningitis | RESP-TB-01 |
| ART timing, CD4 ≥50 | within 8 weeks HIV-TB coinfection | RESP-TB-01 |
| AS HLA-B27 positivity | >90% diagnosis | MSK-RHEUM-02 |
| AS valve area (supportive) | ≤1.0 cm² supportive; small AVA alone does not establish severe AS | PERIOP-RISK-01 |
| AS valve area (supportive) | ≤1.0 cm² supports severity; small AVA alone is insufficient | CV-VALV-01 |
| asbestos latency | 20–40 yr time from exposure to asbestosis/mesothelioma | RESP-OCC-01 |
| ascites sodium | <2 g/day (88 mmol) fluid restriction only if Na <125 mmol/L | NUTR-MNT-01 |
| ASPECTS threshold (0–6 h) | ≥6 thrombectomy without perfusion imaging | NEURO-STROKE-02 |
| aspiration pneumonitis antibiotic threshold | >48 h fever or purulent sputum switch to treating infection | RESP-PNA-01 |
| aspirin hold for primary prevention only | 7–10 days no proven perioperative benefit | PERIOP-MED-01 |
| aspirin primary prevention | do not initiate ≥60 (Grade D); 40–59 with ≥10% 10-yr risk individual decision (Grade C) shared decision-making | PREV-PRIN-02 |
| aspirin start window | 12–28 wk preeclampsia prophylaxis, ideally before 16 wk | CV-PREG-01 |
| aspirin-prophylaxis-dose | 81 mg daily starting after 12 wk, ideally before 16, may begin up to 28 wk | OB-HTN-01 |
| asymptomatic CEA threshold | 70–99% stenosis perioperative stroke/death risk <3% and life expectancy >5 years | CV-MISC-01 |
| atony-share-of-pph | 70–80% most common cause | OB-PPH-01 |
| atropine-dose | 1 mg IV q3–5 min, max 3 mg symptomatic bradycardia | CV-ARR-03 |
| atypical hyperplasia relative risk | ~4–5x future breast cancer risk | REPRO-BRMASS-01 |
| audiometric notch | 4000 Hz noise-induced hearing loss, characteristic not diagnostic | PREV-OCC-01 |
| auto-injector dose child | 0.15 mg ~13–25 kg | IMM-ANAPH-02 |
| auto-injector dose infant | 0.1 mg ~7.5–13 kg | IMM-ANAPH-02 |
| auto-injector dose standard | 0.3 mg ≥25 kg (label cutoff 30 kg) | IMM-ANAPH-02 |
| autonomic dysreflexia definition | SBP rise ≥20–40 mmHg above baseline diagnostic (baseline SBP often 90–110 mmHg in SCI ≥T6); SBP ≥150 mmHg after trigger removal = give antihypertensive | NEURO-SPINE-01 |
| autonomic dysreflexia SCI level | at or above T6 required for the syndrome | NEURO-SPINE-01 |
| AV fistula creation timing | 6–8 months before anticipated dialysis start CKD G5 planning | RENAL-DIAL-01 |
| AV fistula maturation | 6–8 weeks vascular access | RENAL-DIAL-01 |
| Average-risk colonoscopy interval | q10yr | GI-COLON-01 |
| average-risk mammography screening interval | biennial, ages 40–74 USPSTF 2024 | REPRO-BRMASS-01 |
| Average-risk screening start | age 45 | GI-COLON-01 |
| aVR R wave | >3 mm TCA cardiotoxicity | EM-TOX-09 |
| B symptom weight loss threshold | >10% in 6 months Hodgkin/NHL staging | HEME-MALIG-02 |
| B12 after bariatric surgery | 350–1,000 mcg PO daily or 1,000 mcg IM monthly lifelong | NUTR-OBES-01 |
| B6 upper limit | 100 mg/day adult | NUTR-VIT-01 |
| baby blues onset | day 2–5 resolves by 2 wk | OB-PP-01 |
| back pain as presenting symptom | >90% spinal epidural abscess | MSK-SPINE-01 |
| backup after combined method start | 7 days unless started ≤5 days after menses onset pill/patch/ring | REPRO-CONTRA-01 |
| backup after copper IUD start | none copper IUD | REPRO-CONTRA-01 |
| backup after implant/DMPA/LNG-IUD start | 7 days unless ≤5 d (implant) or ≤7 d (DMPA/LNG-IUD) after menses implant/DMPA/LNG-IUD | REPRO-CONTRA-01 |
| backup after progestin-only pill start | 2 days POP | REPRO-CONTRA-01 |
| bacterial CSF glucose ratio | <0.4 CSF:serum glucose — most specific for bacterial meningitis | MULTI-MEN-01 |
| bacterial meningitis CSF glucose | <40 mg/dL (ratio ≤0.4) | NEURO-INF-01 |
| bacterial meningitis CSF protein | >150 mg/dL | NEURO-INF-01 |
| bacterial meningitis CSF WBC | >1,000/µL neutrophilic pleocytosis | NEURO-INF-01 |
| bare-metal stent minimum DAPT before elective surgery | ≥1 month (ideally 3 months) elective non-cardiac surgery | PERIOP-MED-01 |
| bariatric surgery threshold | ≥35 (any comorbidity status), or 30–34.9 with metabolic disease/failed nonsurgical therapy 2022 ASMBS/IFSO; ≥27.5 in Asian patients | MULTI-NUTR-02 |
| bariatric surgery threshold | BMI ≥35; ≥30 with metabolic disease ASMBS/IFSO 2022; ≥27.5 Asian | NUTR-OBES-01 |
| Barrett LGD (if not ablated; EET preferred) | EGD at 6 and 12 mo, then annually | GI-ESO-01 |
| Barrett no-dysplasia surveillance | q3-5 yr | GI-ESO-01 |
| basal 24-h urinary copper threshold | >100 mcg/day classic, supportive; >40 mcg/day may suggest WD in children/presymptomatic patients | NEURO-MISC-01 |
| basal insulin perioperative dose | 75–80% of long-acting analog (~50% of NPH) morning of/night before surgery | ENDO-PERI-01 |
| basilar occlusion NIHSS threshold | ≥10 thrombectomy indication within 24 h | NEURO-STROKE-02 |
| Behçet diagnostic criteria | oral ulcers + ≥2 of 4 genital ulcers, eye involvement, skin lesions, pathergy | SKIN-OTHER-01 |
| Belmont principles | 3 respect for persons, beneficence, justice | SOC-RES-01 |
| Belmont Report | 1979 research ethics principles | SOC-ETH-01 |
| benign adenoma HU cutoff | ≤ 10 HU unenhanced CT | ENDO-ADR-04 |
| berry aneurysm prevalence | 8–12% ADPKD | RENAL-CYST-01 |
| best possible medication history | ≥2 sources admission reconciliation | SOC-QI-07 |
| beta | 0.10–0.20 conventional Type II error threshold | BIO-STAT-01 |
| betamethasone protocol | 12 mg IM ×2, 24h apart 24 0/7–33 6/7 wk (may start 22 0/7); late-preterm course 34 0/7–36 6/7 wk if none previously given and no pregestational diabetes | OB-PTL-01 |
| biopsy window | ≤2 weeks after starting steroids | MSK-OTHER-01 |
| BiPAP IPAP titration ceiling | 20–25 cmH2O ventilatory support | RESP-ARF-01 |
| BiPAP starting EPAP | 4–5 cmH2O initial setting | RESP-ARF-01 |
| BiPAP starting IPAP | 10–12 cmH2O initial setting | RESP-ARF-01 |
| BiPAP trigger | pH <7.35 COPD exacerbation with hypercapnia | RESP-COPD-01 |
| biphasic reaction incidence | ~5% (range 1–20%) usually within 12 h | IMM-ANAPH-02 |
| bipolar association in postpartum psychosis | ~50% strongest underlying diagnosis | PSY-PP-01 |
| bishop-score-favorable | >8 proceed to oxytocin | OB-LD-01 |
| bishop-score-unfavorable | ≤6 ripen cervix first | OB-LD-01 |
| bisphosphonate drug holiday | after 5 y oral / 3 y IV reassess in lower-risk patients | PREV-BONE-01 |
| bisphosphonate drug holiday | after 5 y oral / 3 y IV no longer high-risk; continue to 10 y oral / 6 y IV if high-risk | MSK-BONE-01 |
| bisphosphonate onset | 2–4 days zoledronic acid/pamidronate for hypercalcemia of malignancy | HEME-ONC-01 |
| bite prophylaxis antibiotic duration | 3–5 d amoxicillin-clavulanate for high-risk bite wound | SKIN-PROC-01 |
| bladder fill for cord elevation | 500–700 mL saline | OB-EMER-01 |
| BLL oral chelation threshold | 45–69 µg/dL succimer (DMSA), pediatric | EM-TOX-07 |
| BLL parenteral chelation threshold | ≥70 µg/dL or encephalopathy IM BAL then CaNa2EDTA, pediatric | EM-TOX-07 |
| BLL public health action level | ≥3.5 µg/dL CDC 2021 reference value, pediatric | EM-TOX-07 |
| BNP exclusion cutoff | <100 pg/mL excludes acute HF | RESP-DYSP-01 |
| bone/joint TB therapy | 6–9 months extrapulmonary TB | RESP-TB-01 |
| Bonferroni correction | alpha / number of comparisons multiple-comparison adjustment | BIO-STAT-01 |
| borderline B12 | 200–300 pg/mL obtain MMA | NUTR-VIT-01 |
| Borderline resectable arterial contact | head/uncinate: SMA ≤180° or CHA sparing celiac/hepatic bifurcation; body/tail: celiac ≤180° | GI-PANC-02 |
| botulinum toxin LES effect duration | 6–12 months temporary; for patients unfit for dilation or myotomy | GI-ESO-02 |
| BP target CKD | <130/80 mmHg AHA/ACC 2025, all CKD | RENAL-CKD-01 |
| BP target CKD (intensive) | SBP <120 mmHg KDIGO 2021, when tolerated | RENAL-CKD-01 |
| bp-treatment-goal | 140–150/90–100 mmHg acute severe HTN in pregnancy | OB-HTN-01 |
| bpp-abnormal-0-2 | 0–2 deliver at any viable gestational age | OB-SURV-01 |
| bpp-abnormal-4 | 4 deliver if ≥32 wk; <32 wk extend/repeat same day | OB-SURV-01 |
| bpp-equivocal | 6 repeat in 24h or deliver if term | OB-SURV-01 |
| bpp-reassuring | 8–10 continue routine surveillance | OB-SURV-01 |
| Braden at-risk threshold | ≤18 initiate pressure-redistribution measures | SKIN-ULCER-01 |
| BRCA carrier MRI plus mammography age | 30–75 yr annual screening | REPRO-HERED-01 |
| BRCA carrier MRI-only screening age | 25–29 yr annual breast MRI (mammography only if MRI unavailable) | REPRO-HERED-01 |
| BRCA/high-risk mammography start age | 30 annual MRI plus mammography from this age | PREV-BRCA-01 |
| BRCA/high-risk MRI start age | 25 annual MRI alone, ages 25–29 | PREV-BRCA-01 |
| BRCA1 lifetime breast cancer risk | 60–70% BRCA1 carrier | REPRO-HERED-01 |
| BRCA1 lifetime ovarian cancer risk | 40–60% BRCA1 carrier | REPRO-HERED-01 |
| BRCA1 RRBSO age | 35–40 yr after childbearing complete | REPRO-HERED-01 |
| BRCA2 lifetime breast cancer risk | 45–55% BRCA2 carrier | REPRO-HERED-01 |
| BRCA2 lifetime ovarian cancer risk | 15–25% BRCA2 carrier | REPRO-HERED-01 |
| BRCA2 male prostate screening start | 40 yr PSA-based (BRCA1: consider from 40 yr) | REPRO-HERED-01 |
| BRCA2 RRBSO age | 40–45 yr after childbearing complete | REPRO-HERED-01 |
| breach notification to patients | ≤60 days without unreasonable delay, no later than 60 calendar days after discovery of unsecured PHI breach (45 CFR 164.404) | SOC-CONF-02 |
| breakthrough dose | 10–15% of 24-h opioid dose cancer pain | SOC-EOL-05 |
| breastfeeding iron supplementation start | 4 months AAP, 1 mg/kg/day for exclusively breastfed infants | HEME-ANEM-01 |
| breech-at-term-prevalence | 3–4% singleton pregnancies | OB-LD-03 |
| breech-cesarean-timing | 39 wk after failed/declined ECV | OB-LD-03 |
| bridging hyperventilation target | PaCO2 30–35 mmHg brief use for acute herniation only, not prophylactic | EM-TRAUMA-01 |
| bridging hyperventilation target | PaCO2 30–35 mmHg brief use for acute herniation only | EM-TRAUMA-05 |
| bronchodilator reversibility | ≥12% and ≥200 mL FEV1 improvement | RESP-PFT-01 |
| bullous pemphigoid onset age | >70 yr typical | SKIN-BLIST-01 |
| BUN/Cr prerenal | >20:1 prerenal AKI | RENAL-AKI-01 |
| BUN/Cr ratio marker | >20 | GI-BLEED-02 |
| bupivacaine max dose | 2.5 mg/kg (3 mg/kg with epinephrine) local anesthetic maximum dosing | EM-TOX-11 |
| button battery removal window | ≤2 h | GI-PEDS-01 |
| BV vaginal pH | >4.5 Amsel criteria | REPRO-VAGIN-01 |
| C-spine high-risk age | ≥65 y mandates CT without rotation testing | MSK-FRAC-01 |
| CA 19–9 level raising concern for CCA in PSC | >100 U/mL with a dominant stricture; falsely elevated in active cholangitis | GI-BIL-02 |
| CA 19–9 nonsecretors | 5–10% Lewis-antigen-negative population | HEME-MISC-01 |
| caffeine limit in pregnancy | ≤200 mg/day ACOG | NUTR-PREG-01 |
| CAG repeat | ≥40 Huntington disease full penetrance | NEURO-MOVE-01 |
| Cairo-Bishop phosphorus | ≥4.5 mg/dL adults (≥6.5 mg/dL children) laboratory TLS | HEME-ONC-01 |
| Cairo-Bishop uric acid | ≥8 mg/dL laboratory TLS | HEME-ONC-01 |
| calcitonin tachyphylaxis | 48 hours onset of resistance | ENDO-CA-01 |
| calcium citrate after RYGB | 1,200–1,500 mg/day divided doses; ASMBS 2016 | NUTR-OBES-01 |
| calcium gluconate infusion rate | 0.5–1.5 mg/kg/h elemental calcium severe/refractory hypocalcemia, continuous infusion | ENDO-THY-04 |
| calcium gluconate onset | 1–3 min membrane stabilization; lasts 30–60 min, repeat dose if ECG changes persist after 5 min | RENAL-ELEC-01 |
| calcium intake | 1000–1200 mg/day osteoporosis, deficiency, or on therapy, preferably dietary; not for primary fracture prevention (USPSTF 2025 Grade D, any dose) | PREV-BONE-01 |
| calcium monitoring | q6–12h × 48h hypocalcemia monitoring | ENDO-THY-04 |
| calcium replacement, massive transfusion | 1 g IV calcium chloride (or 3 g calcium gluconate) early, then ~every 4 units; ionized Ca >1.1 mmol/L | HEME-TRANS-02 |
| calcium-gluconate-onset | 1–3 min membrane stabilization | CV-ECG-01 |
| caloric deficit | 500–750 kcal/day ~0.5–1 kg/week loss | NUTR-OBES-01 |
| candidemia treatment duration | ≥14 days after first negative blood culture and symptom resolution uncomplicated candidemia, no metastatic foci | MULTI-FUNGAL-01 |
| candidiasis vaginal pH | <4.5 (normal) KOH prep | REPRO-VAGIN-01 |
| CAP ICU regimen | beta-lactam + macrolide OR beta-lactam + respiratory fluoroquinolone FQ monotherapy insufficient | MULTI-ABX-02 |
| CAP treatment duration | ≥5 days (afebrile ≥48 h) minimum | RESP-PNA-02 |
| capacity elements | 4 understanding, appreciation, reasoning, communication | SOC-CAP-01 |
| Caprini high risk | ≥5 points combined pharmacologic + mechanical prophylaxis | PERIOP-VTE-01 |
| Caprini low risk | 1–2 points mechanical prophylaxis alone | PERIOP-VTE-01 |
| Caprini very low risk | 0 points early ambulation only | PERIOP-VTE-01 |
| carbapenem cross-reactivity | <1% penicillin allergy | IMM-DALLERGY-01 |
| carboprost dose | 0.25 mg IM q15–90min, max 8 doses second-line uterotonic for atony; contraindicated in asthma | OB-EMER-01 |
| cardiogenic shock CI | <2.2 L/min/m² with PCWP >18 mm Hg | CV-HF-02 |
| carotid endarterectomy threshold | ≥70% stenosis symptomatic carotid stenosis | NEURO-STROKE-03 |
| catheter removal after LMWH | ≥12h after last prophylactic dose, ≥24h after last therapeutic dose ASRA guideline | PERIOP-COAG-01 |
| catheter-associated UEDVT anticoagulation | ≥3 months continue as long as the catheter remains in place | EM-CRIT-03 |
| cauda equina decompression window | within 24–48h cauda equina syndrome | MSK-SPINE-01 |
| cauda equina surgical window | 24–48 h decompression to prevent permanent deficit | NEURO-SPINE-01 |
| CDI severe threshold | WBC ≥15,000/µL or Cr >1.5 mg/dL | GI-FUNC-01 |
| CDI severity cutoff | WBC ≥15,000 or Cr >1.5 defines severe vs non-severe CDI | MULTI-GI-01 |
| CEA perioperative risk threshold | <6% symptomatic 50–69% carotid stenosis | NEURO-STROKE-03 |
| cecal diameter closed-loop LBO risk | >10–12 cm competent ileocecal valve, mechanical LBO | GI-OBST-01 |
| cecal diameter perforation risk | >12 cm acute colonic pseudo-obstruction (Ogilvie) | GI-OBST-01 |
| cefazolin prophylaxis timing | ≤60 min before incision surgical site infection | SOC-QI-08 |
| ceftriaxone duration | 1 g/day, maximum 7 days stop earlier once bleeding controlled and vasoactives stopped | GI-BLEED-02 |
| celiac follow-up serology | tTG-IgA at 6 and 12 months, then yearly ACG 2023 | NUTR-MNT-02 |
| central DI desmopressin response | > 50% rise in urine osmolality complete central DI | ENDO-PIT-01 |
| cerclage removal | 36–37 wk | OB-PTL-01 |
| cerclage timing | 12–14 wk | OB-PTL-01 |
| cerebellar hemorrhage surgery threshold | >3 cm | NEURO-HEM-01 |
| cervical co-test interval | q5y ages 30–65 | BIO-SCREEN-01 |
| cervical cytology interval | q3y ages 21–29 | BIO-SCREEN-01 |
| cervical insufficiency US cutoff | <25 mm before 24 wk with prior spontaneous preterm birth <34 wk | OB-PTL-01 |
| cervical screening stop age | 65 with adequate prior negative screening | PREV-PRIN-02 |
| CF pancreatic insufficiency prevalence | 85% of CF patients | RESP-CF-01 |
| cfDNA screening | ≥10 wk aneuploidy screening | OB-PRE-01 |
| cfdna-earliest | ≥10 wk NIPT | OB-PRE-02 |
| CFRD diagnostic OGTT | ≥200 mg/dL (2-hr) oral glucose tolerance test | RESP-CF-01 |
| CFRD screening start age | 10 years annual 2-hour OGTT | RESP-CF-01 |
| chadsvasc-threshold-men | ≥2 anticoagulate | CV-ARR-01 |
| chadsvasc-threshold-women | ≥3 anticoagulate | CV-ARR-01 |
| chancroid treatment | azithromycin 1 g PO ×1 or ceftriaxone 250 mg IM ×1 CDC 2021 | REPRO-VAGIN-01 |
| charcoal window | ≤4 h acetaminophen overdose, protected airway | EM-TOX-03 |
| Charcot triad prevalence | ~50% of acute cholangitis cases | GI-BIL-02 |
| chemoprevention eligibility cutoff | ≥1.67% 5-year Gail-model risk; trial/FDA eligibility, not an automatic trigger | PREV-BRCA-01 |
| chemoprevention treatment threshold | ≥3% 5-year risk, benefit exceeds harm (Gail model) | PREV-BRCA-01 |
| chest compression ratio | 3:1 unique to neonatal resuscitation | PEDS-NB-02 |
| chest tube landmark | 4th–5th ICS, between anterior and midaxillary lines triangle of safety | RESP-PLEFF-01 |
| chest tube removal | no air leak ×24h, drainage <200 mL/day lung fully expanded on CXR | RESP-PTX-01 |
| chest tube removal threshold | <100–200 mL/24 h no air leak | EM-CRIT-03 |
| chest tube site | 4th–5th ICS, anterior axillary line pneumothorax/hemothorax | EM-TRAUMA-04 |
| chest tube site | 4th–5th ICS, just anterior to midaxillary line after decompression | RESP-PTX-01 |
| chest tube size | 28–32 Fr traumatic hemothorax | EM-TRAUMA-04 |
| Child-Pugh A/B/C perioperative mortality | ~10% / ~30% / ~76% | GI-CIRR-01 |
| childhood absence peak age | 4–8 y onset | NEURO-SZ-01 |
| chlamydia in pregnancy regimen | azithromycin 1g PO ×1 doxycycline contraindicated in pregnancy | MULTI-GU-01 |
| chlamydia preferred regimen | doxycycline 100mg BID ×7d non-pregnant adults (2021 CDC update) | MULTI-GU-01 |
| chlamydia treatment | doxycycline 100 mg BID ×7 d 2021 CDC update | REPRO-VAGIN-01 |
| chlamydia/gonorrhea screening age | <25 yr annually sexually active women | REPRO-VAGIN-01 |
| chlamydial conjunctivitis onset | day 5–14 neonatal | REPRO-VAGIN-01 |
| chlorhexidine skin antisepsis concentration | >0.5% in alcohol central line insertion | SOC-QI-08 |
| cholangiocarcinoma lifetime risk in PSC | 10–15% most feared PSC complication | GI-BIL-02 |
| cholecystectomy timing | ideally ≤72 h; up to 7–10 d | GI-BIL-01 |
| chronic (>48 h/unknown) hypernatremia correction limit | ≤ 10–12 mEq/L/24 h prevents cerebral edema; acute (<48 h) may correct ~1 mEq/L/h | ENDO-PIT-01 |
| chronic hydrocortisone dose | 15–25 mg/day divided doses | ENDO-ADR-01 |
| chronic hyponatremia correction limit | ≤8–10 mEq/L/24h avoid osmotic demyelination syndrome | RENAL-ELEC-02 |
| chronic resp acidosis compensation | HCO3 +3.5 per 10 mmHg PaCO2 chronic | RESP-ABG-01 |
| chronic resp alkalosis compensation | HCO3 −5 per 10 mmHg PaCO2 chronic | RESP-ABG-01 |
| chronic steroid suppression risk | ≥5 mg prednisone/day ×≥3 wk (or Cushingoid at any dose) risk of HPA suppression | ENDO-ADR-01 |
| chronic steroid suppression risk | ≥5 mg prednisone/day ×≥3 wk (or Cushingoid at any dose) presume HPA suppression, dose stress steroids for surgery | ENDO-PERI-01 |
| chronic transfusion HbS target | <30% stroke prevention | HEME-SICK-01 |
| chronic-hypertension-treatment-threshold | ≥140/90 mmHg treat with labetalol or nifedipine (CHAP trial) | OB-HTN-01 |
| CIN2+ extended screening duration | 25 years continue screening past age 65, or after hysterectomy, following CIN2+/cancer diagnosis | PREV-CERV-01 |
| cirrhosis protein | 1.2–1.5 g/kg/day AASLD 2021; energy 35 kcal/kg/day | NUTR-MNT-01 |
| cirrhosis protein intake target | 1.2–1.5 g/kg/day do not restrict protein in hepatic encephalopathy | GI-CIRR-02 |
| citalopram max dose | 40 mg/day (20 mg if >60y or hepatic impairment) QTc prolongation limit | PSY-MOOD-02 |
| civil burden of proof | >50% (preponderance of evidence) malpractice | SOC-LAW-02 |
| CIWA-Ar treatment threshold | ≥8–10 symptom-triggered benzodiazepine dosing | EM-TOX-12 |
| CIWA-Ar treatment threshold | ≥8–10 initiate benzodiazepine dosing | PSY-SUD-01 |
| CK diagnostic threshold | >5x ULN rhabdomyolysis | RENAL-RHAB-01 |
| CK peak | 24–72 h after onset then declines with half-life ~36 h | RENAL-RHAB-01 |
| CKD ESA target hemoglobin | 10–11.5 g/dL anemia of CKD | HEME-ANEM-01 |
| CKD protein, non-dialysis | 0.55–0.6 g/kg/day with dietitian supervision KDOQI 2020; KDIGO 2024 suggests 0.8, avoid >1.3 | NUTR-MNT-01 |
| class II blood loss | 750–1500 mL (15–30%) HR 100–120/min, normal SBP | CV-SHOCK-01 |
| class III blood loss | 1500–2000 mL (30–40%) HR 120–140/min, first fall in SBP | CV-SHOCK-01 |
| class IV blood loss | >2000 mL (>40%) massive transfusion 1:1:1 | CV-SHOCK-01 |
| clean wound Td/Tdap threshold | ≥10 yr ≥3 prior doses | SKIN-PROC-01 |
| clinically meaningful weight loss | ≥5–10% improves BP, glucose, lipids | NUTR-OBES-01 |
| clinically significant portal hypertension threshold | ≥25 kPa liver stiffness start NSBB, no screening EGD needed | GI-CIRR-02 |
| CLL diagnostic lymphocyte count | ≥5,000/µL monoclonal B lymphocytes | HEME-MALIG-01 |
| close-in-age exemption gap | ≤3–4 years Romeo and Juliet laws | SOC-CONF-03 |
| clozapine ANC monitoring | weekly ×6mo → every 2 weeks ×6mo → monthly per FDA label (REMS eliminated 2025) | PSY-PSYC-01 |
| clozapine severe neutropenia risk | ~1% baseline and monitoring rationale | PSY-PSYC-01 |
| cluster headache duration | 15–180 min untreated attack | NEURO-HA-01 |
| CML blast crisis threshold | ≥20% blasts; defines transformation to acute leukemia | HEME-MALIG-01 |
| CMV urine PCR window | within 3 weeks of birth confirms congenital vs postnatal acquisition | MULTI-CONG-01 |
| CNI toxicity rank | #1 side effect tacrolimus/cyclosporine nephrotoxicity | IMM-ISUP-01 |
| CNS lymphoma CD4 threshold | <100 cells/µL (typically <50) AIDS-associated primary CNS lymphoma risk | HEME-MALIG-02 |
| co-test interval | q5yr age 30–65; one of three acceptable options (primary HPV preferred, HRSA 2026) | PREV-CERV-01 |
| co-testing interval | q5y ages 30–65, one of three acceptable options | REPRO-CERV-01 |
| coarctation BP gradient | >20 mm Hg upper vs lower extremity | CV-CONG-01 |
| COHb half-life 100% O2 | 60–90 min NRB mask | EM-TOX-02 |
| COHb half-life HBO | 20–30 min hyperbaric O2 | EM-TOX-02 |
| COHb half-life room air | 4–6 h no supplemental O2 | EM-TOX-02 |
| colchicine acute dosing | 1.2 mg then 0.6 mg 1h later acute gout flare | MSK-RHEUM-03 |
| colchicine prophylaxis duration | 3–6 months starting ULT | MSK-RHEUM-03 |
| colonoscopy interval | q10 years average risk | PREV-CRC-01 |
| colonoscopy screening age | 45–75 (individualize 76–85, stop >85) CRC screening | PREV-PRIN-02 |
| colorectal colonoscopy interval | q10y average risk, ages 45–75; individualize 76–85 | BIO-SCREEN-01 |
| combined contraceptive postpartum restriction | first 21 days (category 4) category 3 at 21–42 days with VTE risk factors, and 21 to <30 days if breastfeeding | OB-PP-01 |
| combined hormonal BP contraindication | ≥160/100 mmHg US MEC category 4 | REPRO-CONTRA-01 |
| combined method postpartum deferral | ≥21 d not breastfeeding (≥42 d with VTE risk factors); breastfeeding: Cat 4 <21 d, Cat 3 to 30 d (42 d with VTE risk factors) postpartum initiation | REPRO-CONTRA-01 |
| combined pre/post-capillary PH | PAWP >15 mm Hg + PVR >2 WU Group 2 subtype | CV-PH-01 |
| compensated cirrhosis EGD-avoidance criteria | stiffness <20 kPa + platelets >150,000 Baveno VII elastography stratification | GI-CIRR-02 |
| complete miscarriage β-hCG fall | ≥21–35% over 48 h | OB-ECT-01 |
| complicated effusion glucose | <60 mg/dL mandates chest tube drainage | RESP-PLEFF-01 |
| complicated effusion LDH | >1000 U/L supports but does not alone mandate chest tube drainage | RESP-PLEFF-01 |
| complicated effusion pH | <7.2 mandates chest tube drainage | RESP-PLEFF-01 |
| complicated/endocarditis bacteremia | 4–6 weeks IV S. aureus IE | MULTI-ABX-01 |
| conception after bariatric surgery | wait 12–18 months ASMBS/ACOG | NUTR-PREG-01 |
| congenital hypothyroidism starting dose | 10–15 mcg/kg/day start immediately, do not await confirmatory labs | ENDO-THY-03 |
| congenital hypothyroidism treatment dose | 10–15 mcg/kg/day levothyroxine start ASAP, by 2 wk of life | PEDS-NB-03 |
| congenital varicella syndrome risk | ~0.4% (<13 wk); ~2% (13–20 wk) maternal varicella; rare after 20 wk | MULTI-CONG-01 |
| contact dermatitis peak | 48–72 h type IV delayed hypersensitivity | IMM-HYP-01 |
| continuation phase extension | 7 months (9 total) cavitary CXR + culture still positive at 2 months | RESP-TB-01 |
| continuous in-house duty | 24 h + ≤4 h transition ACGME | SOC-PROF-04 |
| contrast AKI prevention | IV NS 1 mL/kg/h ×12h before and after high-risk contrast | RENAL-AKI-02 |
| contrast AKI risk stratification | <30 high risk; 30–44 individualize; ≥45 negligible eGFR mL/min/1.73m², prophylaxis decision | RENAL-AKI-02 |
| contrast-associated AKI definition | ≥0.3 mg/dL in 48h or ≥1.5× baseline in 7 days contrast, KDIGO criteria | RENAL-AKI-02 |
| control limits | ±3 sigma from mean (estimated process SD) control chart | SOC-QI-04 |
| conventional-power-target | 80% minimum acceptable power (beta = 20%) | BIO-STAT-02 |
| cooling target | <39°C within 30 min then stop active cooling to avoid overshoot | MULTI-ENV-01 |
| copper IUD duration | 10–12 yr Paragard | REPRO-CONTRA-01 |
| copper IUD EC window | ≤120 h most effective emergency contraception | REPRO-CONTRA-02 |
| copper IUD emergency contraception window | ≤5 days post-coital placement | REPRO-CONTRA-01 |
| cord compression dexamethasone dose | 10 mg IV bolus then 4–6 mg every 6 h before imaging; 96-mg regimens add toxicity without benefit | HEME-ONC-01 |
| core temperature prerequisite | ≥36 °C brain death evaluation | SOC-EOL-07 |
| coronary aneurysm threshold | Z-score ≥2.5 echocardiographic criterion for age | PEDS-FEV-01 |
| cosyntropin stimulation threshold | <18 mcg/dL (older assay); <14–15 mcg/dL (newer assay) abnormal (AI confirmed) | ENDO-ADR-01 |
| cow milk after 12 months | ≤16–24 oz/day prevent iron deficiency | NUTR-INF-01 |
| COWS threshold for buprenorphine induction | ≥8–12 moderate withdrawal | PSY-SUD-02 |
| cow’s milk limit | <24 oz/day pediatric iron deficiency prevention | HEME-ANEM-01 |
| CPP target | 60–70 mmHg severe TBI | EM-TRAUMA-05 |
| CPP target | 60–70 mmHg | NEURO-ICP-01 |
| CPPD colchicine prophylaxis | 0.6 mg once or twice daily recurrent CPPD attacks | MSK-RHEUM-03 |
| CRAFFT positive screen | ≥2 of 6 adolescent substance use, prompts further assessment | PREV-MH-01 |
| CRAO thrombolysis window | ≤4.5 h from onset IV alteplase/tenecteplase at a stroke center (off-label, evolving evidence) | NEURO-OPH-01 |
| CRC lymph node minimum for staging | ≥ 12 nodes | GI-COLON-01 |
| CRC screening start age | 45 average risk, USPSTF 2021 (Grade B 45–49; Grade A 50–75) | PREV-CRC-01 |
| CRC screening stop age | 75 Grade A; 76–85 individualized | PREV-CRC-01 |
| creatinine rise threshold | >30% suspect bilateral renal artery stenosis after ACEi/ARB start | CV-HTN-01 |
| critically ill surgical glucose target | 140–180 mg/dL NICE-SUGAR trial | PERIOP-OTHER-01 |
| croup age | 6 months–3 years peak 1–2 years | RESP-PEDAIR-01 |
| croup dexamethasone dose | 0.6 mg/kg PO/IM (max 16 mg) once; 0.15 mg/kg acceptable given for all severities of croup | RESP-PEDAIR-01 |
| croup dexamethasone dose | 0.6 mg/kg PO/IM (max 16 mg), single dose given for all severities of croup | PEDS-INF-01 |
| CRP abnormal | >2 mg/dL febrile infant 22–60 days, inflammatory marker stratification | PEDS-FEV-01 |
| CRT QRS threshold | ≥150 ms especially LBBB morphology | CV-HF-01 |
| cryoprecipitate fibrinogen trigger | <100–150 mg/dL DIC with bleeding | HEME-COAG-01 |
| cryoprecipitate fibrinogen trigger | <100–150 mg/dL active DIC with bleeding | HEME-MAHA-01 |
| cryoprecipitate fibrinogen trigger | <100–150 mg/dL massive transfusion/DIC | HEME-TRANS-02 |
| cryoprecipitate-threshold | fibrinogen <200 mg/dL give cryoprecipitate | OB-PPH-01 |
| cryptococcal antigen screening threshold | CD4 <100 at HIV diagnosis | MULTI-HIV-01 |
| cryptococcal fluconazole maintenance stop | CD4 ≥100 + suppressed viral load ≥3 months after induction/consolidation, with ART deferred 4–6 weeks | MULTI-FUNGAL-01 |
| cryptococcal induction | amphotericin B + flucytosine ×2 weeks then fluconazole consolidation ×8 weeks | MULTI-FUNGAL-01 |
| cryptorchidism prevalence | 3% term, 30% preterm undescended testis | RENAL-PEDS-01 |
| cryptorchidism-associated patent processus vaginalis | ~90% closed during orchiopexy | GI-HERN-01 |
| crystalloid bolus | 30 mL/kg hypotension or lactate ≥4 mmol/L | MULTI-SEP-01 |
| CSF EBV PCR sensitivity | ~80–90% CNS lymphoma in AIDS, specificity >95% | HEME-MALIG-02 |
| CSF hypocretin-1 diagnostic cutoff | <110 pg/mL narcolepsy type 1 | PSY-SLEEP-01 |
| CSF protein GBS | >45 mg/dL albuminocytologic dissociation | NEURO-NM-02 |
| CSF WBC GBS | <10 cells/mm³ albuminocytologic dissociation | NEURO-NM-02 |
| CT angiography detection threshold | ≥ 0.3–0.5 mL/min | GI-BLEED-01 |
| CT sensitivity/specificity (adult) | > 95% | GI-APP-01 |
| CURB-65 admission threshold | 2 score | RESP-PNA-02 |
| CURB-65 inpatient | ≥3 inpatient; ICU per ATS severe-CAP criteria | RESP-PNA-02 |
| CURB-65 outpatient | 0–1 score | RESP-PNA-02 |
| cvs-miscarriage-risk | ~0.2% experienced centers | OB-PRE-02 |
| cvs-window | 10–13 wk chorionic villus sampling | OB-PRE-02 |
| cyanide-suspicion lactate | >8–10 mmol/L smoke inhalation with hypotension/coma despite 100% O2 | EM-BURN-01 |
| cyproheptadine dosing | 12 mg load, then 2 mg q2h serotonin syndrome | MULTI-HYPER-01 |
| cyst infection treatment duration | 4–6 weeks fluoroquinolone | RENAL-CYST-01 |
| cytology-only interval | q3y ages 21–29 | REPRO-CERV-01 |
| D-dimer cutoff age <50 | <500 ng/mL PE exclusion | CV-VTE-01 |
| D-dimer cutoff age ≥50 | <age×10 ng/mL age-adjusted PE exclusion | CV-VTE-01 |
| D-dimer threshold (age <50) | <500 ng/mL age <50 | RESP-PE-01 |
| D-dimer threshold (age ≥50) | <age × 10 ng/mL age ≥50 (age × 10 µg/L FEU) | RESP-PE-01 |
| DAA cure rate | >95% chronic hepatitis C | PREV-ID-01 |
| dabigatran hold before neuraxial block | ≥3 days (CrCl ≥80 mL/min) to ≥5 days (CrCl 30–49 mL/min); avoid if CrCl <30 mL/min ASRA guideline | PERIOP-COAG-01 |
| dabigatran hold before surgery | 1–2 days (normal CrCl), 2–4 days (CrCl 30–50 mL/min, by bleed risk) general non-neuraxial surgery | PERIOP-MED-01 |
| dantrolene cumulative dose | usually ≤10 mg/kg higher doses may be given if signs persist (reconsider diagnosis) | PERIOP-MH-01 |
| dantrolene dose (malignant hyperthermia) | 2.5 mg/kg IV, repeat until signs resolve (may exceed 10 mg/kg) malignant hyperthermia | EM-TOX-10 |
| dantrolene dose (NMS) | 1–2.5 mg/kg IV neuroleptic malignant syndrome | EM-TOX-10 |
| dantrolene initial dose | 2.5 mg/kg IV repeat until symptoms resolve | PERIOP-MH-01 |
| DAPT duration | 21 days minor stroke or high-risk TIA | NEURO-STROKE-02 |
| DAPT duration | 21 days minor stroke or high-risk TIA | NEURO-STROKE-03 |
| DAPT duration post-ACS | 12 months aspirin + ticagrelor/prasugrel, any stent; HBR → P2Y12 monotherapy after 1–3 months; ticagrelor monotherapy acceptable ≥1 month after PCI | CV-ACS-02 |
| DAPT duration post-elective PCI (DES) | 6 months stable CAD; HBR → 1–3 months | CV-ACS-02 |
| DAPT eligibility ABCD2 | ≥4 high-risk TIA | NEURO-STROKE-02 |
| DAPT eligibility NIHSS | ≤3 minor ischemic stroke | NEURO-STROKE-02 |
| DASH systolic reduction | ~11 mmHg in hypertensive adults | NUTR-MNT-01 |
| dating redate threshold (9 0/7–13 6/7 wk) | >7 days 9 0/7–13 6/7 wk | OB-PRE-01 |
| dating redate threshold (<9 0/7 wk) | >5 days <9 0/7 wk | OB-PRE-01 |
| days free of duty | 1 in 7 averaged over 4 weeks ACGME | SOC-PROF-04 |
| DCD hands-off period | 2–5 min (5 min most common) after circulatory arrest before procurement | SOC-LAW-04 |
| dcda-delivery-timing | 38 0/7–38 6/7 wk uncomplicated | OB-MISC-01 |
| DCIS share of screen-detected cancers | 20–25% mammographic screening | REPRO-BRCA-01 |
| DDH bilateral involvement | ~20% (left hip most common) DDH | MSK-PEDS-02 |
| DDH imaging cutoff | <6 mo ultrasound; ≥6 mo X-ray hip imaging modality by age | PEDS-ORTHO-01 |
| DDH Pavlik harness age cutoff | <6 months DDH | MSK-PEDS-02 |
| decompressive laminectomy window | within 8h of symptom onset spinal epidural hematoma; maximizes chance of neurologic recovery | PERIOP-COAG-01 |
| defibrillation energy | biphasic 120–200 J (or manufacturer max if unknown); monophasic 360 J VF/pulseless VT | CV-ARREST-01 |
| dehiscence typical timing | POD 5–10 postoperative day | SKIN-WOUND-02 |
| delay PN in low-risk ICU patient | 7 days if EN not feasible | NUTR-SUPPORT-01 |
| delayed hemolytic reaction onset | 2–10 days post-transfusion | HEME-TRANS-01 |
| delayed primary interval | 3–5 days open before closing a contaminated wound | SKIN-WOUND-02 |
| delayed puberty threshold | no breast by 13 y (girls); testicular volume <4 mL by 14 y (boys) triggers LH/FSH workup | PEDS-GROW-01 |
| delayed-pph-window | 24 h–12 wk postpartum secondary PPH definition | OB-PPH-01 |
| delirium tremens onset | 48–96h after last drink confusion, fever, severe autonomic instability | PERIOP-COMPL-01 |
| delivery threshold | ≥34 weeks with severe features deliver after MgSO4 and antihypertensives | CV-HTN-01 |
| delivery timing diet-controlled | 39 0/7–40 6/7 wk | OB-GDM-01 |
| delivery timing medication-treated | 39 0/7–39 6/7 wk | OB-GDM-01 |
| delivery timing poorly controlled | 37 0/7–38 6/7 wk individualized | OB-GDM-01 |
| delivery-threshold-without-severe-features | 37 wk delivery | OB-HTN-01 |
| delta-delta concurrent alkalosis | >2 delta-delta ratio | RENAL-ABG-01 |
| delta-delta concurrent NAGMA | <1 delta-delta ratio | RENAL-ABG-01 |
| delta-delta pure HAGMA | 1–2 ΔAG/ΔHCO3 | RESP-ABG-01 |
| delta-delta pure HAGMA | 1–2 delta-delta ratio | RENAL-ABG-01 |
| denosumab dosing | SC every 6 months RANK-L inhibitor | MSK-BONE-01 |
| depression screening age | ≥18 years (incl. pregnant/postpartum) USPSTF Grade B | PREV-MH-01 |
| DEXA screening age | ≥65 (women) universal screening; men ≥70 per Endocrine Society/BHOF, USPSTF insufficient evidence | MSK-BONE-01 |
| dexamethasone dose | 0.15 mg/kg IV q6h ×2–4 days (adults 10 mg IV q6h ×4 days) 10–20 min before or with first antibiotic dose | MULTI-MEN-01 |
| dexamethasone dose (bacterial meningitis) | 0.15 mg/kg IV q6h ×4 days | NEURO-INF-01 |
| dexamethasone dose (cord compression) | 10 mg bolus, then 4 mg q6h malignant epidural cord compression | NEURO-SPINE-01 |
| dexamethasone testing dose | 4 mg IV alternative only if cosyntropin testing must occur during treatment (no assay interference); hydrocortisone 100 mg IV preferred | ENDO-ADR-01 |
| dexamethasone timing | 10–20 min before or with 1st antibiotic dose adults and children >6 weeks | MULTI-MEN-01 |
| DGI-ceftriaxone-dose | 1 g IV daily disseminated gonococcal infection | MSK-INF-01 |
| DI polyuria threshold | > 3 L/day or > 50 mL/kg/day diagnostic criterion | ENDO-PIT-01 |
| diagnostic mammography age for palpable mass | ≥30 yr diagnostic imaging for a palpable mass (screening begins at 40) | REPRO-BRMASS-01 |
| diagnostic threshold | ≥2 of 4 values abnormal | OB-GDM-01 |
| dialysis AG threshold (ethylene glycol) | anion gap > 27 ethylene glycol hemodialysis indication | EM-TOX-05 |
| dialysis level threshold | >50 mg/dL (without ADH blockade) on fomepizole, methanol >70 mg/dL; ethylene glycol mainly AG >27 or AKI (level >50 mmol/L ≈310 mg/dL or osmolal gap >50) | EM-TOX-05 |
| dialysis pH/AG threshold (methanol) | pH ≤ 7.15 or anion gap > 24 methanol hemodialysis indication | EM-TOX-05 |
| dialysis protein | 1.0–1.2 g/kg/day KDOQI 2020 | NUTR-MNT-01 |
| DIC platelet transfusion trigger | <50,000/µL with active bleeding | HEME-MAHA-01 |
| DIC platelet transfusion trigger (bleeding) | <50,000/µL DIC, bleeding | HEME-COAG-01 |
| DIC platelet transfusion trigger (no bleeding) | <10,000–20,000/µL DIC, no bleeding | HEME-COAG-01 |
| dietary calcium in stone formers | 1,000–1,200 mg/day do not restrict | NUTR-MNT-02 |
| digoxin level for Fab | ≥15 ng/mL any time or ≥10 ng/mL at 6 h acute ingestion | CV-TOX-01 |
| dirty wound Td/Tdap threshold | ≥5 yr ≥3 prior doses | SKIN-PROC-01 |
| disability waiting period for Medicare | 24 months Social Security disability benefits | SOC-QI-11 |
| discriminatory zone | 1500–2000 mIU/mL β-hCG with no IUP on TVUS; may run as high as 3500 mIU/mL | OB-ECT-01 |
| dissection mortality | ~1%/hour untreated type A, first 48 h | CV-AORTA-01 |
| dissection target | HR <60/min and SBP 100–120 mm Hg within minutes; beta-blockade established first | CV-HTN-02 |
| dissection target heart rate | 60–80/min (≤60/min commonly taught) medical management of all acute dissections, including type A pre-op | CV-AORTA-01 |
| dissection target SBP | <120 mmHg within 20 min medical management of all acute dissections | CV-AORTA-01 |
| Diuretic starting doses | spironolactone 100 mg : furosemide 40 mg | GI-CIRR-01 |
| Diverticulitis colonoscopy timing | 6–8 wk after resolution | GI-COLON-01 |
| DKA bicarbonate | <18 mEq/L diagnosis | ENDO-DM-04 |
| DKA glucose | ≥200 mg/dL (or any glucose with known diabetes) diagnosis | ENDO-DM-04 |
| DKA pH | <7.30 diagnosis | ENDO-DM-04 |
| DOAC hold before neuraxial block | ≥3 days (longer with reduced renal function) apixaban/rivaroxaban | PERIOP-COAG-01 |
| DOAC hold before surgery | 1–2 days longer if CrCl <50 mL/min | CV-VTE-01 |
| DOAC hold without bridging | 1–2 days low/high bleed risk, no bridge | PERIOP-COAG-01 |
| DOAC start after AF-related stroke (1-3-6-12 heuristic) | ~1d TIA; ~3d minor; ~6d moderate; ~12–14d severe/large AHA/ASA 2021 2–14 d reasonable; ELAN/OPTIMAS earlier (≤48 h minor/moderate, ~6–7 d major) | NEURO-STROKE-03 |
| dog bite primary closure window | <8 h irrigated extremity wound (not hand/foot) | SKIN-PROC-01 |
| door-to-balloon | ≤90 min first medical contact-to-device at a PCI-capable center (≤120 min if transfer) | CV-ACS-01 |
| door-to-needle | ≤30 min fibrinolysis when PCI unavailable within 120 min | CV-ACS-01 |
| Doppler sensitivity | ~88% torsion diagnosis | RENAL-SCROT-01 |
| dose recheck interval | 6–8 weeks after any levothyroxine dose change | ENDO-THY-03 |
| Down syndrome ALL risk | 20–30x general population hematologic surveillance | MULTI-GEN-01 |
| Down syndrome recurrence risk | ~1% above age-related baseline standard nondisjunction; 10–15% (maternal) or 2–5% (paternal) Robertsonian carrier, 100% if 21;21 Robertsonian | MULTI-GEN-01 |
| DPP lifestyle benefit | 58% reduction progression from prediabetes to T2DM | PREV-CVM-01 |
| DPP lifestyle risk reduction | 58% vs 31% with metformin | ENDO-DM-01 |
| DR screening T1DM | 5 yr after diagnosis then q1–2yr if no retinopathy and controlled, else annually | NEURO-OPH-02 |
| DR screening T2DM | at diagnosis then q1–2yr if no retinopathy and controlled, else annually | NEURO-OPH-02 |
| drainage timing grade I cholangitis | within 24 h if no antibiotic response mild (Tokyo grade I) | GI-BIL-02 |
| DRESS corticosteroid taper | 6–8 wk or longer prednisone ~1 mg/kg/day; rapid taper causes relapse | SKIN-DRUG-01 |
| DRESS onset | 2–8 weeks after starting the culprit drug | SKIN-DRUG-01 |
| driving pressure target | ≤15 cmH2O ARDS mortality predictor, supplemental to plateau/tidal volume targets | RESP-VENT-01 |
| driving restriction | 3–12 months seizure-free interval, varies by state | NEURO-SZ-01 |
| drug fever window | POD 7+ Wonder drugs | PERIOP-FEVER-01 |
| drug-eluting stent minimum DAPT before elective surgery | ≥6 months (≥12 months if ACS) elective non-cardiac surgery; ≥3 months may be considered after non-ACS DES when delay risk outweighs stent-thrombosis risk | PERIOP-MED-01 |
| DT mortality untreated | 5–15% delirium tremens | PSY-SUD-01 |
| DXA screening trigger | amenorrhea ≥6 months bone density screening | PSY-EAT-01 |
| E. coli UTI share | ~80% pediatric UTI | RENAL-PEDS-01 |
| early A1c overt diabetes | ≥6.5% first-trimester screen, diagnoses pregestational diabetes | OB-GDM-01 |
| early DEXA screening threshold | FRAX ~9.3% benchmark (not a fixed cutoff) triggers screening before age 65 in postmenopausal women with risk factors | REPRO-MENO-01 |
| early fasting glucose overt diabetes | ≥126 mg/dL first-trimester screen, diagnoses pregestational diabetes | OB-GDM-01 |
| early postoperative fever window | POD 0–2 Wind (inflammatory response, not atelectasis) | PERIOP-FEVER-01 |
| early vs late dumping | 10–30 min vs 1–3 h after meals | NUTR-OBES-01 |
| ECMO consideration threshold | P/F <50 >3 h, P/F <80 >6 h, or pH <7.25 with PaCO2 ≥60 >6 h VV-ECMO after optimized ventilation, proning, paralysis | RESP-ARDS-01 |
| ectopic rupture risk window | 6–8 wk | OB-ECT-01 |
| ecv-success-rate | ~50–60% version attempt | OB-LD-03 |
| ecv-timing | 37 wk offered | OB-LD-03 |
| EDH observation criteria | <15 mm thick, <5 mm shift | NEURO-HEM-01 |
| EDH surgical volume threshold | >30 mL | NEURO-HEM-01 |
| EFW cesarean offer (diabetic) | ≥4500 g diabetic patient | OB-GDM-01 |
| EFW cesarean offer (nondiabetic) | ≥5000 g nondiabetic patient | OB-GDM-01 |
| EGD timing (suspected UGIB) | ≤ 24 h | GI-BLEED-01 |
| EGD timing (suspected variceal bleeding) | ≤ 12 h | GI-BLEED-01 |
| EGD timing non-variceal UGIB | ≤24 h | GI-BLEED-02 |
| EGD timing variceal UGIB | ≤12 h | GI-BLEED-02 |
| eGFR stop threshold | >30% acute decline from baseline assess volume status/other causes; may continue below eGFR 20 until dialysis if tolerated | ENDO-DM-02 |
| EGPA eosinophil threshold | ≥1000/µL ACR/EULAR 2022 classification criteria | RESP-HEMO-01 |
| elderly/CAD starting dose | 25–50 mcg/day levothyroxine | ENDO-THY-03 |
| elective induction | ≥39 wk | OB-PRE-01 |
| elective surgery delay after PCI | ≥6 months (chronic coronary disease DES) / ≥12 months (ACS DES) elective surgery requiring antiplatelet interruption; time-sensitive DES surgery ≥3 months if delay risk exceeds cardiac risk | CV-ACS-02 |
| elevated blood lead level | ≥3.5 µg/dL (CDC reference value) confirm with venous level; ≥20 → environmental investigation (CDC; some jurisdictions act lower); ≥45 → chelation | PREV-OCC-01 |
| elevated BP | 120–129/<80 mm Hg - | CV-HTN-01 |
| emergency psychiatric hold | ≤72 h (varies by state) involuntary commitment | SOC-LAW-03 |
| emergent dialysis acidosis | pH <7.20 AEIOU | RENAL-DIAL-01 |
| emergent dialysis hyperkalemia | K+ >6.5 mEq/L with ECG changes AEIOU | RENAL-DIAL-01 |
| EMG/NCS optimal timing | ≥3 weeks after injury reliable interpretation of nerve conduction studies | PERIOP-NERVE-01 |
| empiric steroid dose | prednisone 2 mg/kg/day (max 60 mg) pediatric MCD | RENAL-GN-01 |
| endarterectomy timing | within 2 weeks of qualifying TIA/stroke | NEURO-STROKE-03 |
| endometrial biopsy age threshold | ≥45 yr AUB workup | REPRO-AUB-01 |
| endometrioma excision indication | symptomatic, enlarging, or suspicious (not routine before IVF) weigh loss of ovarian reserve | REPRO-ENDOM-01 |
| endometriosis prevalence in infertility | 30–50% infertile women | REPRO-ENDOM-01 |
| enoxaparin prophylactic dose | 40 mg SQ daily moderate-risk general/GYN/urologic surgery | PERIOP-VTE-01 |
| enteral feeding start | within 24–48h of ICU admission hemodynamically stable patients | MULTI-NUTR-01 |
| EoE threshold | ≥15 eosinophils/hpf esophageal biopsy | NUTR-MNT-02 |
| eosinophil threshold for ICS | ≥300 cells/µL Group E, add ICS to LAMA + LABA | RESP-COPD-01 |
| eosinophil threshold for triple therapy | ≥100 cells/µL persistent exacerbation on dual bronchodilation | RESP-COPD-01 |
| eosinophiluria sensitivity | 30–60% AIN | RENAL-AKI-02 |
| EPDS positive screen | ≥10 | OB-PP-01 |
| epididymitis age threshold | 35 years one factor (with sexual practices and STI risk) guiding empiric antibiotic selection, not a strict cutoff | RENAL-SCROT-01 |
| epidural abscess antibiotic duration | 6–8 weeks IV antibiotics after drainage | NEURO-SPINE-01 |
| epidural abscess triad frequency | ~15% spinal epidural abscess | MSK-SPINE-01 |
| epilepsy risk after febrile seizure | 1–2% simple febrile seizure, vs ~1% general population | NEURO-SZ-02 |
| epilepsy risk with complex features | up to ~10% complex features, neurodevelopmental abnormality, or family history | NEURO-SZ-02 |
| epinephrine dose | 0.01 mg/kg IM (max 0.5 mg adult) anaphylaxis, 1 mg/mL, anterolateral thigh; repeat every 5–15 min as needed | RESP-DYSP-01 |
| epinephrine IM dose | 0.01 mg/kg, max 0.5 mg anterolateral thigh; auto-injector 0.15 mg 15–30 kg, 0.3 mg ≥30 kg | NUTR-MNT-02 |
| epinephrine redosing interval | every 3–5 min neonatal resuscitation, HR persistently <60/min | PEDS-NB-02 |
| episodes without skin findings | ~20% anaphylaxis | IMM-ANAPH-01 |
| ER/PR-positive share of breast cancer | ~70% receptor subtype | REPRO-BRCA-01 |
| ERA-uveitis-screening-interval | every 12 months asymptomatic ERA (HLA-B27+, sacroiliitis) | MSK-RHEUM-02 |
| ERCP timing grade II cholangitis | within 24–48 h moderate (Tokyo grade II) | GI-BIL-02 |
| ERCP timing severe cholangitis | within 12 h Reynolds pentad / Tokyo grade III | GI-BIL-02 |
| erythema nodosum duration | 3–6 weeks self-limited; no biopsy/excision needed | SKIN-OTHER-01 |
| esophageal perforation treatment window | <24 h mortality rises with delayed diagnosis/treatment; not all leaks require operative repair | GI-ESO-02 |
| ET platelet threshold | ≥450,000/µL sustained | HEME-MPN-01 |
| ethanol osmolal correction | ethanol/3.7 added to calculated osmolality when ethanol is present | EM-TOX-05 |
| evidence collection window | ≤120 h (typical; per local protocol)+ per protocol forensic evidence collection | REPRO-MISC-01 |
| expectant management hCG ceiling | <200 mIU/mL low, declining, asymptomatic, no rupture | OB-ECT-01 |
| expected ACEi creatinine rise | ≤ 30% first 1–2 weeks of therapy | ENDO-DM-06 |
| expected β-hCG decline | ≥15% day 4 to day 7 post-methotrexate | OB-ECT-01 |
| extended commitment standard | clear and convincing evidence judicial hearing | SOC-LAW-03 |
| extended LMWH duration after major abdominal/pelvic cancer surgery | 28 days post-op VTE prophylaxis | PERIOP-VTE-01 |
| extended prophylaxis duration after total hip/knee arthroplasty | up to 35 days post-op VTE prophylaxis | PERIOP-VTE-01 |
| extended VTE prophylaxis after hip/knee arthroplasty | 10–35 days from day of surgery | CV-VTE-01 |
| exudate LDH ratio | >0.6 pleural/serum LDH, Light’s criteria | RESP-PLEFF-01 |
| exudate protein ratio | >0.5 pleural/serum protein, Light’s criteria | RESP-PLEFF-01 |
| face-to-face evaluation | within 1 h violent restraint or seclusion | SOC-LAW-03 |
| facial bite closure window | <24 h any bite type, after irrigation/debridement, with amoxicillin-clavulanate | SKIN-PROC-01 |
| false-negative Doppler rate | up to 12% torsion | RENAL-SCROT-01 |
| FAP sigmoidoscopy start | age 10–12 | GI-COLON-01 |
| fasciotomy threshold (absolute) | >30 mmHg compartment pressure | MSK-COMP-01 |
| fasciotomy threshold (delta) | ≤30 mmHg diastolic BP minus compartment pressure | MSK-COMP-01 |
| Fasting gastrin diagnostic of ZES | > 1000 pg/mL with gastric pH < 2 | GI-GAST-01 |
| fasting glucose target | <95 mg/dL | OB-GDM-01 |
| favorable AML cytogenetics | t(8;21) or inv(16) core-binding factor AML | HEME-MALIG-01 |
| febrile neutropenia ANC | <500/µL definition | HEME-ONC-01 |
| febrile neutropenia temperature | ≥38.3°C single or ≥38.0°C sustained 1 h definition | HEME-ONC-01 |
| febrile seizure age range | 6 mo–5 yr definition | NEURO-SZ-02 |
| febrile seizure fever threshold | ≥38°C definition | NEURO-SZ-02 |
| febrile seizure recurrence risk | ~30% after first simple febrile seizure | NEURO-SZ-02 |
| Fecal elastase EPI threshold | < 200 mcg/g stool | GI-PANC-02 |
| feeding frequency | 8–12 feeds/day newborn breastfeeding | NUTR-INF-01 |
| ferritin diagnostic cutoff | <30 ng/mL confirms iron deficiency anemia | HEME-ANEM-01 |
| ferritin diagnostic threshold | >300 ng/mL men; >200 ng/mL women hemochromatosis | GI-LIV-01 |
| ferritin IDA cutoff | <30 ng/mL specific regardless of inflammation | HEME-ANEM-02 |
| fetal bradycardia threshold | <110 bpm ≥10 min hypoxia, maternal hypotension, congenital heart block | OB-FHR-01 |
| fetal tachycardia threshold | >160 bpm ≥10 min maternal fever/chorioamnionitis, β-agonists, fetal anemia/hypoxia | OB-FHR-01 |
| FEUrea intrinsic | >50% on diuretics | RENAL-AKI-01 |
| FEUrea prerenal | <35% on diuretics | RENAL-AKI-01 |
| FFP dose | 10–15 mL/kg coagulopathic bleeding; MTP 1:1:1; TTP exchange ~1–1.5 plasma volumes/day | HEME-TRANS-02 |
| fgr-delivery-absent-edv | 33–34 wk | OB-SURV-01 |
| fgr-delivery-decreased-diastolic-flow | 37 wk | OB-SURV-01 |
| fgr-delivery-normal-doppler | 38–39 wk 37 wk if EFW <3rd percentile | OB-SURV-01 |
| fgr-delivery-reversed-edv | 30–32 wk | OB-SURV-01 |
| fgr-magnesium-threshold | <32 wk | OB-SURV-01 |
| fgr-steroid-threshold | routine 24 0/7–33 6/7 wk; 34 0/7–36 6/7 wk consider one betamethasone course if delivery likely within 7 d and no prior course (avoid in pregestational diabetes) | OB-SURV-01 |
| FHH calcium-to-creatinine clearance ratio | < 0.01 distinguishes FHH from primary hyperparathyroidism | ENDO-CA-01 |
| FIB-4 high-risk threshold | >2.67 high risk → hepatology referral (1.3–2.67 → VCTE or ELF, refer if LSM ≥8 kPa) | GI-LIV-01 |
| FIB-4 low-risk threshold | <1.30 repeat in 1–2 y if T2DM or ≥2 metabolic risk factors, otherwise 2–3 y | GI-LIV-01 |
| fibrinogen threshold | <150–200 mg/dL give cryoprecipitate or fibrinogen concentrate | EM-TRAUMA-02 |
| fibrinolysis BP contraindication | >180/110 mm Hg despite treatment, absolute contraindication | CV-ACS-01 |
| fibrinolysis window | ≤12 h from symptom onset (12–24 h if ongoing ischemia), STEMI only, never NSTEMI | CV-ACS-01 |
| fibroadenoma age range | 15–35 y most common benign breast tumor | REPRO-BRMASS-01 |
| fidaxomicin dose | 200 mg PO BID ×10 d | GI-FUNC-01 |
| FIGO high-risk cutoff | ≥7 multiagent EMA-CO | OB-GTD-01 |
| finasteride PSA reduction | ~50% 5-alpha reductase inhibitor | RENAL-LUTS-01 |
| FiO2 0.6 PEEP | 10 cmH2O ARDSNet lower-PEEP table | RESP-ARDS-01 |
| firearm-associated DV homicide risk | ~5-fold increase firearm present in IPV situation | PREV-SAFE-01 |
| First-degree relative screening start | age 40 or 10 yr before youngest diagnosis, whichever earlier if FDR/advanced adenoma diagnosed <60 or ≥2 FDRs; single FDR ≥60 → start at 40 with average-risk (q10yr) interval | GI-COLON-01 |
| first-seizure recurrence risk | ≥60% over 10 years remote structural insult/lesion or epileptiform EEG (ILAE 2014 epilepsy); nocturnal seizure alone falls short | NEURO-SZ-01 |
| first-stage-total | 0–10 cm complete dilation | OB-LD-01 |
| first-trimester combined screening | 11 0/7–13 6/7 wk aneuploidy screening | OB-PRE-01 |
| first-trimester-screen-window | 11–14 wk PAPP-A + beta-hCG + NT | OB-PRE-02 |
| Fistula-in-ano incidence after perianal abscess | ~50% | GI-ANOR-01 |
| FIT interval | annual average risk | PREV-CRC-01 |
| FL transformation to DLBCL | 2–3%/year follicular lymphoma | HEME-MALIG-02 |
| flail chest definition | ≥2 adjacent ribs, ≥2 fracture sites each flail chest | EM-TRAUMA-04 |
| fluoride varnish | every 3–6 months from eruption to age 5 USPSTF 2021 (start); AAP (interval) | NUTR-VIT-02 |
| fluoxetine dose for bulimia | 60 mg/day higher than standard depression dosing | PSY-EAT-01 |
| FMEA risk priority number | severity × occurrence × detectability prospective risk ranking | SOC-QI-01 |
| FMR1 premutation POI risk | 20% female premutation carriers | REPRO-MENO-01 |
| FMT efficacy | ~90% second or subsequent CDI recurrence | MULTI-GI-01 |
| FNA threshold high/intermediate-suspicion | ≥1 cm ATA 2015 | ENDO-THY-01 |
| FNA threshold low-suspicion | ≥1.5 cm ATA 2015 | ENDO-THY-01 |
| FNA threshold very-low-suspicion | ≥2 cm ATA 2015 (spongiform); differs from TI-RADS | ENDO-THY-01 |
| FNHTR temperature rise | ≥1°C febrile non-hemolytic reaction | HEME-TRANS-01 |
| folate for prior NTD | 4 mg daily from ≥1 month pre-conception | NUTR-VIT-01 |
| folic acid (prior NTD) | 4 mg/day ≥1–3 months before conception through 12 weeks | NUTR-PREG-01 |
| folic acid (standard risk) | 0.4–0.8 mg/day ≥1 month before conception through first 2–3 months (USPSTF 2023) | NUTR-PREG-01 |
| folic acid dose (AEDs) | ≥0.4 mg/day women of childbearing potential on antiseizure medication | NEURO-SZ-01 |
| folic acid dose (prior NTD) | 4 mg prior neural tube defect-affected pregnancy | OB-PRE-01 |
| folic acid dose (standard risk) | 0.4–0.8 mg standard risk | OB-PRE-01 |
| folic acid dose for high-risk pregnancy | 4 mg/day prior NTD-affected pregnancy; antiseizure medication exposure: ≥0.4 mg/day (higher doses often used, benefit uncertain) | PSY-MOOD-04 |
| fosphenytoin dose | 20 mg PE/kg IV status epilepticus second-line | NEURO-SZ-01 |
| fosphenytoin dose | 20 mg PE/kg IV established status epilepticus | NEURO-SZ-02 |
| FPIES onset | 1–4 h after ingestion repetitive vomiting, IgE negative | NUTR-MNT-02 |
| FPIES vomiting onset | 1–4 h after ingestion | IMM-HYP-01 |
| fractional bicarbonate excretion | >15% confirms proximal (type 2) RTA after alkali load | RENAL-ABG-01 |
| Fragile X full mutation | >200 CGG repeats FMR1 gene — methylation silencing | MULTI-GEN-01 |
| frailty phenotype | ≥3 of 5 criteria Fried; 1–2 = prefrail | NUTR-ASSESS-01 |
| FRAX treatment threshold | hip ≥3% or major fracture ≥20% 10-year risk | MSK-BONE-01 |
| frontotemporal dementia onset | 45–65 y typical age | NEURO-DEM-01 |
| frostbite rewarming temperature | 37–39°C once refreezing is not a risk | MULTI-ENV-01 |
| FTT weight threshold | <2nd percentile or crossing ≥2 major percentiles WHO charts <2 y | NUTR-INF-01 |
| full enteral caloric goal | 25–30 kcal/kg/day standard ICU patient without refeeding risk, once advanced from trophic feeding | MULTI-NUTR-01 |
| fulminant vancomycin dose | 500 mg PO QID | GI-FUNC-01 |
| functional asplenia onset | by age 5 years autosplenectomy | HEME-SICK-01 |
| functional capacity threshold | ≥4 METs proceed without cardiac testing | PERIOP-RISK-01 |
| functional capacity threshold | ≥4 METs proceed to surgery regardless of RCRI | CV-PERIOP-01 |
| functional capacity threshold for surgery clearance | ≥4 METs proceed to surgery without stress testing | CV-CAD-01 |
| FVC failure threshold | <20 mL/kg neuromuscular respiratory failure; elective intubation | RESP-ARF-01 |
| G-CSF primary prophylaxis threshold | ≥20% regimen-related febrile neutropenia risk | HEME-ONC-01 |
| G6PD assay retest interval | ~3 months (at least several weeks) after acute hemolytic episode, avoids false-normal from reticulocytosis | HEME-HEMOL-01 |
| Gastric ulcer repeat EGD | 8–12 wk if suspicious features, inadequate biopsy, or persistent symptoms | GI-GAST-01 |
| gastrinoma fasting gastrin | > 10× ULN with gastric pH < 2 measured off PPI when safe | ENDO-ONC-01 |
| Gastroparesis diagnostic retention | > 10% at 4 h | GI-GAST-01 |
| GB wall thickening threshold | >3–4 mm | GI-BIL-01 |
| GBS culture timing | 36 0/7–37 6/7 wk | OB-PRE-01 |
| GBS prophylaxis adequacy | ≥4 h IV penicillin, ampicillin, or cefazolin before delivery; clindamycin or vancomycin inadequate regardless of duration | IMM-DALLERGY-01 |
| GBS symptom onset after trigger | 1–3 wk post-infectious latency | NEURO-NM-02 |
| gbs-screening-window | 36 0/7–37 6/7 wk vaginal-rectal culture | OB-LD-01 |
| GC-adjusted FRAX pharmacotherapy threshold | major ≥10% or hip >1% glucocorticoid-induced osteoporosis | MSK-BONE-01 |
| GCA biopsy window | within 2 weeks of starting steroids | IMM-VASC-01 |
| GCA prednisone dose | 40–60 mg/day (1 mg/kg/day) suspected GCA | MSK-OTHER-01 |
| GCS intubation threshold | ≤8 airway protection | EM-TRAUMA-01 |
| GCS range | 3–15 Glasgow Coma Scale | EM-TRAUMA-01 |
| GCT threshold | ≥130–140 mg/dL institution-specific, proceed to 3-h OGTT | OB-GDM-01 |
| GDM diagnostic OGTT | fasting ≥95 / 1h ≥180 / 2h ≥155 / 3h ≥140 mg/dL (≥2 abnormal) Carpenter-Coustan | ENDO-DM-03 |
| GDM minimum carbohydrate | 175 g/day with ≥71 g protein and 28 g fiber | NUTR-PREG-01 |
| GDM progression to T2DM | 50% within 10 years | ENDO-DM-03 |
| GDM screening window | 24–28 wk 50 g glucose challenge test | ENDO-DM-03 |
| GDM targets | fasting <95; 1-h <140; 2-h <120 mg/dL ADA 2026 / ACOG | NUTR-PREG-01 |
| gene therapy approval age | ≥12 years exa-cel/lovo-cel | HEME-SICK-01 |
| genital herpes suppressive therapy | valacyclovir 500 mg–1 g once daily ≥6 recurrences/year | REPRO-VAGIN-01 |
| germ cell tumor risk in CAIS | ~1–2% in adulthood; <1% before puberty gonadectomy timing | REPRO-AMEN-01 |
| gestational weight gain, normal BMI | 25–35 lb IOM 2009; obese BMI 11–20 lb | NUTR-PREG-01 |
| gestational-hypertension-definition | ≥140/90 mmHg after 20 wk, no proteinuria/end-organ dysfunction; deliver 37 wk | OB-HTN-01 |
| GGO follow-up | CT at 6–12 mo, then q2y to 5y pure ground-glass nodule ≥6 mm | RESP-ONC-01 |
| giant cell arteritis ESR | often >100 mm/h supportive lab finding | NEURO-HA-01 |
| giant coronary aneurysm threshold | ≥8 mm or Z-score ≥10 long-term aspirin plus warfarin or LMWH | CV-PEDS-01 |
| GINA control score | 0=well-controlled, 1–2=partly controlled, 3–4=uncontrolled 4 criteria over past 4 weeks | RESP-ASTHMA-01 |
| Glasgow-Blatchford low-risk score | 0–1 safe for outpatient management | GI-BLEED-01 |
| GLIM low BMI | <20 kg/m2 (age <70); <22 kg/m2 (age ≥70) non-Asian adults | NUTR-ASSESS-01 |
| GLIM reduced intake | ≤50% of requirement >1 week etiologic criterion | NUTR-ASSESS-01 |
| GLIM weight loss | >5% in 6 mo or >10% beyond 6 mo phenotypic criterion | NUTR-ASSESS-01 |
| GLP-1 RA hold before surgery | if high risk: 1 wk (weekly) or day-of (daily) aspiration risk from delayed gastric emptying | ENDO-PERI-01 |
| glucagon dose | 1 mg IM/SC severe hypoglycemia | ENDO-DM-05 |
| glucocorticoid bisphosphonate threshold | prednisone ≥2.5 mg/day for ≥3 months glucocorticoid-induced osteoporosis, calcium/vitamin D + risk assessment | MSK-BONE-01 |
| glucose target | 144–180 mg/dL critically ill; insulin infusion started at glucose ≥180 mg/dL | MULTI-SEP-01 |
| GnRH agonist duration limit | ≤6 months without add-back bone loss | REPRO-ENDOM-01 |
| GnRH agonist preoperative duration | 3 mo typical; ≤6 mo without add-back, ≤12 mo with add-back bone loss limit | REPRO-FIBR-01 |
| GnRH agonist preoperative use limit | ≤6 mo without add-back (≤12 mo with add-back) bone loss risk | REPRO-FIBR-01 |
| GnRH antagonist duration | ≤24 months with add-back elagolix/relugolix | REPRO-FIBR-01 |
| GOLD airflow limitation grade | mild ≥80% | moderate 50–79% | severe 30–49% | very severe <30% post-bronchodilator FEV1 % predicted | RESP-PFT-01 |
| gonococcal conjunctivitis onset | day 2–5 neonatal | REPRO-VAGIN-01 |
| gonococcal-arthritis-duration | 7–10 days disseminated gonococcal arthritis | MSK-INF-01 |
| gonorrhea treatment | ceftriaxone 500 mg IM ×1 (1 g if ≥150 kg) 2021 CDC update | REPRO-VAGIN-01 |
| GRACE score | >140 NSTEMI → angiography within 24 h | CV-ACS-01 |
| grade 2 ICI pneumonitis steroid dose | 1–2 mg/kg/day prednisone hold checkpoint inhibitor | RESP-ONC-01 |
| grade 3–4 ICI pneumonitis steroid-refractory | 48–72 h add infliximab or mycophenolate | RESP-ONC-01 |
| grade I wound | <1 cm Gustilo-Anderson | MSK-FRAC-05 |
| grade II wound | 1–10 cm Gustilo-Anderson | MSK-FRAC-05 |
| grade IIIA wound | >10 cm Gustilo-Anderson | MSK-FRAC-05 |
| GRV holding threshold | ≥500 mL with intolerance signs routine GRV monitoring not recommended | NUTR-SUPPORT-01 |
| GVHD acute vs chronic (traditional) | ~day 100 (convention) post-HSCT | IMM-TXP-01 |
| H. pylori eradication testing washout | ≥ 4 wk post-antibiotics, ≥ 2 wk off PPI | GI-GAST-01 |
| H. pylori therapy duration | 14 days bismuth quadruple therapy first-line | GI-GAST-01 |
| HAC Reduction Program penalty | 1% worst-performing quartile | SOC-QI-11 |
| HAE type I prevalence | ~85% of HAE cases; low C1-INH quantity | IMM-ANGIO-01 |
| HAE type II prevalence | ~15% of HAE cases; dysfunctional C1-INH | IMM-ANGIO-01 |
| haloperidol QTc threshold | ≥500 ms or Δ≥60 ms avoid or switch to a lower-risk antipsychotic before dosing | EM-CRIT-02 |
| HAP/VAP MRSA risk | IV antibiotics <90 days, or unit MRSA >10–20% add vancomycin/linezolid | RESP-PNA-02 |
| HAP/VAP onset | ≥48h after admission (HAP) or intubation (VAP) | MULTI-ABX-02 |
| HAP/VAP treatment duration | 7 days standard course, not 14 days | MULTI-ABX-02 |
| HAPE altitude threshold | >2500 m onset 2–4 days after ascent | RESP-OCC-01 |
| HbA2 beta-thal trait | >3.5% hemoglobin electrophoresis | HEME-ANEM-02 |
| HBIG/vaccine window | within 12 h of birth HBsAg-positive mother | PREV-ID-01 |
| HBO indications | COHb >25%, syncope/coma, or pregnancy with COHb >15% severe CO poisoning | EM-BURN-01 |
| HBO protocol | 2.5–3 ATA for 90–120 min standard CO poisoning session, repeat within 24 h if indicated | EM-TOX-02 |
| HBO threshold | >25% COHb (>15% or fetal distress in pregnancy) hyperbaric O2 indication | EM-TOX-02 |
| HbS goal exchange transfusion | <30% severe ACS/stroke | HEME-SICK-02 |
| HBV DNA treatment threshold (HBeAg-negative) with elevated ALT | >2,000 IU/mL plus ALT >2x ULN | GI-HEP-01 |
| HBV DNA treatment threshold (HBeAg-positive) with elevated ALT | >20,000 IU/mL plus ALT >2x ULN | GI-HEP-01 |
| HBV reactivation prophylaxis duration | ≥6–12 months after completion (≥12–18 months after anti-CD20) start 1–2 weeks before | GI-HEP-01 |
| HBV screening age | ≥18 years one-time; CDC 2023 triple panel, USPSTF 2020 remains Grade B risk-based | PREV-ID-01 |
| HBV/HCV follow-up testing | 6 mo sexual assault | REPRO-MISC-01 |
| HCC surveillance interval | every 6 months cirrhosis (any cause) or high-risk chronic hepatitis B; liver ultrasound ± AFP | PREV-ONC-01 |
| HCC surveillance interval | every 6 months ultrasound ± AFP in cirrhotics and high-risk HBV carriers | GI-LIV-02 |
| HCC surveillance interval in chronic HBV | every 6 months ultrasound ± AFP | GI-HEP-01 |
| HCM ICD LVEF | <50% primary-prevention risk marker | CV-CM-01 |
| HCM SCD risk wall thickness | ≥30 mm ICD indication | CV-CM-01 |
| HCM wall thickness | ≥15 mm (≥13 mm with family history) diagnostic threshold | CV-CM-01 |
| HCO3 normal | 22–26 mEq/L reference range | RESP-ABG-01 |
| HCV screening ages | 18–79 years universal one-time | PREV-ID-01 |
| head of bed elevation | 30–45° ventilated patients | SOC-QI-08 |
| head-of-bed elevation | 30–45° VAP bundle | PREV-HAI-01 |
| head-of-bed elevation | 30–45° enteral feeding aspiration prevention | NUTR-SUPPORT-01 |
| heat stroke threshold | ≥40°C + CNS dysfunction defining criterion is mental status change | MULTI-ENV-01 |
| HELLP steroid delay | None HELLP <34 wk, stable, to complete corticosteroids | OB-HTN-01 |
| hemodialysis threshold (lithium) | > 4.0 mEq/L with impaired kidney function; > 5.0 mEq/L suggested; any level with decreased consciousness, seizures, or dysrhythmia EXTRIP 2015 lithium | EM-TOX-08 |
| hemodialysis threshold (lithium) | recommended: >4.0 mEq/L with impaired kidney function, or decreased consciousness, seizures, life-threatening dysrhythmia at any level; suggested: >5.0, significant confusion, or expected time to <1.0 >36 h EXTRIP 2015 criteria | PSY-MOOD-04 |
| hemodialysis threshold (salicylate) | > 100 mg/dL (> 90 with impaired kidney function) salicylate level | EM-TOX-04 |
| hemophilia A share | 80% of hemophilia cases | HEME-COAG-02 |
| hemorrhagic stroke target | 140 mm Hg (keep 130–150) SBP with nicardipine | CV-HTN-02 |
| HepA dosing | 2 doses, ≥6 months apart at-risk adults | PREV-IMM-02 |
| HER2-positive share of breast cancer | ~20% receptor subtype | REPRO-BRCA-01 |
| herald patch size | 2–4 cm pityriasis rosea | SKIN-MORPH-01 |
| herbal supplement hold | 1–2 weeks before surgery St. John’s wort, ginkgo, garlic, ginseng | PERIOP-MED-01 |
| HF fluid restriction | 1.5–2 L/day hyponatremia or refractory congestion only | NUTR-MNT-01 |
| HFNC max flow | 60 L/min heated humidified oxygen | RESP-ARF-01 |
| HFNC starting flow/FiO2 | 40–60 L/min titrate FiO2 to SpO2 92–96% | RESP-ARF-01 |
| HG weight loss threshold | >5% prepregnancy weight | OB-MISC-01 |
| Hgb rise per unit PRBC | ~1 g/dL transfusion | HEME-ANEM-01 |
| HH phlebotomy target ferritin | 50–100 ng/mL therapeutic phlebotomy induction | HEME-MISC-01 |
| HIDA nonfilling time | 60 min (persists 30 min post-morphine); 3–4 h delayed imaging without morphine | GI-BIL-01 |
| high-dose amoxicillin for AOM | 80–90 mg/kg/day first-line therapy | PEDS-INF-01 |
| high-dose amoxicillin for CAP | 90 mg/kg/day outpatient bacterial CAP, age ≥3 mo | PEDS-INF-01 |
| high-dose DST suppression cutoff | > 50% historically indicated a pituitary source; low-accuracy and now largely abandoned (Pituitary Society 2021) | ENDO-ADR-02 |
| high-intensity statin | atorvastatin 40–80 mg; rosuvastatin 20–40 mg clinical ASCVD, any age | CV-ACS-02 |
| high-quality CPR | rate 100–120/min, depth 5–6 cm, pauses <10 s ACLS | CV-ARREST-01 |
| high-risk screening starting age | MRI from 25–30 yr; mammography from 30 yr BRCA carrier/chest radiation/lifetime risk ≥20% | REPRO-BRMASS-01 |
| highest-risk period post-discharge | 1–4 weeks completed suicide risk window | PSY-SUIC-01 |
| Hill sign | popliteal SBP exceeds brachial SBP by >60 mm Hg sign of severe AR (20–40 mm Hg = mild) | CV-VALV-01 |
| hip-dislocation-reduction-window | ≤6 h to limit avascular necrosis risk | MSK-JOINT-02 |
| hip-fracture-time-to-surgery | ≤48 h target from admission to operative fixation | MSK-FRAC-04 |
| hip-fracture-VTE-duration | 10–14 days (up to 35 days) LMWH or alternative VTE prophylaxis after hip fracture surgery | MSK-FRAC-04 |
| HIT platelet drop | >50% from baseline, day 5–10 | CV-VTE-01 |
| HIV CD4 threshold for live vaccines (adult) | ≥200 cells/µL MMR and varicella exception | PREV-IMM-02 |
| HIV CD4 threshold for live vaccines (pediatric) | <15% (or <200/µL if ≥5 y) below this, MMR/varicella contraindicated; at or above, indicated | PEDS-WELL-01 |
| HIV PEP window | ≤72 h sexual assault postexposure prophylaxis | REPRO-MISC-01 |
| HIV post-exposure prophylaxis | start ≤72 h; 28 days sexual or occupational exposure | SOC-LAW-01 |
| HIV screening ages | 15–65 years universal one-time; USPSTF 2019 Grade A | PREV-ID-01 |
| HIV-positive screening interval | annual x3 yr then q3y (cytology); co-testing q3y from age 30 begin by age 21 or within 1 yr of sexual debut | REPRO-CERV-01 |
| HIV/syphilis follow-up testing | 6 wk, 3 mo, 6 mo sexual assault | REPRO-MISC-01 |
| HOB elevation | 30–45° VAP prevention bundle | EM-CRIT-01 |
| hold/reduce IV lipid | TG >400 mg/dL PN | NUTR-SUPPORT-01 |
| hospice benefit periods | 90 days, 90 days, then unlimited 60-day periods Medicare recertification | SOC-EOL-04 |
| hospice bereavement support | up to 1 year after death | SOC-EOL-04 |
| hospice prognosis | ≤6 months if disease runs its expected course | SOC-EOL-04 |
| hospice respite care | ≤5 days inpatient per episode | SOC-EOL-04 |
| Hospital VBP withhold | 2% Medicare inpatient payments | SOC-QI-11 |
| HPA suppression threshold (high) | ≥ 20 mg/day prednisone-equivalent × ≥ 3 weeks, or cushingoid assume suppressed | ENDO-ADR-02 |
| HPA suppression threshold (moderate) | ≥ 5 mg/day prednisone-equivalent × ≥ 3 weeks may be suppressed — taper and stress-dose | ENDO-ADR-02 |
| HPV attributable fraction | ~70% types 16/18 | REPRO-CERV-01 |
| HPV catch-up age | through 26 (shared decision 27–45) HPV vaccination | PREV-IMM-01 |
| HPV dosing | 2 doses if started <15 y; 3 doses if started ≥15 y age at first dose | PEDS-WELL-01 |
| HPV vaccine dosing | 2 doses (<15 y) or 3 doses (≥15 y) Gardasil 9 series | REPRO-CERV-01 |
| HRS urine sodium | <10 mEq/L reflects splanchnic-vasodilation-driven sodium retention | GI-CIRR-02 |
| HRS-AKI creatinine criteria | ≥0.3 mg/dL rise in 48 h or ≥50% from baseline ICA-AKI diagnostic criteria | GI-CIRR-02 |
| HRS-AKI definition | Cr rise ≥0.3 mg/dL/48h or ≥50%/7d (fixed >2.5 mg/dL threshold abandoned) hepatorenal syndrome, KDIGO AKI criteria in cirrhosis with ascites | RENAL-AKI-01 |
| HS splenectomy delay | ≥5 years hereditary spherocytosis, when possible | HEME-HEMOL-01 |
| HT initiation window | ≤10 yr from menopause or age <60 timing hypothesis | REPRO-MENO-01 |
| Hunger Vital Sign look-back | 12 months food insecurity screen | SOC-SDOH-01 |
| HUS onset after diarrhea | 5–10 days typical STEC HUS | HEME-MAHA-01 |
| hydrocortisone dose | 200 mg/day (50 mg IV q6h) septic shock, empiric, no ACTH testing | EM-CRIT-01 |
| hydrocortisone dose | 200 mg/day (50 mg IV q6h) vasopressor-refractory septic shock | CV-SHOCK-01 |
| hydrocortisone trigger | norepinephrine ≥0.25 µg/kg/min for ≥4h ongoing/refractory vasopressor requirement | MULTI-SEP-01 |
| hydroxyurea hold ANC | <2,000/µL hold dose; younger patients with low baseline counts may tolerate ANC ≥1,250/µL | HEME-SICK-01 |
| hydroxyurea hold hemoglobin | <4.5 g/dL myelosuppression, hold dose | HEME-SICK-01 |
| hydroxyurea hold platelets | <80,000/µL myelosuppression, hold dose | HEME-SICK-01 |
| hydroxyurea offer age (NHLBI) | ≥9 months sickle cell disease | HEME-SICK-01 |
| hydroxyurea start age | 9 months offered to all children with HbSS/HbSβ0 regardless of symptoms (BABY HUG) | HEME-SICK-02 |
| hyperbaric oxygen indication | COHb >25% (>15% in pregnancy) carbon monoxide poisoning | SKIN-PEARL-01 |
| hypercalcemia hydration rate | 200–300 mL/h IV isotonic saline, first-line therapy | HEME-ONC-01 |
| hypercalcemia severe threshold | ≥14 mg/dL corrected calcium, medical emergency | HEME-ONC-01 |
| hypercalcemia threshold | > 10.5 mg/dL corrected for albumin | ENDO-CA-01 |
| hyperkalemia emergent-treatment threshold | >6.5 mEq/L treatment trigger | RENAL-ELEC-01 |
| hyperkalemia-treat-threshold | ≥6.5 mEq/L emergent treatment (shift + removal); calcium gluconate when ECG changes are present | CV-ECG-01 |
| hypernatremia correction rate | ≤0.5 mEq/L/h prevents cerebral edema during correction | PEDS-RENAL-01 |
| hyperplasia with atypia progression to carcinoma | ~30% untreated | REPRO-ENDCA-01 |
| hypertensive crisis | SBP >180 and/or DBP >120 mm Hg - | CV-HTN-01 |
| hypertensive emergency | SBP >180 and/or DBP >120 mm Hg with acute end-organ damage | CV-HTN-02 |
| hypertensive urgency | SBP >180 and/or DBP >120 mm Hg without acute end-organ damage | CV-HTN-02 |
| hypertonic saline correction limit | 4–6 mEq/L first 6h, ≤8–10 mEq/L/24h prevents osmotic demyelination | MULTI-FE-01 |
| hypertonic saline Na target | 145–155 mEq/L 3% or 23.4% NaCl | NEURO-ICP-01 |
| hypertriglyceridemia pancreatitis threshold | >1000 mg/dL IV insulin/dextrose infusion ± plasmapheresis | GI-PANC-01 |
| hyperventilation target | PaCO₂ 30–35 mmHg | NEURO-ICP-01 |
| hypoalbuminemia leak risk threshold | <3.5 g/dL anastomotic leak risk factor | PERIOP-COMPL-01 |
| hypoalbuminemia threshold | <2.5–3.5 g/dL nephrotic syndrome | RENAL-GN-01 |
| hypoglycemia alert value (level 1) | <70 mg/dL patients with diabetes on treatment (ADA) | ENDO-DM-05 |
| hypoglycemia level 2 | <54 mg/dL patients with diabetes (ADA) | ENDO-DM-05 |
| hypoglycemia level 2 | <54 mg/dL ADA 2026 | NUTR-MNT-01 |
| hypoglycemia rule of 15 | 15 g carbohydrate; recheck at 15 min glucose <70 mg/dL, conscious | NUTR-MNT-01 |
| hypoglycemia workup threshold (no diabetes) | <55 mg/dL Whipple triad, Endocrine Society | ENDO-DM-05 |
| hypokalemia-mild | 3.0–3.5 mEq/L oral repletion | CV-ECG-01 |
| hypokalemia-severe | <2.5 mEq/L emergent IV repletion | CV-ECG-01 |
| hypomagnesemia threshold | <1.7 mg/dL lower limit of normal; PTH secretion/action impaired mainly <~1.2 mg/dL; replete Mg in refractory hypocalcemia | ENDO-THY-04 |
| hyponatremia correction limit (high ODS risk) | ≤ 8 mEq/L/24 h Na ≤105 mEq/L, alcohol use, malnutrition, hypokalemia, liver disease | ENDO-PIT-01 |
| hyponatremia correction limit (standard risk) | ≤ 10–12 mEq/L/24 h standard risk patients | ENDO-PIT-01 |
| hypotension threshold adult | <90 mmHg or >30% drop anaphylaxis criterion 3 | IMM-ANAPH-01 |
| hypotension threshold pediatric | <70 mmHg (1 mo–1y); <70+(2×age) mmHg (1–10y); <90 mmHg (11–17y) anaphylaxis criterion 3 | IMM-ANAPH-01 |
| hypothermia-mild | 32–35°C shivering, tachycardia | CV-ECG-01 |
| hypothermia-moderate | 28–32°C Osborn waves, AFib | CV-ECG-01 |
| hypothermia-severe | <28°C VF risk, fixed pupils | CV-ECG-01 |
| hypothermic resuscitation cutoff | ≥32°C minimum rewarming before stopping resuscitation | MULTI-ENV-01 |
| hypoxemia intubation threshold | SpO2 <88% persistent despite NIV | RESP-ARF-01 |
| I-PASS medical error reduction | 23% resident handoffs | SOC-QI-06 |
| I-PASS preventable adverse event reduction | 30% resident handoffs | SOC-QI-06 |
| I2-high-heterogeneity | ~75% substantial disagreement; random-effects model preferred | BIO-EBM-01 |
| I2-low-heterogeneity | ~25% studies largely agree | BIO-EBM-01 |
| I2-moderate-heterogeneity | ~50% moderate disagreement between studies | BIO-EBM-01 |
| I2-substantial-threshold | >50% generally considered substantial heterogeneity (Cochrane Handbook v6.4) | BIO-EBM-01 |
| IAH grade I | 12–15 mmHg intra-abdominal hypertension grading | PERIOP-COMPL-01 |
| IAH grade II | 16–20 mmHg intra-abdominal hypertension grading | PERIOP-COMPL-01 |
| IAH grade III | 21–25 mmHg intra-abdominal hypertension grading | PERIOP-COMPL-01 |
| IAH grade IV | >25 mmHg intra-abdominal hypertension grading | PERIOP-COMPL-01 |
| IAH range | ≥12 mmHg intra-abdominal hypertension; graded I–IV | PERIOP-COMPL-01 |
| IBD colon cancer surveillance start | 8 yr after symptom onset colitis extending beyond the rectum (left-sided or extensive) | GI-IBD-01 |
| IBD surveillance start | 8 years after diagnosis ulcerative colitis or Crohn colitis (PSC-associated: at PSC diagnosis, annual) | PREV-CRC-01 |
| ibuprofen benefit age range | 6–17 years slows lung decline | RESP-CF-01 |
| ICD wait post-MI | ≥40 days primary prevention | CV-HF-01 |
| ICD wait post-revascularization | ≥90 days primary prevention | CV-HF-01 |
| ice pack test duration | 2 min ptosis improvement test | NEURO-NM-01 |
| ICH BP target | ~140 mmHg (130–150) | NEURO-HEM-01 |
| ICP bile acid diagnostic threshold | ≥10 μmol/L most sensitive and specific test | GI-LIV-01 |
| ICP bile acid threshold | ≥10 μmol/L diagnostic | OB-MISC-01 |
| ICP delivery timing | 36 0/7 wk if bile acids ≥100; 36 0/7–39 0/7 wk if <100 μmol/L SMFM Consult Series | GI-LIV-01 |
| ICP delivery timing | 36 0/7 wk if bile acids ≥100; 36 0/7–39 0/7 wk if 40–99; 38 0/7–39 0/7 wk if <40 μmol/L SMFM Consult Series | OB-MISC-01 |
| ICP high-risk bile acids | ≥100 μmol/L deliver at 36 0/7 wk (34 0/7–36 0/7 wk only with prior ICP stillbirth or worsening hepatic dysfunction) | OB-MISC-01 |
| ICP target | <22 mmHg Brain Trauma Foundation | EM-TRAUMA-05 |
| ICP treatment threshold | >22 mmHg | NEURO-ICP-01 |
| ICU energy first week | 12–25 kcal/kg/day ASPEN 2022 | NUTR-SUPPORT-01 |
| ICU protein | 1.2–2.0 g/kg/day actual body weight | NUTR-SUPPORT-01 |
| IDC share of invasive breast cancer | 70–80% histologic subtype | REPRO-BRCA-01 |
| IgA deficiency prevalence in celiac disease | ~3% causes false-negative anti-tTG IgA | GI-CEL-01 |
| IgA nephropathy hematuria onset | 1–3 days after URI, normal C3 | IMM-SERO-01 |
| IgA vasculitis peak age | 3–10 years childhood vasculitis | IMM-VASC-01 |
| IgA vasculitis resolution | 4–6 weeks self-limited course | IMM-VASC-01 |
| IIH LP opening pressure | >25 cmH₂O diagnostic threshold | NEURO-ICP-01 |
| IIH opening pressure | >25 cm H2O LP diagnostic threshold | NEURO-HA-01 |
| ILC share of invasive breast cancer | ~15% histologic subtype | REPRO-BRCA-01 |
| ileal resection threshold for B12 | >60 cm lifelong B12 | NUTR-SUPPORT-01 |
| IM epinephrine dose adult | 0.3–0.5 mg 1:1,000 concentration, anterolateral thigh | IMM-ANAPH-02 |
| IM epinephrine dose pediatric | 0.01 mg/kg max 0.3–0.5 mg | IMM-ANAPH-02 |
| IM midazolam dose | 10 mg (>40 kg) or 5 mg (13–40 kg) single dose, no IV access | NEURO-SZ-02 |
| imaging delay for mechanical LBP | 4–6 weeks low back pain without red flags | MSK-SPINE-01 |
| implant typical-use failure | 0.05% etonogestrel implant | REPRO-CONTRA-01 |
| in-house call frequency | no more often than every 3rd night, averaged over 4 weeks ACGME | SOC-PROF-04 |
| incidentaloma malignancy size cutoff | > 4 cm independent risk factor | ENDO-ADR-04 |
| independent double-check | 2 qualified clinicians high-alert medications | SOC-QI-07 |
| indeterminate desmopressin response | 10–50% rise in urine osmolality partial central DI vs nephrogenic DI; needs hypertonic saline–stimulated copeptin | ENDO-PIT-01 |
| indomethacin cutoff | <32 wk PDA closure risk beyond | OB-PTL-01 |
| induction offered/considered | 41 0/7–41 6/7 wk antenatal surveillance | OB-PRE-01 |
| induction recommended | ≥42 0/7 wk (by 42 6/7 wk) post-term | OB-PRE-01 |
| infant head TBSA | 18% rule of 9s | EM-BURN-01 |
| infant vitamin D | 400 IU daily breastfed/partially breastfed from birth | NUTR-INF-01 |
| infant vitamin D | 400 IU/day breastfed infants from first days of life | NUTR-PREG-01 |
| infertility threshold | 12 mo (<35 y) or 6 mo (≥35 y) definition | REPRO-INFERT-01 |
| inflammatory back pain stiffness | >30 min morning stiffness | MSK-RHEUM-02 |
| inhibitor incidence severe hem A | 20–30% anti-factor VIII antibodies | HEME-COAG-02 |
| initial antivenom dose (pit viper) | 4–6 vials Fab, or 10 vials F(ab')2 infused over 60 min; redose until progression stops | EM-TOX-11 |
| initial fluid bolus (pancreatitis) | 10 mL/kg only if hypovolemic (WATERFALL trial goal-directed fluids) | GI-PANC-01 |
| initial fluid bolus (septic shock) | 30 mL/kg crystalloid septic shock resuscitation | EM-CRIT-01 |
| initial fluid bolus (septic shock) | 30 mL/kg crystalloid hypotension or lactate ≥4 mmol/L | CV-SHOCK-01 |
| initial PEEP | 5 cmH2O standard starting setting | RESP-VENT-01 |
| initial respiratory rate | 12–20/min standard starting setting | RESP-VENT-01 |
| initial rest after concussion | 24–48 h before starting return-to-activity protocol | NEURO-TBI-01 |
| initial symptomatic correction goal | 4–6 mEq/L rise in first hours stop seizures/AMS | RENAL-ELEC-02 |
| inpatient glucose target | 140–180 mg/dL ADA 2026 | NUTR-SUPPORT-01 |
| inpatient PID regimen | ceftriaxone 1 g IV + doxycycline + metronidazole alternative to IV cefoxitin + doxycycline, or clindamycin + gentamicin | MULTI-GU-01 |
| insulin infusion rate (adult) | 0.1 units/kg/h DKA | ENDO-DM-04 |
| insulin infusion rate (pediatric) | 0.05–0.1 units/kg/h pediatric DKA; ≥1h after IV fluids; check K first; no bolus | ENDO-DM-04 |
| insulin resistance prevalence | 50–70% PCOS | REPRO-PCOS-01 |
| insulin+dextrose onset | 15–30 min K+ shift into cells | RENAL-ELEC-01 |
| insulin-dextrose-onset | 15–30 min intracellular K+ shift | CV-ECG-01 |
| insulinoma fast duration | 72 h diagnostic gold standard | ENDO-DM-05 |
| intensive systolic target | <120 mm Hg high-risk non-diabetic patients | CV-HTN-01 |
| interarm SBP differential | >20 mmHg aortic dissection recognition | CV-AORTA-01 |
| interstitial cystitis symptom duration | ≥6 weeks bladder pain/pressure worsened by filling, with normal urinalysis/culture | REPRO-MISC-01 |
| Interval appendectomy timing | 6–8 wk | GI-APP-01 |
| intestinal adaptation | up to 2 years post-resection | NUTR-SUPPORT-01 |
| intra-abdominal hypertension | ≥12 mmHg grades I–IV, without organ dysfunction | EM-CRIT-03 |
| intraoperative PTH drop | ≥50% Miami criterion for successful excision | ENDO-THY-04 |
| intrinsic FeNa | >2% ATN | RENAL-AKI-01 |
| intubation FVC threshold | <20 mL/kg myasthenic/neuromuscular respiratory failure | NEURO-NM-01 |
| intubation FVC threshold | <20 mL/kg respiratory failure | NEURO-NM-02 |
| intubation MEP threshold | <40 cmH2O myasthenic/neuromuscular respiratory failure; part of 20-30-40 rule | NEURO-NM-01 |
| intubation NIF threshold | weaker than −30 cmH2O myasthenic/neuromuscular respiratory failure | NEURO-NM-01 |
| iodine delay after PTU | ≥ 1 hour thyroid storm treatment sequence | ENDO-THY-02 |
| iodine in pregnancy/lactation | 150 mcg daily supplement | NUTR-VIT-02 |
| iodine supplement | 150 mcg/day pregnancy and lactation (RDA 220 mcg pregnancy, 290 mcg lactation) | NUTR-PREG-01 |
| IPF PFT pattern | restrictive with low DLCO HRCT shows UIP pattern | RESP-ILD-01 |
| IPV screening population | all women of reproductive age USPSTF Grade B | PREV-SAFE-01 |
| iron deficiency anemia — cow’s milk threshold | >24 oz/day risk factor for toddler iron deficiency anemia | PEDS-HEME-01 |
| iron for breastfed preterm infant | 2 mg/kg/day from 1 to 12 months AAP | NUTR-INF-01 |
| iron for breastfed term infant | 1 mg/kg/day from 4 months until iron-rich foods | NUTR-INF-01 |
| iron overload screen | transferrin saturation >45% then HFE genotype | NUTR-VIT-02 |
| iron RDA in pregnancy | 27 mg/day anemia Hb <11 g/dL (T1/T3), <10.5 g/dL (T2) | NUTR-PREG-01 |
| iron repletion trigger | HD: TSAT ≤30% + ferritin ≤500; non-HD: ferritin <100, or 100–299 + TSAT <25% before ESA | RENAL-CKD-01 |
| IRT screening cutoff | 95th–99th percentile (~60–75 ng/mL) newborn screening positive threshold | RESP-CF-01 |
| isolation discontinuation | 3 negative AFB smears 8–24h apart airborne precautions | RESP-TB-01 |
| isotretinoin-contraception | 2 forms iPLEDGE | OB-MED-01 |
| ITP second-line therapy threshold | ≥3 months steroid-dependent or unresponsive → TPO-receptor agonist or rituximab | HEME-PLT-01 |
| ITP splenectomy timing | ≥12 months from diagnosis deferred even in refractory disease | HEME-PLT-01 |
| IUD removal threshold in PID | 48–72 h no improvement on antibiotics | REPRO-VAGIN-01 |
| IV calcium gluconate dose | 1–2 g (10–20 mL of 10% solution) IV over 10–20 min symptomatic post-thyroidectomy hypocalcemia | ENDO-THY-04 |
| IV epinephrine dose cardiac arrest | 1 mg (0.1 mg/mL) cardiac arrest only | IMM-ANAPH-02 |
| IV epinephrine infusion rate | 1–10 mcg/min titrated, IM-refractory anaphylaxis | IMM-ANAPH-02 |
| IV magnesium dose for TdP | 2 g IV push first-line regardless of serum Mg level | CV-ARR-04 |
| IV magnesium sulfate (adult) | 2 g over 20 min severe or refractory exacerbation | RESP-ASTHMA-01 |
| IV methylprednisolone | 1 g/day × 3–5 days acute MS relapse | NEURO-DEMY-01 |
| IV thiamine dose | 500 mg IV TID × 3–5 days Wernicke encephalopathy, then oral | NEURO-TOX-01 |
| IV vitamin K dose | 10 mg major bleeding on warfarin | HEME-COAG-01 |
| iv-kcl-rate-central | ≤40 mEq/h central line with monitoring | CV-ECG-01 |
| iv-kcl-rate-peripheral | ≤10–20 mEq/h peripheral line | CV-ECG-01 |
| IVC plethora | >2.1 cm, <50% respiratory collapse elevated right-sided pressures on echo | CV-PERI-01 |
| IVIG dose (GBS) | 0.4 g/kg/day × 5 days GBS treatment | NEURO-NM-02 |
| IVIG dose (Kawasaki disease) | 2 g/kg single infusion, within 10 days of fever onset | CV-PEDS-01 |
| IVIG dose (Kawasaki disease) | 2 g/kg single infusion over 10–12 h for Kawasaki disease | PEDS-FEV-01 |
| IVIG/aspirin window | within 10 days of fever onset, to reduce coronary aneurysm risk | SKIN-PEDS-01 |
| Jarisch-Herxheimer onset | within 24 h of treatment fever/myalgia, supportive care | REPRO-VAGIN-01 |
| JIA age | <16 years definition | MSK-PEDS-01 |
| JIA duration | ≥6 weeks definition | MSK-PEDS-01 |
| joint replacement bundled episode | 30–90 days CJR used 90 days (ended 2024); CMS TEAM model (2026) uses 30-day post-discharge episodes | SOC-QI-11 |
| juice limit age 1–3 years | ≤4 oz/day AAP 2017; none <12 months | NUTR-INF-01 |
| kappa 0.21–0.40 | 0.21–0.40 fair agreement | BIO-VALID-01 |
| kappa 0.41–0.60 | 0.41–0.60 moderate agreement | BIO-VALID-01 |
| kappa 0.61–0.80 | 0.61–0.80 substantial agreement | BIO-VALID-01 |
| kappa 0.81–1.00 | 0.81–1.00 almost perfect agreement | BIO-VALID-01 |
| kappa 0–0.20 | 0–0.20 slight agreement | BIO-VALID-01 |
| kappa <0 | <0 poor agreement | BIO-VALID-01 |
| Kasai portoenterostomy window | <8 weeks of age | GI-PEDS-01 |
| Kasai procedure window | <60 days biliary atresia — best outcome; results worse after 90 days | PEDS-NB-01 |
| Kawasaki fever duration | ≥5 days plus ≥4 of five criteria | IMM-VASC-01 |
| Kawasaki fever duration | ≥5 days plus ≥4 of 5 CRASH criteria | SKIN-PEDS-01 |
| Kawasaki fever duration for diagnosis | ≥5 days plus ≥4 of 5 criteria | CV-PEDS-01 |
| Kawasaki IVIG window | within 10 days of fever onset reduces coronary artery aneurysm risk | IMM-VASC-01 |
| keloid excision recurrence without adjuvant therapy | 50–80% excision alone | SKIN-WOUND-01 |
| kocher-criteria-count | ≥3 of 4 >90% probability of pediatric hip septic arthritis | MSK-INF-01 |
| L-glutamine approval age | ≥5 years Endari | HEME-SICK-01 |
| Lachman flexion angle | 20–30° most sensitive ACL test | MSK-JOINT-01 |
| lactation extra calories | ~330 kcal/day (0–6 mo); ~400 kcal/day (6–12 mo) IOM | NUTR-PREG-01 |
| lactulose target | 2–3 soft bowel movements/day hepatic encephalopathy first-line therapy | GI-CIRR-02 |
| lamotrigine-level-drop | up to 50% increased clearance in pregnancy | OB-MED-01 |
| large-core ASPECTS | 3–5 may still benefit from thrombectomy | NEURO-STROKE-02 |
| late latent syphilis | benzathine PCN G 2.4 MU IM weekly ×3 total 7.2 MU | MULTI-GU-01 |
| late VKDB window | 2 weeks–6 months (mostly 2–8 weeks) breastfed infants without prophylaxis | NUTR-VIT-02 |
| latent TB regimens | 3HP ×12wk, 4R ×4mo, or 3HR ×3mo preferred over INH ×9mo | MULTI-TB-01 |
| latent-phase-limit-multipara | No fixed arrest cutoff reassuring prolonged latent phase alone does not justify cesarean | OB-LD-01 |
| latent-phase-limit-nullipara | No fixed arrest cutoff reassuring prolonged latent phase alone does not justify cesarean | OB-LD-01 |
| LCP age range | 4–10 years Legg-Calvé-Perthes | MSK-PEDS-02 |
| LDCT age range | 50–80 USPSTF 2021 | PREV-LUNG-01 |
| LDCT screening age | 50–80 years USPSTF 2021 | RESP-ONC-01 |
| LDCT screening pack-years | ≥20 pack-years current smoker or quit ≤15 y | RESP-ONC-01 |
| LDL-C add-on threshold | ≥70 mg/dL despite maximally tolerated statin after ACS → ezetimibe and/or PCSK9 inhibitor | CV-ACS-02 |
| ldl-target-ascvd | <70 mg/dL secondary prevention | CV-PREV-01 |
| ldl-target-veryhighrisk | <55 mg/dL recurrent ASCVD events | CV-PREV-01 |
| lead reference value | ≥3.5 µg/dL triggers venous confirmation + exposure history | PEDS-HEME-01 |
| leak warning HR | >120/min earliest sign after bariatric surgery | NUTR-OBES-01 |
| LEMS re-screening interval | every 3–6 months for 2 years no tumor found on initial workup | RESP-ONC-01 |
| levetiracetam dose (SE) | 60 mg/kg IV status epilepticus second-line | NEURO-SZ-01 |
| levetiracetam dose (SE) | 60 mg/kg IV established status epilepticus | NEURO-SZ-02 |
| levonorgestrel EC window | ≤72 h (best) oral emergency contraception; less effective BMI ≥30 | REPRO-CONTRA-01 |
| levonorgestrel emergency contraception | best ≤72 h; up to 120 h after unprotected intercourse | SOC-LAW-01 |
| levonorgestrel IUD duration | 8 yr (Mirena/Liletta 52-mg); 5 yr (Kyleena); 3 yr (Skyla) FDA-approved contraceptive duration (Mirena HMB: 5 yr) | REPRO-CONTRA-01 |
| levothyroxine-dose-increase | ~25–30% on confirming pregnancy | OB-MED-01 |
| levothyroxine-dose-increase | ~25–30% known hypothyroidism, immediately upon confirmed pregnancy | OB-MISC-01 |
| LGV treatment | doxycycline 100 mg BID ×21 d CDC 2021 | REPRO-VAGIN-01 |
| liberation FiO2/PEEP | FiO2 ≤40%, PEEP ≤8 cmH2O readiness for SBT | RESP-VENT-02 |
| lichen sclerosus vulvar cancer risk | 4–5% lifetime differentiated VIN progression | REPRO-MISC-01 |
| lidocaine max dose | 4.5 mg/kg (7 mg/kg with epinephrine) local anesthetic maximum dosing | EM-TOX-11 |
| life expectancy cutoff | <10 years stop cancer screening | PREV-PRIN-02 |
| light sedation target | RASS 0 to −2 ICU sedation | EM-CRIT-01 |
| Lille score threshold for stopping steroids | ≥0.45 at day 7 predicts steroid nonresponse | GI-LIV-01 |
| LIMA-to-LAD graft patency | >90% at 10 years | CV-CAD-01 |
| lipid emulsion bolus dose | 1.5 mL/kg IV (20% solution) LAST | PERIOP-OTHER-01 |
| lithium therapeutic range (acute mania) | 0.8–1.2 mEq/L acute mania dosing | PSY-MOOD-04 |
| lithium therapeutic range (maintenance) | 0.6–0.8 mEq/L (up to 1.0 if needed) maintenance dosing | PSY-MOOD-04 |
| lithium toxicity threshold | >1.5 mEq/L symptomatic toxicity | PSY-MOOD-04 |
| LMWH prophylactic hold before neuraxial block | ≥12h ASRA guideline | PERIOP-COAG-01 |
| LMWH resume after catheter removal | ≥4h ASRA guideline | PERIOP-COAG-01 |
| LMWH therapeutic hold before neuraxial block | ≥24h ASRA guideline | PERIOP-COAG-01 |
| LNG-EC BMI cutoff | ≥30 kg/m² reduced levonorgestrel efficacy | REPRO-CONTRA-02 |
| LNG-EC window | ≤72 h (reduced efficacy to 120 h) levonorgestrel emergency contraception | REPRO-CONTRA-02 |
| LNG-IUD EC window | ≤5 days 52-mg LNG-IUD as emergency contraception | REPRO-CONTRA-01 |
| LNG-IUD EC window | ≤5 days off-label EC option | REPRO-CONTRA-02 |
| long-term O2 criteria | PaO2 ≤55 mmHg or SpO2 ≤88% resting, or PaO2 56–59 mmHg with cor pulmonale/polycythemia/pulmonary HTN | RESP-COPD-01 |
| long-term O2 duration | ≥15 hr/day COPD | RESP-COPD-01 |
| lorazepam challenge dose | 1–2 mg IV catatonia diagnostic test | PSY-EMERG-01 |
| lorazepam dose | 0.1 mg/kg IV (max 4 mg) status epilepticus first-line | NEURO-SZ-01 |
| lorazepam dose | 0.1 mg/kg IV (max 4 mg) first-line benzodiazepine | NEURO-SZ-02 |
| lorazepam maintenance for catatonia | 6–24 mg/day may be required | PSY-EMERG-01 |
| low grip strength | <27 kg men; <16 kg women EWGSOP2 sarcopenia | NUTR-ASSESS-01 |
| low-dose aspirin after Kawasaki | 3–5 mg/kg/day until 4–6-week echo shows no coronary changes | CV-PEDS-01 |
| low-FODMAP elimination | 2–6 weeks then reintroduction | NUTR-MNT-02 |
| low-lying-placenta-followup | ~32 wk (36 wk if still low-lying) repeat transvaginal ultrasound after 18–22 wk anatomy scan | OB-HEM-01 |
| low-mercury fish | 8–12 oz/week 2–3 servings; avoid high-mercury species | NUTR-PREG-01 |
| LR potassium content | 4 mEq/L clinically negligible K+ load in most patients; reserve normal saline if hyperkalemia is severe | RENAL-RHAB-01 |
| LR-negative-strong-rule-out | <0.1 likelihood ratio negative; strong evidence to rule out disease | BIO-TEST-02 |
| LR-positive-strong-rule-in | >10 likelihood ratio positive; strong evidence to rule in disease | BIO-TEST-02 |
| LRINEC risk cutoffs | ≥6 intermediate; ≥8 high CRP, WBC, hemoglobin, sodium, creatinine, glucose | MULTI-SSTI-01 |
| LRINEC threshold | ≥6 supports diagnosis; a low score does not exclude it | SKIN-INF-03 |
| lung abscess treatment duration | 4–6 weeks clindamycin or amoxicillin-clavulanate | RESP-PNA-01 |
| lung cancer LDCT criteria | ≥20 pack-years ages 50–80, current or quit ≤15y | BIO-SCREEN-01 |
| lung LDCT stop age | 80 lung cancer screening | PREV-PRIN-02 |
| lupus nephritis prevalence | ~50% of SLE patients | IMM-SLE-01 |
| LVP albumin replacement | 6–8 g/L removed if > 5 L | GI-CIRR-01 |
| Lynch colonoscopy interval | q1–2yr from age 20–25 | GI-COLON-01 |
| Lynch syndrome start age | 20–25 or 2–5 y before youngest affected relative (if diagnosed <25) | PREV-CRC-01 |
| MAC prophylaxis threshold | CD4 <50 weekly azithromycin only if ART deferred/viremic | MULTI-HIV-01 |
| macroalbuminuria | > 300 mg/g UACR | ENDO-DM-06 |
| macule/papule size cutoff | 1 cm primary lesion classification | SKIN-MORPH-01 |
| Maddrey discriminant function severe threshold | ≥32 alcoholic hepatitis severity cutoff for steroid treatment | GI-LIV-01 |
| magnesium neuroprotection cutoff | <32 wk | OB-PTL-01 |
| magnesium-loading-dose | 4–6 g IV over 20–30 min seizure prophylaxis | OB-HTN-01 |
| magnesium-maintenance | 1–2 g/hr infusion | OB-HTN-01 |
| magnesium-toxicity-hold | RR <12/min or UOP <30 mL/hr hold infusion | OB-HTN-01 |
| maintenance fluid formula | 100/50/20 mL/kg/day Holliday-Segar method by 10-kg weight tier | PEDS-RENAL-01 |
| maintenance fluid rate (pancreatitis) | ~1.5 mL/kg/h reassess frequently to avoid overload | GI-PANC-01 |
| maintenance fluid rate (pediatric, Holliday-Segar) | 4-2-1 rule 4 mL/kg/h first 10kg + 2 mL/kg/h next 10kg + 1 mL/kg/h beyond 20kg | MULTI-FE-01 |
| major-surgery stress-dose hydrocortisone | 100 mg IV at induction, then 50 mg IV q6h (or 200 mg/24h infusion) × 24–48h, then taper chronic steroid users, major surgery | PERIOP-MED-01 |
| malignant otitis externa antibiotic duration | 6–8 weeks IV anti-pseudomonal therapy | NEURO-ENT-01 |
| malignant transformation (complete mole) | 15–20% complete mole | OB-GTD-01 |
| malignant transformation (partial mole) | <5% partial mole | OB-GTD-01 |
| mammography interval | q2y ages 40–74 | BIO-SCREEN-01 |
| mammography interval | q2y average risk, ages 40–74 | PREV-BRCA-01 |
| mammography screening age | 40–74 breast cancer screening; Grade I beyond 75 | PREV-PRIN-02 |
| mammography start age | 40 USPSTF 2024, average risk, Grade B | PREV-BRCA-01 |
| mannitol dose | 0.25–1 g/kg IV osmotherapy for raised ICP | EM-TRAUMA-05 |
| mannitol dose | 0.25–1 g/kg IV bolus (1 g/kg common for herniation) | NEURO-ICP-01 |
| MAOI-SSRI washout | 2 wk (5 wk after stopping fluoxetine) switching antidepressant classes | PSY-EMERG-02 |
| MAP reduction | ≤25% first hour of emergency treatment | CV-HTN-02 |
| MAP target | ≥65 mmHg septic shock | EM-CRIT-01 |
| MAP target | ≥65 mmHg septic and other shock resuscitation | CV-SHOCK-01 |
| MAP target | ≥65 mmHg septic shock resuscitation | MULTI-SEP-01 |
| Marjolin ulcer latency | decades (mean ~30 yr) chronic wound or burn to SCC | SKIN-CA-02 |
| MASCC low-risk score | ≥21 candidate for outpatient oral antibiotics | HEME-ONC-01 |
| MASLD weight loss | ≥5% steatosis; 7–10% MASH; ≥10% fibrosis AASLD 2023 | NUTR-MNT-01 |
| massive hemoptysis volume | >200–300 mL/24h or any amount causing hemodynamic instability or respiratory failure | RESP-HEMO-01 |
| massive PE definition | SBP <90 mmHg ≥15 min or cardiac arrest/vasopressor requirement | RESP-PE-01 |
| massive-transfusion-ratio | ~1:1:1 RBC:plasma:platelets | OB-PPH-01 |
| mastitis antibiotic trigger | no improvement after 12–24 h of conservative care ABM 2022 | NUTR-INF-01 |
| maternal cardiac arrest perimortem cesarean threshold | 4 min no ROSC → incise; deliver by 5 min (prep at arrest) | OB-EMER-01 |
| maternal HBV DNA threshold for antiviral prophylaxis | >200,000 IU/mL give tenofovir 28–32 weeks gestation | GI-HEP-01 |
| max fluid per thoracentesis | 1–1.5 L prevents re-expansion pulmonary edema | RESP-PLEFF-01 |
| maximum HRRP penalty | 3% of Medicare base payments excess readmissions | SOC-QI-09 |
| maximum HRRP penalty | 3% of Medicare base payments excess readmissions | SOC-QI-11 |
| maximum prophylactic antibiotic duration | no doses after wound closure clean and clean-contaminated cases (CDC 2017); never >24 h | SOC-QI-08 |
| maximum respiratory rate ARDS | 35/min to maintain minute ventilation with low tidal volume | RESP-VENT-01 |
| maximum tensile strength | ≤80% remodeling phase; never reaches baseline | SKIN-WOUND-01 |
| MCD steroid response | >90% children age 1–10 | RENAL-GN-01 |
| MCDA surveillance interval | q2wk growth ultrasound | OB-MISC-01 |
| mcda-delivery-timing | 34 0/7–37 6/7 wk uncomplicated | OB-MISC-01 |
| MCV macrocytic cutoff | >100 fL anemia classification | HEME-ANEM-01 |
| MCV microcytic cutoff | <80 fL anemia classification | HEME-ANEM-01 |
| MDS-to-AML blast threshold | ≥20% transformation | HEME-MPN-01 |
| measles vitamin A dose | 200,000 IU (≥12 mo); 100,000 IU (6–11 mo); 50,000 IU (<6 mo) daily x 2 days | NUTR-VIT-02 |
| Meckel diverticulum rule of 2s | 2% / 2 ft / 2 in / age 2 painless rectal bleeding in a child | PEDS-SURG-01 |
| Medicare eligibility age | ≥65 years or ESRD, ALS, or disability | SOC-QI-11 |
| Medicare Part B coinsurance | 20% after deductible | SOC-QI-11 |
| Medicare skilled nursing facility qualifying stay | ≥3 inpatient midnights observation days excluded | SOC-QI-09 |
| Medicare skilled nursing limit | ≤100 days per benefit period | SOC-QI-11 |
| medication overuse threshold (NSAID) | ≥15 days/month medication overuse headache | NEURO-HA-01 |
| medication overuse threshold (triptan/opioid) | ≥10 days/month medication overuse headache | NEURO-HA-01 |
| MEN2 pheochromocytoma penetrance | up to ~50% highest with RET codon 634 and MEN2B | ENDO-ONC-01 |
| MEN2A MTC penetrance | ~100% virtually all MEN2A patients develop MTC | ENDO-ONC-01 |
| MEN2A prophylactic thyroidectomy | at or before age 5 high-risk RET codon 634, guided by calcitonin | ENDO-ONC-01 |
| MEN2B prophylactic thyroidectomy | within the first year of life highest-risk RET codon (M918T) | ENDO-ONC-01 |
| meningococcal prophylaxis window | within 24h close contacts of confirmed case | MULTI-MEN-01 |
| Mentzer index IDA | >13 MCV/RBC ratio | HEME-ANEM-02 |
| Mentzer index thalassemia | <13 MCV/RBC ratio | HEME-ANEM-02 |
| metabolic alkalosis compensation | PaCO2 = 0.7×HCO3 + 21 ± 2 metabolic alkalosis | RENAL-ABG-01 |
| metabolic monitoring on SGAs | glucose/A1c and lipids baseline, 12 wk, then annually; weight at 4, 8, 12 wk, then quarterly APA 2020 | PSY-PSYC-02 |
| metabolic surgery BMI | ≥35 kg/m² (≥32.5 Asian); option at ≥30 (≥27.5 Asian) with T2DM indication | ENDO-DM-02 |
| metastatic TNBC pembrolizumab eligibility | PD-L1 CPS ≥10 chemo-immunotherapy addition | REPRO-BRCA-01 |
| metformin B12 monitoring | periodic; esp. ≥4 years or neuropathy ADA 2026 | NUTR-VIT-01 |
| metformin contrast hold | at iodinated contrast → recheck creatinine; restart 48 h after if stable eGFR <30, AKI (any eGFR), or arterial catheter study with possible renal emboli | ENDO-DM-02 |
| metformin eGFR contraindication | <30 mL/min/1.73m² hold metformin | ENDO-DM-02 |
| metformin hold | 48h if eGFR <30 or AKI (ACR); eGFR 30–60 or intra-arterial (FDA) lactic acidosis risk | RENAL-AKI-02 |
| metformin prediabetes threshold | BMI ≥35 kg/m² age <60 y or prior GDM | ENDO-DM-01 |
| methacholine contraindication | FEV1 <60% predicted (or <1.5 L) bronchospasm risk | RESP-PFT-01 |
| methacholine positive | FEV1 drop ≥20% at PC20 ≤8 mg/mL (PD20 ≤400 µg) | RESP-PFT-01 |
| methemoglobinemia treatment threshold | >20% if symptomatic; >30% even if asymptomatic MetHb level triggering methylene blue; avoid in G6PD deficiency | RESP-DYSP-01 |
| methotrexate conception avoidance | ≥3 mo after treatment (teratogen) | OB-ECT-01 |
| methotrexate dose (ectopic pregnancy) | 50 mg/m² IM single-dose protocol | OB-ECT-01 |
| methotrexate dose (rheumatoid arthritis) | 15–25 mg weekly never dosed daily | IMM-RA-01 |
| methotrexate mass size limit | <3.5–4 cm relative contraindication as size approaches upper range | OB-ECT-01 |
| methotrexate β-hCG ceiling | <5000 mIU/mL ideal for eligibility | OB-ECT-01 |
| methotrexate-washout | ≥3 months stop before conception | OB-MED-01 |
| methylene blue dose | 1–2 mg/kg IV methemoglobinemia | EM-TOX-02 |
| methylergonovine dose | 0.2 mg IM second-line uterotonic for atony; contraindicated in hypertension/preeclampsia | OB-EMER-01 |
| Metoclopramide maximum duration | ≤ 12 wk | GI-GAST-01 |
| MgSO4 loading dose | 4–6 g IV over 15–20 min seizure prophylaxis | CV-PREG-01 |
| MgSO4 maintenance | 1–2 g/h seizure prophylaxis infusion | CV-PREG-01 |
| MGUS progression rate | ~1%/year to multiple myeloma | HEME-MISC-01 |
| MH dantrolene dose | 2.5 mg/kg IV, up to 10 mg/kg repeat until symptoms resolve | MULTI-HYPER-01 |
| microalbuminuria | 30–300 mg/g UACR | ENDO-DM-06 |
| midluteal progesterone | >3 ng/mL confirms ovulation | REPRO-INFERT-01 |
| mifepristone-dose | 200 mg PO missed abortion, given before misoprostol | OB-SAB-01 |
| migraine duration | 4–72 h untreated attack | NEURO-HA-01 |
| Milan criteria | single tumor ≤5 cm, or up to 3 tumors each ≤3 cm, no vascular invasion, no extrahepatic spread | GI-CIRR-01 |
| Milan criteria | single tumor ≤5 cm, or up to 3 tumors each ≤3 cm, no vascular invasion, no extrahepatic spread liver transplant eligibility | GI-LIV-02 |
| mild IPSS | <8 BPH watchful waiting | RENAL-LUTS-01 |
| mild TBI LOC | <30 min GCS 13–15, PTA <24 h | NEURO-TBI-01 |
| minimum ETT size | ≥8.0 mm large-bore tube for suctioning in massive hemoptysis | RESP-HEMO-01 |
| minimum IRB members | 5 ≥1 scientist, ≥1 nonscientist, ≥1 unaffiliated | SOC-RES-02 |
| minimum tidal volume | 4 mL/kg IBW permissive hypercapnia floor when plateau pressure remains high | RESP-VENT-01 |
| MIPS payment adjustment | up to ±9% Medicare Part B | SOC-QI-11 |
| misoprostol-dose | 800 mcg vaginal 24 h after mifepristone | OB-SAB-01 |
| mitral valve area for balloon valvuloplasty | ≤1.5 cm² symptomatic severe MS, pliable leaflets, no LA thrombus | CV-VALV-02 |
| mixing study interpretation | correction = deficiency no correction = inhibitor; incubate 1–2 h to unmask a time-dependent FVIII inhibitor | HEME-COAG-02 |
| MMA borderline B12 range | 200–300 pg/mL check MMA when B12 falls in this range | HEME-ANEM-01 |
| MME reassessment threshold | ≥50 MME/day reassess carefully before increasing; offer naloxone if overdose risk is elevated | PSY-SUD-03 |
| MMF induction dose | 2–3 g/day Class III/IV lupus nephritis | IMM-SLE-01 |
| moderate HTN threshold | 140-159/90-99 mmHg Category 3, combined hormonal contraceptives | REPRO-CONTRA-02 |
| moderate IPSS | 8–19 BPH alpha-blocker | RENAL-LUTS-01 |
| moderate variability | 6–25 bpm | OB-FHR-01 |
| moderate-surgery stress-dose hydrocortisone | 50 mg IV, then 25 mg IV q8h × 24h chronic steroid users, moderate surgery | PERIOP-MED-01 |
| morbilliform onset | 7–14 days first exposure; 1–3 days on re-exposure | SKIN-DRUG-01 |
| morning cortisol diagnostic | <3 mcg/dL adrenal insufficiency | ENDO-ADR-01 |
| MSLT sleep latency | ≤8 min | NEURO-MISC-01 |
| MSLT sleep latency cutoff | ≤8 min plus ≥2 SOREMPs — both required | PSY-SLEEP-01 |
| MTP activation | ≥10 units/24 h or ≥4 units/1 h massive transfusion protocol | HEME-TRANS-02 |
| MTP ratio | 1:1:1 pRBC:FFP:platelets | EM-TRAUMA-02 |
| MTX-monitoring-interval | 2–4 wk initially → 12 wk maintenance CBC, LFTs, creatinine | MSK-RHEUM-01 |
| MTX-preconception-washout | 1–3 months stop before conception | MSK-RHEUM-01 |
| MTX-start-window | within 3 months of RA diagnosis | MSK-RHEUM-01 |
| multilevel epidural abscess involvement | 15–30% spinal epidural abscess | MSK-SPINE-01 |
| myeloma marrow plasma cell threshold | ≥10% diagnostic criterion | HEME-MISC-01 |
| myoglobinuria RBC/HPF | 0–4/HPF dipstick-microscopy discordance | RENAL-RHAB-01 |
| myxedema coma temperature | < 95°F (35°C) diagnostic feature | ENDO-THY-03 |
| NAC window most effective | ≤8 h post-ingestion N-acetylcysteine | EM-TOX-03 |
| naloxone co-prescribe threshold | ≥50 MME/day opioid overdose risk factor | EM-TOX-06 |
| naloxone dose | 0.4–2 mg IV/IM/IN, repeat q2–3 min opioid overdose | EM-TOX-06 |
| naloxone half-life | 30–90 min shorter than most opioids | EM-TOX-06 |
| naltrexone opioid-free window | 7–10 days precipitated withdrawal prevention | PSY-SUD-02 |
| narcolepsy CSF hypocretin cutoff | ≤110 pg/mL type 1 narcolepsy | NEURO-MISC-01 |
| necrotizing fasciitis mortality | 20–40% even with prompt surgical treatment | MULTI-SSTI-01 |
| needle decompression site | 4th–5th ICS, anterior midaxillary line (adults); 2nd ICS midclavicular line (children) tension pneumothorax | EM-TRAUMA-01 |
| needle decompression site | 4th–5th ICS, anterior midaxillary line (adults); 2nd ICS midclavicular line (children) tension pneumothorax | EM-TRAUMA-04 |
| needle decompression site | 4th–5th ICS, anterior midaxillary line (adults); 2nd ICS midclavicular line (children) tension pneumothorax | RESP-PTX-01 |
| neonatal fever threshold | ≥38.0°C rectal age ≤21 days triggers full workup; 22–28 days risk-stratified | MULTI-FEVER-01 |
| neonatal glucose screening | 30–60 min of life infants of diabetic mothers | ENDO-DM-03 |
| neonatal HBIG/vaccine window | ≤12 h of birth infants of HBsAg-positive mothers | GI-HEP-01 |
| neonatal HSV duration | 14 days (SEM) or 21 days (CNS/disseminated) IV acyclovir | MULTI-CONG-01 |
| neonatal hypoglycemia escalation (4–24h) | <35 mg/dL IV D10W if persists despite feeding | ENDO-DM-03 |
| neonatal hypoglycemia escalation (birth–4h) | <25 mg/dL IV D10W if persists despite feeding | ENDO-DM-03 |
| neostigmine threshold | cecum >12 cm or no improvement in 24–48 h | GI-OBST-01 |
| nephrogenic DI desmopressin response | < 10% rise in urine osmolality no renal response to ADH | ENDO-PIT-01 |
| nephrology referral eGFR | <30 mL/min/1.73m² (G4–G5) referral trigger | RENAL-CKD-01 |
| nephrology referral UACR | ≥300 mg/g (A3) referral trigger | RENAL-CKD-01 |
| nephropathy target BP | < 130/80 mmHg diabetic nephropathy | ENDO-DM-06 |
| nephrotic proteinuria | >3.5 g/day or UPCR >3–3.5 g/g adult | RENAL-GN-01 |
| neuromuscular blockade duration | ≤48 h cisatracurium infusion in severe ARDS with persistent dyssynchrony | RESP-VENT-01 |
| neuromuscular blockade duration | ≤48 h cisatracurium | RESP-ARDS-01 |
| neuroprognostication wait | ≥72 h after return to normothermia | CV-ARREST-01 |
| newborn vitamin K | 1 mg IM once within 6 h of birth; 0.3–0.5 mg/kg if ≤1,500 g | NUTR-VIT-02 |
| newborn weight loss evaluation | >10% of birth weight first week | NUTR-INF-01 |
| NG vs PEG cutoff | 4–6 weeks expected duration of enteral need | NUTR-SUPPORT-01 |
| NIF failure threshold | weaker than −30 cmH2O neuromuscular respiratory failure; elective intubation | RESP-ARF-01 |
| NIF intubation threshold | weaker than −30 cmH₂O weakening inspiratory force | NEURO-NM-02 |
| nimodipine course | 21 days | NEURO-HEM-01 |
| nirsevimab eligibility | <8 months entering first RSV season | RESP-BRO-01 |
| NIV ABG recheck | 1–2 hours after starting NIV; failure to improve pH/PaCO2 → intubate | RESP-ARF-01 |
| NIV absolute contraindication | GCS <8 inability to protect airway | RESP-ARF-01 |
| NMS antipsychotic rechallenge | ≥2 wk after resolution choose low-potency/atypical agent, low dose, slow titration, avoid depot forms | PSY-EMERG-02 |
| NMS CK elevation | often >1000 rhabdomyolysis marker | PSY-EMERG-02 |
| NNS mammography | ~1,000–2,000 to prevent 1 breast-cancer death (~10-y trials); varies by age (≈1,900 at 40s, ≈1,300 at 50s, ≈400 at 60s) | PREV-PRIN-01 |
| noise exposure threshold | ≥85 dB over 8 h noise-induced hearing loss risk; OSHA action level (TWA ≥85 dBA) | PREV-OCC-01 |
| noise-induced hearing loss notch | 4000 Hz | NEURO-ENT-02 |
| non-severe/severe CDI duration | 10 days oral fidaxomicin or vancomycin | MULTI-GI-01 |
| nonreactive-extension | 40 min before further testing | OB-SURV-01 |
| nonviable-crl | ≥7 mm no cardiac activity | OB-SAB-01 |
| nonviable-msd | ≥25 mm no embryo | OB-SAB-01 |
| normal anion gap | 8–12 mEq/L anion gap | RENAL-ABG-01 |
| normal BP | <120/80 mm Hg 2025 AHA/ACC | CV-HTN-01 |
| normal FHR baseline | 110–160 bpm | OB-FHR-01 |
| normal growth velocity age 3–12 | 5–7 cm/yr below 5 cm/yr suggests growth hormone deficiency or other pathology | PEDS-GROW-01 |
| normal IUP β-hCG rise | ≥35% over 48 h | OB-ECT-01 |
| normal osmolal gap | ≤10 above this suggests toxic alcohol | PSY-SUD-01 |
| NOWS onset heroin | 24–72 h neonatal withdrawal onset | PSY-SUD-02 |
| NOWS onset methadone | up to 5–7 d longer half-life delays onset | PSY-SUD-02 |
| NPH diagnostic LP volume | 30–50 mL large-volume lumbar puncture | NEURO-EXAM-01 |
| NPH diagnostic LP volume | 30–50 mL | NEURO-ICP-01 |
| NPH tap-test volume | 30–50 mL CSF removed for gait assessment | NEURO-DEM-01 |
| NSAID avoidance in pregnancy | ≥20 weeks oligohydramnios and ductus closure risk | NEURO-HA-01 |
| NSAID-avoid-window | ≥20 wk oligohydramnios risk | OB-MED-01 |
| NSAID-ductus-risk-window | ≥30 wk premature ductus arteriosus closure | OB-MED-01 |
| NSBB titration | propranolol/nadolol to HR 55–60/min, SBP >90 mmHg carvedilol fixed 6.25 mg daily → twice daily (max 12.5 mg/day) | GI-BLEED-02 |
| NT-proBNP exclusion cutoff | <300 pg/mL excludes acute HF | RESP-DYSP-01 |
| Oakland score low-risk (LGIB) | ≤ 8 safe for outpatient colonoscopy | GI-BLEED-01 |
| obese ICU protein | 2.0 g/kg IBW (BMI 30–40); up to 2.5 g/kg IBW (BMI ≥40) hypocaloric high-protein | NUTR-SUPPORT-01 |
| obesity pharmacotherapy BMI | ≥30 kg/m² (≥27 + comorbidity) indication | ENDO-DM-02 |
| observation after cardiac arrest | ≥24 h before brain death evaluation (from arrest, or from rewarming if hypothermia was used) | SOC-EOL-07 |
| observation duration extended | ≥6 h or admit severe reaction or >1 epinephrine dose | IMM-ANAPH-02 |
| observation duration minimum | ~1 h non-severe reaction, single epinephrine dose, prompt response | IMM-ANAPH-02 |
| obstructive FEV1/FVC | <0.70 post-bronchodilator | RESP-PFT-01 |
| OCD SSRI trial length | 8–12 wk adequate trial before switching; longer than MDD’s 4–6 wk | PSY-ANX-01 |
| OCP risk reduction | 40–50% ovarian cancer protective effect | REPRO-OVCA-01 |
| OGTT 1-h | ≥180 mg/dL Carpenter-Coustan | OB-GDM-01 |
| OGTT 2-h | ≥155 mg/dL Carpenter-Coustan | OB-GDM-01 |
| OGTT 2-hr glucose cutoffs | normal <140, IGT 140–199, diabetes ≥200 mg/dL 75-g OGTT | REPRO-PCOS-01 |
| OGTT 3-h | ≥140 mg/dL Carpenter-Coustan | OB-GDM-01 |
| OGTT fasting | ≥95 mg/dL Carpenter-Coustan | OB-GDM-01 |
| OHS BMI threshold | ≥30 obesity hypoventilation syndrome | RESP-OSA-01 |
| OHS PaCO2 threshold | >45 mmHg obesity hypoventilation syndrome, no other cause | RESP-OSA-01 |
| older-adult protein target | 1.0–1.2 g/kg/day 1.2–1.5 g/kg/day with illness | NUTR-ASSESS-01 |
| oligoarticular ANA positivity | 70–80% uveitis risk | MSK-PEDS-01 |
| oligoarticular joint count | ≤4 joints in first 6 months classification | MSK-PEDS-01 |
| oligoclonal bands | >90% positive in MS CSF | NEURO-DEMY-01 |
| oligohydramnios-bpp-delivery | ≥36–37 wk deliver regardless of overall BPP score | OB-SURV-01 |
| oligohydramnios-delivery-timing | 36 0/7–37 6/7 wk isolated, otherwise normal pregnancy | OB-SURV-01 |
| oligohydramnios-threshold | AFI <5 cm or DVP <2 cm definition | OB-SURV-01 |
| OME observation period | 3 months | NEURO-ENT-01 |
| onset (NMS) | days to weeks NMS after an antipsychotic or antiemetic change | EM-TOX-10 |
| onset (serotonin syndrome) | <24 h serotonin syndrome after a serotonergic drug change | EM-TOX-10 |
| onychomycosis treatment duration | 12 wk toenails / 6 wk fingernails oral terbinafine | SKIN-INF-02 |
| optic neuritis MS conversion | ~50% within 15 years of a single episode | NEURO-DEMY-01 |
| OR ≈ RR threshold | <10% outcome risk in the unexposed/control group for OR to approximate RR | BIO-MEAS-02 |
| OR-approximates-RR-threshold | <10% outcome risk below which OR approximates RR | BIO-STUDY-01 |
| oral B12 replacement | 1,000–2,000 mcg daily including pernicious anemia | NUTR-VIT-01 |
| oral bisphosphonate CrCl cutoff | <30–35 mL/min contraindication — use IV zoledronic acid or denosumab | PREV-BONE-01 |
| oral glucose dose | 15–20 g conscious patient | ENDO-DM-05 |
| oral-to-IV morphine ratio | 3:1 opioid conversion | SOC-EOL-05 |
| orchiopexy timing | refer at 6 months (corrected age); complete orchiopexy by 18 months cryptorchidism | RENAL-PEDS-01 |
| ORS sodium | ≥90 mmol/L short bowel/high-output stoma | NUTR-SUPPORT-01 |
| ORT volume | 50–100 mL/kg over 3–4 h | GI-PEDS-01 |
| osmolal gap | >10 with HAGMA suggests methanol or ethylene glycol | RENAL-ABG-01 |
| osmolal gap threshold | >10 mOsm/kg toxic alcohol screening | EM-TOX-05 |
| osmolal gap toxic alcohol | >10 mOsm/kg elevated with AGMA | RESP-ABG-01 |
| osteomyelitis-duration | 4–6 weeks total (IV or highly bioavailable oral) 6 weeks for vertebral osteomyelitis | MSK-INF-01 |
| osteomyelitis-duration-pediatric | ~3–4 weeks children with acute hematogenous osteomyelitis (brief IV then oral) | MSK-INF-01 |
| osteomyelitis-XR-lag | 10–14 days time before plain X-ray changes appear | MSK-INF-01 |
| osteopenia T-score | below -1.0 and above -2.5 DEXA; -2.5 or lower = osteoporosis | PREV-BONE-01 |
| osteoporosis DEXA screening | women aged ≥65 average-risk women; earlier if elevated fracture risk | BIO-SCREEN-01 |
| osteoporosis T-score | ≤-2.5 DEXA hip or spine | PREV-BONE-01 |
| Ottawa knee age cutoff | ≥55 y X-ray indication | MSK-FRAC-01 |
| outpatient PID regimen | ceftriaxone 500 mg IM ×1 + doxycycline 100 mg BID ×14 d + metronidazole 500 mg BID ×14 d CDC 2021 | REPRO-VAGIN-01 |
| overlap detachment | 10–30% BSA epidermal detachment | SKIN-DRUG-01 |
| oxytocin half-life | 3–5 min | OB-FHR-01 |
| P2Y12 hold before surgery | clopidogrel 5 d, ticagrelor 3–5 d, prasugrel 7 d high bleeding-risk elective surgery | CV-ACS-02 |
| pack-year threshold | ≥20 USPSTF 2021, down from 30 | PREV-LUNG-01 |
| PaCO2 normal | 35–45 mmHg reference range | RESP-ABG-01 |
| PAD antithrombotic add-on | rivaroxaban 2.5 mg BID + aspirin low bleeding risk | CV-PAD-01 |
| Paget osteosarcoma risk | <1% rare complication | MSK-BONE-01 |
| PAH PCWP | ≤15 mm Hg precapillary (Group 1 PAH) | CV-PH-01 |
| palivizumab eligibility | <29 weeks gestational age high-risk premature infants, historical use | RESP-BRO-01 |
| palm method | ≈1% TBSA scattered burns | EM-BURN-01 |
| Pancreatic cancer risk at 20 yr (chronic pancreatitis) | ~4% | GI-PANC-02 |
| Pap-alone interval | q3yr age 21–29 | PREV-CERV-01 |
| papillary muscle rupture timing | 3–5 days post-MI - | CV-HF-02 |
| papillary thyroid cancer 10-yr survival | >95% prognosis | ENDO-THY-01 |
| papilloma-associated malignancy rate | ~10% underlying DCIS/invasive cancer in pathologic bloody discharge | REPRO-BRMASS-01 |
| parathyroidectomy calcium criterion | > 1 mg/dL above ULN asymptomatic primary hyperparathyroidism (2022 Workshop) | ENDO-CA-01 |
| parenteral nutrition threshold | after 7 days if enteral not feasible in a previously well-nourished patient; start earlier if malnourished | MULTI-NUTR-01 |
| Pareto principle | 80% of problems from 20% of causes prioritization | SOC-QI-04 |
| Parkland first-8-hour timing | half the volume, from time of burn not time of arrival | EM-BURN-01 |
| Parkland formula | 4 mL × kg × %TBSA/24 h (LR) original formula, burns >20% TBSA | EM-BURN-01 |
| Parkland starting estimate (updated) | 2 mL × kg × %TBSA (adult); 3 mL (child); 4 mL (electrical) ATLS 10th ed/ABA, titrate to urine output | EM-BURN-01 |
| pathologic jaundice cutoff | <24 h of life | GI-PEDS-01 |
| patient education reading level | ≤6th grade discharge instructions | SOC-QI-09 |
| patient education reading level | ≤6th grade health literacy | SOC-SDOH-01 |
| PCI transfer window | ≤120 min anticipated first medical contact-to-device, transfer for primary PCI | CV-ACS-01 |
| PCP prophylaxis threshold | CD4 <200 TMP-SMX | MULTI-HIV-01 |
| PCV15→PPSV23 interval | ≥1 year ≥8 weeks if immunocompromising condition, asplenia, CSF leak, or cochlear implant | PREV-IMM-01 |
| peanut introduction (high risk) | 4–6 months severe eczema and/or egg allergy | NUTR-INF-01 |
| pediatric adenosine dose | 0.1 mg/kg rapid IV push, infant SVT | CV-ARR-02 |
| pediatric concurrent care age | <21 years Medicaid/CHIP hospice plus curative care | SOC-EOL-04 |
| pediatric Crohn EEN | 6–8 weeks sole-source formula for induction | NUTR-MNT-02 |
| pediatric exam interval | ≥12 h between two examinations brain death in children (term newborn ≥37 weeks corrected gestational age through 17 years) | SOC-EOL-07 |
| pediatric fluid bolus (anaphylaxis) | 20 mL/kg anaphylactic hypotension, repeated as needed | IMM-ANAPH-02 |
| pediatric fluid bolus (DKA) | 10–20 mL/kg pediatric DKA: 10–20 mL/kg NS over 20–30 min; shock: rapid 20 mL/kg boluses with reassessment | ENDO-DM-04 |
| pediatric lead screening ages | 12 and 24 months at-risk/Medicaid populations | PREV-OCC-01 |
| pediatric maintenance fluid tonicity | isotonic (D5 NS or D5 LR/Plasma-Lyte + KCl) AAP 2018; ages 28 days–18 years | MULTI-FE-01 |
| pediatric migraine ibuprofen dose | 10 mg/kg first-line abortive | NEURO-HA-01 |
| pediatric nephrotic proteinuria | ≥40 mg/m²/h or UPC ≥2 children | RENAL-GN-01 |
| pediatric obesity threshold | ≥95th percentile BMI defines obesity, not merely overweight | PREV-CVM-01 |
| pediatric synchronized cardioversion dose | 0.5–1 J/kg unstable infant SVT | CV-ARR-02 |
| Pediatric ultrasound sensitivity | ~85% | GI-APP-01 |
| pediatric UOP target | 1 mL/kg/h burn resuscitation | EM-BURN-01 |
| PEG after stroke | dysphagia >2–3 weeks AHA/ASA 2019 | NUTR-GER-01 |
| pemphigus vulgaris onset age | 40–60 yr typical | SKIN-BLIST-01 |
| penicillin prophylaxis duration | 2 months to ≥5 years sickle cell disease | HEME-SICK-01 |
| penicillin prophylaxis window | 2 months – 5 years HbSS/HbSβ0, functional asplenia from infancy | HEME-SICK-02 |
| penicillin-allergic early syphilis (nonpregnant) | doxycycline 100 mg BID ×14 d CDC 2021 | REPRO-VAGIN-01 |
| penicillin-cephalosporin cross-reactivity | 1–2% far below historical 10% estimate | IMM-DALLERGY-01 |
| PEP window | within 72h ideally ≤24h; 28-day 3-drug course | MULTI-HIV-01 |
| Percutaneous drainage threshold | abscess > 3 cm | GI-COLON-01 |
| Percutaneous drainage threshold | abscess > 3 cm | GI-APP-01 |
| pericardial thickening | >4 mm CT/MRI finding supporting constrictive pericarditis | CV-PERI-01 |
| perihilar (Klatskin) tumor proportion | 60–70% of cholangiocarcinomas | GI-BIL-02 |
| perimortem cesarean timing | prepare at arrest; start by 4 min, deliver by 5 no ROSC, fundus at or above umbilicus | CV-ARREST-01 |
| perinatal HBV prophylaxis window | within 12h of birth hepatitis B vaccine ± HBIG depending on maternal HBsAg status | MULTI-CONG-01 |
| perioperative factor VIII target | ~100% major surgery or major/intracranial bleeding in hemophilia | HEME-COAG-02 |
| perioperative glucose target | <200 mg/dL SSI prevention | SOC-QI-08 |
| perioperative glucose target | 100–180 mg/dL within 4 h of surgery; 140–180 mg/dL if critically ill; avoid 80–110 mg/dL | ENDO-PERI-01 |
| perioperative STOP-BANG high risk | ≥5 preoperative risk stratification | RESP-OSA-01 |
| peripartum cardiomyopathy EF | <45% last month of pregnancy to 5 months postpartum | CV-CM-01 |
| peripartum cardiomyopathy pregnancy counseling threshold | LVEF <50% persistent advise against future pregnancy | CV-CM-01 |
| peripartum cardiomyopathy recurrence | ~20% (recovered EF) to 30–50% (EF not recovered) future pregnancy risk | CV-CM-01 |
| peripheral KCl max concentration | 10 mEq/100 mL ≤10 mEq/h peripherally; ≤20 mEq/h (up to 40 mEq/h emergency) centrally with cardiac monitoring | MULTI-FE-01 |
| peripheral PN osmolarity limit | ≤900 mOsm/L peripheral vein | NUTR-SUPPORT-01 |
| permissive HTN threshold | 220/120 mmHg no tPA, treat only above | NEURO-STROKE-02 |
| permissive hypercapnia pH floor | ≥7.20 ARDSNet goal 7.30–7.45; raise RR first (max 35); bicarbonate or +1 mL/kg Vt only if pH <7.15 | RESP-VENT-01 |
| permissive hypercapnia pH floor | ≥7.20 accepted | RESP-ARDS-01 |
| permissive hypotension target | SBP 80–90 mmHg penetrating trauma without TBI | EM-TRAUMA-02 |
| permissive hypotension target | SBP 80–90 mmHg penetrating trauma, pre-hemostasis | HEME-TRANS-02 |
| permissive stroke BP | up to 220/120 mm Hg no thrombolysis planned | CV-HTN-02 |
| persistent air leak | >5–7 days indication for pleurodesis | RESP-PTX-01 |
| persisting post-concussive symptoms | >4 weeks warrants multidisciplinary evaluation; ≥3 months historically defined post-concussive syndrome | NEURO-TBI-01 |
| PERT dosing | lipase 40,000–50,000 units per meal, with food | GI-PANC-02 |
| PGE1 target SpO2 in HLHS | 75–85% HLHS/duct-dependent systemic flow; avoid high-flow O2 | CV-CONG-01 |
| PH definition | mPAP >20 mm Hg right heart catheterization; revised from >25 mm Hg | CV-PH-01 |
| pharmacologic prophylaxis timing | UFH/enoxaparin ~2 h preop (abdominal) or 12–24 h postop; arthroplasty LMWH ≥12 h pre or 12–24 h postop ≥12 h between prophylactic LMWH and neuraxial needle | PERIOP-VTE-01 |
| pharmacotherapy BMI threshold | ≥30 or ≥27 with comorbidity adult obesity pharmacotherapy eligibility | MULTI-NUTR-02 |
| phase I size | 20–80 subjects safety and dosing | SOC-RES-02 |
| phase II size | 100–300 subjects efficacy and dosing | SOC-RES-02 |
| phase III size | 300–3,000 subjects randomized comparison | SOC-RES-02 |
| phenobarbital dose (SE) | 15 mg/kg IV alternative when benzodiazepine unavailable | NEURO-SZ-02 |
| phenoxybenzamine duration | 10–14 days alpha-blockade before beta-blockade and surgery | CV-HTN-02 |
| pheochromocytoma incidental discovery rate | ~30–60% found incidentally on imaging, without hypertension or symptoms | ENDO-ADR-03 |
| phototherapy threshold example | ~18 mg/dL at 48 h term infant, no risk factors, AAP 2022 curve | PEDS-NB-01 |
| PHP monitoring duration | 5 years substance use disorder monitoring contract | SOC-PROF-01 |
| PHPT age criterion | < 50 y asymptomatic surgical criterion | ENDO-CA-01 |
| PHPT eGFR/CrCl criterion | < 60 mL/min asymptomatic surgical criterion | ENDO-CA-01 |
| PHPT T-score/fracture criterion | ≤ −2.5 or vertebral fracture asymptomatic surgical criterion | ENDO-CA-01 |
| PHPT urine calcium criterion | > 250 mg (women)/> 300 mg (men) 24-h urine, asymptomatic surgical criterion (as is imaging-detected nephrolithiasis/nephrocalcinosis) | ENDO-CA-01 |
| phyllodes excision margin | ≥1 cm wide excision, borderline/malignant only | REPRO-BRMASS-01 |
| physiologic jaundice peak (term) | day 3–5 | GI-PEDS-01 |
| pituitary macroadenoma threshold | ≥10 mm size cutoff prompting surgical consideration with mass effect | ENDO-PIT-01 |
| pityriasis rosea duration | 6–8 weeks self-limited; no treatment required | SKIN-INFLAM-01 |
| PKU blood Phe target | 120–360 µmol/L lifelong; <360 before and during pregnancy | NUTR-MNT-02 |
| plasma free metanephrines sensitivity | ~97% most sensitive screening test | ENDO-ADR-03 |
| plateau pressure target | ≤30 cmH2O barotrauma threshold | RESP-VENT-01 |
| platelet count before warfarin in HIT | >150,000/µL bridge to warfarin | CV-VTE-01 |
| platelet threshold, neurosurgery | <100,000/µL neurosurgery/ophthalmic surgery | HEME-TRANS-02 |
| platelet threshold, procedure | <50,000/µL major surgery or active bleeding | HEME-TRANS-02 |
| platelet threshold, prophylactic | <10,000/µL stable patients | HEME-TRANS-02 |
| PM/DM CK | >1,000 IU/L (often >10x ULN) active disease | MSK-OTHER-01 |
| PMR ESR | >40 (often 80–100) diagnosis | MSK-OTHER-01 |
| PMR prednisone dose | 12.5–25 mg/day initial therapy | MSK-OTHER-01 |
| PN dextrose infusion ceiling | ≤4–5 mg/kg/min adult | NUTR-SUPPORT-01 |
| pneumatic dilation perforation risk | ~2% (1–5%) per procedure | GI-ESO-02 |
| pneumococcal conjugate vaccine eligibility age | ≥50 (or 19–49 with risk factors) PCV20/PCV21 single dose, or PCV15→PPSV23 sequential | PREV-IMM-01 |
| POI age cutoff | <40 y premature ovarian insufficiency | REPRO-AMEN-01 |
| POI definition | <40 yr premature ovarian insufficiency | REPRO-MENO-01 |
| POI diagnostic FSH threshold | >25 IU/L once (repeat if unclear) with ≥4 months oligo/amenorrhea | REPRO-MENO-01 |
| POI hormone therapy duration | until ~age 51 systemic estrogen ± progestin, does not follow shortest-duration rule | REPRO-MENO-01 |
| poison ivy steroid taper | 2–3 weeks minimum course to avoid rebound | SKIN-INFLAM-01 |
| polyarticular joint count | ≥5 joints classification | MSK-PEDS-01 |
| polycystic ovary threshold | ≥20 follicles/ovary or volume ≥10 mL, or elevated AMH (adults) ultrasound/AMH criterion | REPRO-PCOS-01 |
| polyhydramnios-idiopathic-proportion | ~60% most common category, before identifiable maternal cause | OB-SURV-01 |
| polyhydramnios-threshold | AFI ≥24 cm or DVP ≥8 cm definition | OB-SURV-01 |
| POP missed-dose window | >3 h (norethindrone/norgestrel); ≥48 h (drospirenone; 7-day backup) triggers backup contraception | REPRO-CONTRA-01 |
| positive screen | SpO2 <90%, or 90–94%/>3% difference persisting after one repeat between right hand and either foot → echocardiography | CV-CONG-01 |
| post-arrest fever avoidance | >37.5°C avoided for ≥72 h worsens neurologic outcome | CV-ARREST-01 |
| post-discharge follow-up call | 48–72 h high-risk patients | SOC-QI-09 |
| post-discharge suicide window | ≤7 days sentinel event definition | SOC-QI-01 |
| post-discharge visit | ≤7 days for HF; 7–14 days for other high-risk patients high-risk patients | SOC-QI-09 |
| post-epinephrine observation | ≥2 hours monitor for rebound stridor | RESP-PEDAIR-01 |
| post-evacuation surveillance | 3 mo monthly after normalization, complete mole | OB-GTD-01 |
| post-evacuation surveillance partial | 1 mo single confirmatory normal value after normalization, partial mole | OB-GTD-01 |
| post-MI ICD wait | ≥40 days (≥90 days after revascularization) LVEF ≤35% on GDMT (or ≤30% with NYHA I) | CV-ACS-02 |
| post-MI MRA | eplerenone or spironolactone LVEF ≤40% with HF symptoms or diabetes; Cr ≤2.5 (men)/≤2.0 (women) mg/dL, K+ <5.0 mEq/L | CV-ACS-02 |
| post-MI surgical delay | ≥60 days historical minimum after MI without coronary intervention; active ACS and post-PCI timing assessed separately | PERIOP-RISK-01 |
| post-obstructive diuresis | >200 mL/h after bladder decompression | RENAL-AKI-01 |
| Post-op CEA surveillance | q3–6 mo × 2 yr, then q6 mo to 5 yr | GI-COLON-01 |
| post-radiation surveillance start | 8 y after radiation, or age 25 (later) prior chest/mantle radiation ages 10–30 | PREV-BRCA-01 |
| post-RYGB zinc:copper supplement ratio | 8–15 mg zinc per 1 mg copper ASMBS | NUTR-VIT-02 |
| post-splenectomy vaccination timing | ≥14 d post-op or before discharge encapsulated organism prophylaxis | EM-TRAUMA-03 |
| post-stroke BP target | <130/80 mmHg chronic secondary prevention | NEURO-STROKE-03 |
| post-stroke LDL target | <70 mg/dL atherosclerotic ischemic stroke/TIA | NEURO-STROKE-03 |
| post-tPA BP target | <180/105 mmHg for 24 h | CV-HTN-02 |
| post-tPA BP target | <180/105 mmHg 24 h after alteplase | NEURO-STROKE-02 |
| post-trauma fetal monitoring | ≥4 h pregnancy ≥20 weeks; 24 h if abnormal findings | OB-EMER-01 |
| post-treatment monitoring | ≥24h ICU observation with dantrolene 1 mg/kg q4–6h recurrence risk (~20%) | PERIOP-MH-01 |
| posterior dislocation miss rate | ~50% AP X-ray alone | MSK-JOINT-02 |
| posterior-lead ST elevation | ≥0.5 mm V7–V9 confirmation of posterior MI | CV-ACS-01 |
| postmenopausal endometrial stripe threshold | >4 mm biopsy trigger | REPRO-AUB-01 |
| postmenopausal endometrial stripe threshold | >4 mm triggers biopsy; ≤4 mm without persistent bleeding needs no biopsy | REPRO-ENDCA-01 |
| postmenopausal simple cyst threshold | <10 cm observe with serial ultrasound if CA-125 normal | REPRO-OVCA-01 |
| postop antibiotic duration | stop at incision closure never >24 h | PREV-HAI-01 |
| postop dialysis resumption | 24–48h after surgery if stable perioperative | RENAL-DIAL-01 |
| postoperative urinary catheter removal | ≤24 h absent ongoing indication | SOC-QI-08 |
| postoperative urinary retention threshold | >400–600 mL bladder scan no voiding 6–8h after surgery | PERIOP-COMPL-01 |
| postpartum depression DSM-5 onset | pregnancy to 4 wk postpartum peripartum-onset specifier, duration ≥2 wk | OB-PP-01 |
| postpartum estrogen avoidance | <21 days VTE risk | REPRO-CONTRA-02 |
| postpartum GDM screening | 4–12 wk 75 g OGTT | ENDO-DM-03 |
| postpartum psychosis onset | days 2–3 to 2 weeks postpartum most commonly day 2–3 | OB-PP-01 |
| postpartum psychosis onset | days 2–3 to 2 weeks postpartum rapid onset distinguishes from PPD | PSY-PP-01 |
| postpartum psychosis risk with bipolar disorder | 25–50% | OB-PP-01 |
| postpartum-preeclampsia-window | ≤6 wk postpartum can present | OB-HTN-01 |
| potassium for digoxin Fab | >5.0 mEq/L acute toxicity | CV-TOX-01 |
| potentially fatal level | >100 mg/dL serum salicylate | EM-TOX-04 |
| POUR threshold | >300–400 mL postoperative bladder scan | RENAL-LUTS-01 |
| power | 0.80–0.90 1 − beta, conventional target | BIO-STAT-01 |
| PPGL extra-adrenal rate | ~15–20% paraganglioma vs adrenal pheochromocytoma | ENDO-ADR-03 |
| PPGL germline mutation rate | ~30–40% hereditary PPGL (MEN2, VHL, NF1, SDHx) | ENDO-ADR-03 |
| PPGL metastatic rate | ~10–15% higher with SDHB; 'metastatic' replaces 'malignant' (WHO 2017) | ENDO-ADR-03 |
| pph-definition | ≥1000 mL cumulative, or any volume with hypovolemia signs within 24h of birth, any route; >500 mL after vaginal birth warrants vigilance | OB-PPH-01 |
| PPI washout before gastrin testing | ≥ 1 wk | GI-GAST-01 |
| PPROM delivery threshold | 34 0/7 wk | OB-PTL-01 |
| PPV-example-low-prevalence | ~16% 95% sensitivity/specificity test at 1% prevalence | BIO-TEST-01 |
| pr-first-degree | >200 ms first-degree AV block | CV-ARR-03 |
| pralidoxime window | give ASAP; aging varies by agent — minutes (soman) to hours (sarin) to days (some pesticides) before AChE aging | EM-TOX-09 |
| PRBC threshold, cardiac surgery | <7.5 g/dL cardiac surgery | HEME-ANEM-01 |
| PRBC threshold, cardiac surgery | <7.5 g/dL cardiac surgery | HEME-TRANS-02 |
| PRBC threshold, CVD/orthopedic | <8 g/dL preexisting cardiovascular disease or orthopedic surgery | HEME-ANEM-01 |
| PRBC threshold, CVD/orthopedic | <8 g/dL CVD or orthopedic surgery; not ACS (after MINT, ~10 g/dL reasonable in MI) | HEME-TRANS-02 |
| PRBC threshold, restrictive | <7 g/dL most stable hospitalized patients | HEME-ANEM-01 |
| PRBC threshold, restrictive | <7 g/dL most stable inpatients | HEME-TRANS-02 |
| pre-emptive TIPS window | within 72 h (ideally 24 h) Child-Pugh C 10–13, or Child-Pugh B >7 with active bleeding at endoscopy | GI-BLEED-02 |
| pre-emptive TIPS window | within 72 h (ideally 24 h) high-risk variceal bleeders | GI-CIRR-02 |
| pre-op alpha-blockade duration | 7–14 days phenoxybenzamine or doxazosin before surgery | ENDO-ADR-03 |
| pre-op Lugol iodine course | 10 days before thyroidectomy | ENDO-THY-02 |
| pre-splenectomy vaccination timing | ≥2 weeks pre-op pneumococcal, meningococcal (MenACWY + MenB), Hib | HEME-HEMOL-01 |
| pre-splenectomy vaccination window | ≥2 weeks before elective surgery pneumococcal conjugate, MenACWY, MenB, Hib | MULTI-VAX-01 |
| pre-tPA BP target | ≤185/110 mmHg before alteplase | NEURO-STROKE-02 |
| pre-tPA BP threshold | <185/110 mmHg before alteplase | CV-HTN-02 |
| pre-tPA BP threshold | <185/110 mmHg must lower before thrombolysis | NEURO-STROKE-01 |
| prediabetes HbA1c | 5.7–6.4% diagnosis | ENDO-DM-01 |
| prednisone course | 40 mg PO × 5 days COPD exacerbation, no taper | RESP-COPD-01 |
| preductal SpO2 target at 1 min | 60–65% term infant | PEDS-NB-02 |
| preductal SpO2 target at 10 min | 85–95% term infant | PEDS-NB-02 |
| preeclampsia BP threshold | ≥140/90 mmHg after 20 weeks | CV-PREG-01 |
| preeclampsia-bp-threshold | ≥140/90 mmHg two occasions ≥4h apart, after 20 wk | OB-HTN-01 |
| pregnancy anemia threshold (1st/3rd trimester) | <11 g/dL hemoglobin | OB-PRE-01 |
| pregnancy anemia threshold (2nd trimester) | <10.5 g/dL hemoglobin, physiologic dilution | OB-PRE-01 |
| pregnancy chlamydia test-of-cure | 4 weeks post-treatment; retest at 3 months pregnancy | REPRO-VAGIN-01 |
| pregnancy test follow-up | 2 wk sexual assault | REPRO-MISC-01 |
| pregnancy TSH check interval | q4 wk through midgestation after dose increase | ENDO-THY-03 |
| pregnancy TSH goal | < 2.5 mIU/L first trimester, if trimester-specific range unavailable | ENDO-THY-03 |
| premature thelarche age | usually <2 y isolated breast budding, benign | PEDS-GROW-01 |
| preop antibiotic timing | ≤60 min before incision; 120 min for vancomycin or a fluoroquinolone | PREV-HAI-01 |
| preop dialysis window | within 24h before surgery perioperative | RENAL-DIAL-01 |
| preoperative fasting — breast milk | 4h ASA guideline | PERIOP-OTHER-01 |
| preoperative fasting — clear liquids | 2h ASA guideline | PERIOP-OTHER-01 |
| preoperative fasting — fatty meal | 8h ASA guideline | PERIOP-OTHER-01 |
| preoperative fasting — light meal/formula | 6h ASA guideline | PERIOP-OTHER-01 |
| prerenal FeNa | <1% prerenal AKI | RENAL-AKI-01 |
| pressure injury protein | 1.25–1.5 g/kg/day energy 30–35 kcal/kg/day (NPIAP 2019) | NUTR-GER-01 |
| preterm labor gestational window | 20 0/7–36 6/7 wk | OB-PTL-01 |
| prevent-ascvd-age-window | 30–79 y no ASCVD/subclinical atherosclerosis; LDL-C 70–189 mg/dL; assess separate indications first | CV-PREV-01 |
| prevent-ascvd-risk-borderline | 3–<5% 10-year ASCVD risk (PREVENT) — risk enhancers/CAC discussion | CV-PREV-01 |
| prevent-ascvd-risk-intermediate-high | 5–<10% intermediate, ≥10% high 10-year PREVENT-ASCVD risk; intermediate: ≥ moderate intensity; high: high intensity | CV-PREV-01 |
| prevent-ascvd-risk-low | <3% 10-year PREVENT-ASCVD risk; lifestyle unless separate lipid-lowering indication | CV-PREV-01 |
| previa-cesarean-timing | 36 0/7–37 6/7 wk complete previa, stable, planned cesarean | OB-HEM-01 |
| priapism duration | >4 h ischemic/urologic emergency | HEME-SICK-02 |
| primary amenorrhea age | 15 y with 2° sexual characteristics or 13 y without definition | REPRO-AMEN-01 |
| primary closure window | ~12–18 h (a guide, not a rigid cutoff) longer on face/scalp; individualize by contamination and host factors | SKIN-WOUND-02 |
| primary nocturnal enuresis age | ≥5 y diagnostic age threshold; bedwetting before 5 is normal | PEDS-RENAL-01 |
| primary-prevention ICD EF threshold | ≤35% after ≥3 months optimal GDMT | CV-HF-01 |
| primary/secondary syphilis | benzathine PCN G 2.4 MU IM ×1 early disease | MULTI-GU-01 |
| procalcitonin abnormal | >0.5 ng/mL febrile infant 22–60 days, inflammatory marker stratification | PEDS-FEV-01 |
| procalcitonin low-risk cutoff | ≤0.5 ng/mL 8–60 days; <0.25 ng/mL is the adult LRTI cutoff, not pediatric | MULTI-FEVER-01 |
| procalcitonin stop threshold | >80% fall from peak or <0.5 ng/mL antibiotic discontinuation | RESP-PNA-02 |
| progesterone challenge duration | 10 days medroxyprogesterone anovulation test | REPRO-AMEN-01 |
| prognosis for assisted death eligibility | ≤6 months terminal illness | SOC-EOL-06 |
| prolactinoma prolactin cutoff | > 200 ng/mL strongly suggests prolactinoma | ENDO-PIT-01 |
| proliferative breast lesion without atypia relative risk | ~1.5–2x future breast cancer risk | REPRO-BRMASS-01 |
| proliferative phase | days 4–21 collagen deposition, angiogenesis | SKIN-WOUND-01 |
| prolonged deceleration | ≥15 bpm drop, 2–10 min | OB-FHR-01 |
| prone positioning duration | ≥16 h/day PROSEVA | RESP-ARDS-01 |
| prone positioning threshold | P/F <150 start prone positioning ≥16 h/day in moderate-severe ARDS | RESP-VENT-01 |
| prone positioning threshold | P/F <150 on FiO2 ≥0.6, PEEP ≥5 despite lung-protective ventilation; precedes ECMO | RESP-ARDS-01 |
| prophylactic cefazolin timing | within 60 min of incision surgical antibiotic prophylaxis | PERIOP-COMPL-01 |
| prophylactic vancomycin timing | within 120 min of incision surgical antibiotic prophylaxis | PERIOP-COMPL-01 |
| propofol infusion syndrome risk window | >48 h at >4 mg/kg/h high-dose prolonged infusion, ~67 mcg/kg/min | EM-CRIT-02 |
| protamine dose for enoxaparin | 1 mg per 1 mg partial (~60%) reversal, dose given within 8 h | CV-VTE-01 |
| protamine dose for UFH | 1 mg per 100 units reversal, heparin given in prior 2–3 h | CV-VTE-01 |
| protein in older adults | 1.0–1.2 g/kg/day 1.2–1.5 g/kg/day with illness | NUTR-GER-01 |
| protein target for wound healing | >1.25 g/kg/day established pressure injury | SKIN-ULCER-01 |
| proteinuria-threshold | ≥300 mg/24h or P:C ≥0.3 or ≥2+ dipstick preeclampsia | OB-HTN-01 |
| provoked PE duration | 3 months anticoagulation | RESP-PE-01 |
| PSA screening stop age | ≥70 y USPSTF Grade D | PREV-ONC-01 |
| PSA shared decision-making | 55–69 y USPSTF Grade C | PREV-ONC-01 |
| PSA shared-decision age | 55–69 prostate cancer screening; Grade C | PREV-PRIN-02 |
| PSC cholangiocarcinoma surveillance interval | every 6–12 months MRI/MRCP ± CA 19–9 | GI-BIL-02 |
| PSC gallbladder polyp cholecystectomy threshold | ≥8 mm annual gallbladder imaging | GI-BIL-02 |
| PSC-associated colitis surveillance | annual starting at PSC diagnosis | GI-IBD-01 |
| PSGN C3 normalization | by 8 wk low C3 at presentation | PEDS-RENAL-01 |
| PSGN complement recovery | by 8 weeks persistent low C3 argues against PSGN | IMM-SERO-01 |
| PSGN hematuria onset | 1–3 weeks post-pharyngitis or 3–6 weeks post-skin infection low C3 | IMM-SERO-01 |
| PSP small threshold, ACCP | <3 cm apex-to-cupola upright CXR | RESP-PTX-01 |
| PSP small threshold, BTS | <2 cm interpleural distance at the hilum upright CXR | RESP-PTX-01 |
| pubertal gynecomastia resolution time | 6 mo-2 yr natural history | REPRO-BRMASS-01 |
| pulse ox screen timing | 24–48 h of life pre- and post-ductal SpO2 | CV-CONG-01 |
| pulsus paradoxus | >10 mmHg cardiac tamponade | CV-PERI-01 |
| PV JAK2 positivity | >95% JAK2 V617F mutation | HEME-MPN-01 |
| PV phlebotomy target | <45% hematocrit | HEME-MPN-01 |
| pyloric channel length | ≥17 mm ultrasound diagnosis of pyloric stenosis | PEDS-SURG-01 |
| pyloric muscle thickness | ≥4 mm ultrasound diagnosis of pyloric stenosis | PEDS-SURG-01 |
| pyridoxine dose in INH overdose | gram-for-gram or 5 g empiric INH-induced refractory seizures | MULTI-TB-01 |
| pyridoxine for INH overdose | 1 g per 1 g INH; 5 g if unknown IV | NUTR-VIT-01 |
| pyridoxine treatment dose | 100–200 mg/day established isoniazid-induced neuropathy | NEURO-NM-03 |
| pyridoxine with isoniazid | 25–50 mg daily at-risk groups | NUTR-VIT-01 |
| pyuria threshold | ≥5 WBC/hpf UTI diagnosis | RENAL-PEDS-01 |
| QRS widening threshold | >100 ms TCA toxicity; predicts seizures (>160 ms predicts ventricular arrhythmias) | EM-TOX-09 |
| quad-screen-window | 15–22 wk AFP/hCG/estriol/inhibin A | OB-PRE-02 |
| quit-time cutoff | ≤15 years current or former smoker | PREV-LUNG-01 |
| R wave in aVR for TCA toxicity | >3 mm predicts toxicity | CV-TOX-01 |
| RA-morning-stiffness | >60 min duration supporting RA over osteoarthritis | MSK-RHEUM-01 |
| rabies PEP vaccine schedule | days 0, 3, 7, 14 previously unvaccinated | MULTI-MISC-01 |
| rabies vaccine schedule, previously vaccinated | days 0, 3 no immune globulin | SKIN-PROC-01 |
| rabies vaccine schedule, unvaccinated | RIG + vaccine days 0, 3, 7, 14 add day 28 if immunocompromised | SKIN-PROC-01 |
| RASS target | 0 to −2 light sedation goal | EM-CRIT-02 |
| RCRI Class IV | ≥3 points ~11% major cardiac complications (Lee); ACC/AHA elevated risk is RCRI ≥2 (MACE ≥1%) | PERIOP-RISK-01 |
| RCRI low risk | 0–1 points <1% 30-day MACE | PERIOP-RISK-01 |
| RCRI predictors | 6, 1 point each high-risk surgery, IHD, HF, cerebrovascular disease, insulin-treated DM, creatinine >2.0 mg/dL | CV-PERIOP-01 |
| reactive arthritis HLA-B27 | 60–80% diagnosis | MSK-RHEUM-02 |
| reactive arthritis onset | 1–4 weeks after infection diagnosis | MSK-RHEUM-02 |
| reactive-nst-after32wk | ≥2 accel ≥15 bpm × ≥15 s / 20 min after 32 wk | OB-SURV-01 |
| reactive-nst-before32wk | ≥2 accel ≥10 bpm × ≥10 s / 20 min before 32 wk | OB-SURV-01 |
| readmission measurement window | 30 days HRRP | SOC-QI-09 |
| reassessment interval | 1–6 months negative initial weight-loss workup | NUTR-ASSESS-01 |
| recommended exercise | ≥150 min/wk moderate intensity | OB-PRE-01 |
| records access response | ≤30 days (+30-day extension once) HIPAA right of access | SOC-CONF-02 |
| recurrence risk by inheritance | AR 25%, AD 50% recurrence risk per pregnancy | MULTI-GEN-02 |
| recurrent AOM threshold | ≥3 in 6 mo or ≥4 in 12 mo (≥1 in past 6 mo) | NEURO-ENT-01 |
| recurrent candidiasis regimen | induction fluconazole 150 mg q72h ×3 doses, then 150 mg weekly ×6 mo ≥3 episodes/year | REPRO-VAGIN-01 |
| recurrent-loss-threshold | ≥2 losses definition | OB-SAB-01 |
| refeeding rate (high-risk) | 10–20 kcal/kg/day (5–10 if extreme) BMI <14–16, malnutrition >10 days, low K/PO4/Mg | PSY-EAT-01 |
| refeeding rate (mild-moderate adolescent AN) | ~1400–2000 kcal/day higher-calorie refeeding protocol | PSY-EAT-01 |
| refeeding starting calories | 10–20 kcal/kg/day advance over 4–7 days | MULTI-NUTR-01 |
| refractory SE | failed benzodiazepine + one second-line agent AES timeline >40 min → continuous infusion, intubation, cEEG | NEURO-SZ-02 |
| regain birth weight | by 10–14 days term newborn | NUTR-INF-01 |
| relaxed HbA1c target | <8% elderly, comorbid, severe hypoglycemia history | ENDO-DM-01 |
| renal-bladder ultrasound timing | after first febrile UTI 2–24 mo; early if not improving post-UTI imaging | RENAL-PEDS-01 |
| repeat DEXA interval | ~2 years after starting/changing therapy; longer if low baseline risk | PREV-BONE-01 |
| repeat interval | q5–15 min no maximum dose in life-threatening anaphylaxis | IMM-ANAPH-02 |
| repeat-us-interval | 7–14 d equivocal viability | OB-SAB-01 |
| repositioning interval | q2h prevention | SKIN-ULCER-01 |
| rescreen interval | 3 y normal screening result | ENDO-DM-01 |
| Resectability at diagnosis | 15–20% | GI-PANC-02 |
| Resectable SMV/portal vein contact | ≤180°, no vein irregularity | GI-PANC-02 |
| resident weekly duty limit | 80 h/week averaged over 4 weeks ACGME | SOC-PROF-04 |
| resistant hypertension | ≥3 agents including a diuretic at optimal doses, or controlled on ≥4 definition | CV-HTN-02 |
| respiratory acidosis compensation (acute) | +1 mEq/L HCO3 per 10 mmHg PaCO2 acute respiratory acidosis | RENAL-ABG-01 |
| respiratory acidosis compensation (chronic) | +3.5–4 mEq/L HCO3 per 10 mmHg PaCO2 chronic respiratory acidosis | RENAL-ABG-01 |
| respiratory alkalosis compensation (acute) | −2 mEq/L HCO3 per 10 mmHg PaCO2 acute respiratory alkalosis | RENAL-ABG-01 |
| respiratory alkalosis compensation (chronic) | −4–5 mEq/L HCO3 per 10 mmHg PaCO2 chronic respiratory alkalosis | RENAL-ABG-01 |
| rest after 24-h duty | ≥14 h off ACGME | SOC-PROF-04 |
| rest between shifts | ≥8 h off between scheduled duty periods ACGME | SOC-PROF-04 |
| resting tremor frequency | 4–6 Hz Parkinson disease | NEURO-MOVE-01 |
| restraint order duration adults | 4 h violent restraint | SOC-LAW-03 |
| restraint order duration age <9 years | 1 h violent restraint | SOC-LAW-03 |
| restraint order duration ages 9–17 years | 2 h violent restraint | SOC-LAW-03 |
| restrictive cardiomyopathy e' | <7 cm/s reduced tissue Doppler distinguishes from constriction | CV-CM-01 |
| restrictive TLC | <80% predicted confirmed only by body plethysmography | RESP-PFT-01 |
| retained-placenta-threshold | >30 min 3rd stage | OB-PPH-01 |
| retinopathy target A1c | < 7% slows progression of nonproliferative disease | ENDO-DM-06 |
| return-to-OR interval | 24–48h repeat debridement until clean | MULTI-SSTI-01 |
| return-to-play step duration | ≥24 h minimum per step | NEURO-TBI-01 |
| reversibility | ≥12% and ≥200 mL FEV1 improvement post-bronchodilator | RESP-ASTHMA-01 |
| rewarm-before-declaring-death | ≥32°C resuscitation endpoint | CV-ECG-01 |
| RhoGAM dose | 300 μg IM 28 wk, Rh-negative unsensitized | OB-PRE-01 |
| RhoGAM dose/timing | 300 µg IM 28 weeks + after sensitizing events + within 72h postpartum if infant Rh-positive | MULTI-CONG-01 |
| rhogam-forgo-threshold | <12 wk spontaneous/induced abortion, anti-D may be omitted | OB-PRE-02 |
| RI continuation phase | 4 months rifampin + isoniazid | RESP-TB-01 |
| riluzole survival benefit | ~3 months ALS | NEURO-EXAM-01 |
| RIPE intensive phase | 2 months rifampin + isoniazid + pyrazinamide + ethambutol | RESP-TB-01 |
| rituximab regimen | 1 g IV ×2 doses, 2 wk apart pemphigus vulgaris first-line | SKIN-BLIST-01 |
| RLS ferritin repletion threshold | ≤75 ng/mL check before/with RLS pharmacotherapy | PSY-SLEEP-01 |
| RLS iron repletion threshold | ferritin ≤75 ng/mL or TSAT <20% | NEURO-MISC-01 |
| RLS iron threshold (AASM 2024) | oral if ferritin ≤75 ng/mL and TSAT <45%; IV (e.g., ferric carboxymaltose) if ferritin ≤100 ng/mL or TSAT <20% repletion improves symptoms | HEME-ANEM-02 |
| RLS TSAT threshold | <20% iron repletion indication | PSY-SLEEP-01 |
| Rochester low-risk WBC | 5,000–15,000/mm³ bands <1,500/mm³ (band:PMN <0.2) | MULTI-FEVER-01 |
| romosozumab duration | 12 monthly doses then transition to antiresorptive | MSK-BONE-01 |
| rotavirus first-dose cutoff | ≤14 wk 6 d series must start before this age | PEDS-WELL-01 |
| rotavirus series completion | ≤8 mo 0 d last allowable dose | PEDS-WELL-01 |
| Rotterdam criteria | 2 of 3 PCOS diagnosis | REPRO-PCOS-01 |
| routine periconceptional folate | 0.4–0.8 mg daily USPSTF 2023 | NUTR-VIT-01 |
| routine time alone with adolescent | beginning at 11–12 years AAP preventive visit | SOC-CONF-03 |
| ROX index success threshold | ≥4.88 at 2/6/12 h; failure <2.85 (2 h), <3.47 (6 h), <3.85 (12 h) | RESP-ARF-01 |
| RPGN crescent threshold | ≥50% of glomeruli histologic definition of crescentic GN | RENAL-GN-02 |
| RRSO timing | 35–40 (BRCA1); 40–45 (BRCA2) risk-reducing salpingo-oophorectomy | PREV-BRCA-01 |
| RSBI threshold | <105 predicts successful extubation; RR ÷ TV in liters | RESP-VENT-02 |
| RSV maternal vaccine timing | ≥14 d before delivery nirsevimab/clesrovimab not needed if this is met | PEDS-WELL-01 |
| RSV vaccination age | ≥50 years with chronic lung disease (COPD) | RESP-COPD-01 |
| RSV vaccine risk-based floor | ≥50 y recommended with increased-risk conditions | PEDS-GER-01 |
| RSV vaccine routine floor | ≥75 y routine recommendation, ACIP | PEDS-GER-01 |
| RSV vaccine timing in pregnancy | 32–36 weeks gestation September–January; Abrysvo only | PREV-IMM-02 |
| run chart shift | ≥6 consecutive points on one side of median nonrandom signal | SOC-QI-04 |
| run chart trend | ≥5 consecutive points increasing or decreasing nonrandom signal | SOC-QI-04 |
| rupture-risk-low-transverse | 0.5–0.9% TOLAC | OB-LD-03 |
| rupture-risk-vertical-corporal | ~4–9% (some sources 2–9%) TOLAC contraindicated | OB-LD-03 |
| SAAG portal HTN cutoff | ≥ 1.1 g/dL | GI-CIRR-01 |
| safe arm abduction limit | ≤90° brachial plexus injury prevention | PERIOP-NERVE-01 |
| safe ascent rate | ≤500 m/day sleeping altitude gain above 3000 m | RESP-OCC-01 |
| SAH BP target | SBP <160 mmHg | NEURO-HEM-01 |
| SAH CT sensitivity | ~100% at <6 h; ~86% after 6 h | NEURO-HEM-01 |
| salicylate hemodialysis threshold | pH ≤7.20 or level >90–100 mg/dL salicylate toxicity | RENAL-ABG-01 |
| saline infusion confirmatory | aldosterone remains >10 ng/dL after 2 L over 4 h | CV-HTN-02 |
| saline infusion confirmatory cutoff | > 10 ng/dL aldosterone after 2 L NS over 4 hours | ENDO-ADR-04 |
| sarcoidosis Stage I remission | 60–90% spontaneous remission of asymptomatic BHL-only disease; observe, do not treat | RESP-ILD-01 |
| SBP albumin dosing | 1.5 g/kg IV day 1, 1 g/kg day 3, with antibiotics especially creatinine >1, BUN >30, or bilirubin >4 mg/dL; reduces HRS/mortality | MULTI-MISC-01 |
| SBP diagnostic threshold | ascitic PMN ≥250 cells/mm³ or positive culture | MULTI-MISC-01 |
| SBT duration | 30–120 min low pressure support or T-piece trial | RESP-VENT-02 |
| SBT failure RR | >35/min failure criterion | RESP-VENT-02 |
| scabies retreatment interval | 1 wk repeat permethrin application | SKIN-INF-02 |
| scalp stimulation reassurance | ≥15 bpm ×15 sec acceleration implies pH >7.20 | OB-FHR-01 |
| scaphoid occult fracture rate | 15–20% initial X-ray | MSK-FRAC-01 |
| scaphoid repeat imaging | 7–14 d negative initial X-ray with high suspicion | MSK-FRAC-01 |
| SCC low-risk excision margin | 4–6 mm wide local excision | SKIN-CA-02 |
| SCC metastatic rate | 2–5% cutaneous SCC | SKIN-CA-02 |
| SCC risk transplant | 65–250x chronic immunosuppression, cutaneous squamous cell carcinoma | IMM-ISUP-01 |
| SCD minimum wear time | ≥18h/day mechanical prophylaxis effectiveness | PERIOP-VTE-01 |
| SCFE age range | 10–16 years SCFE | MSK-PEDS-02 |
| SCFE bilateral involvement | 20–40% SCFE | MSK-PEDS-02 |
| scheduled dose increase | 25–50% moderate pain; 50–100% severe pain opioid titration | SOC-EOL-05 |
| Schober test | <5 cm expansion restricted lumbar flexion | MSK-RHEUM-02 |
| SCID curative HSCT window | ideally <3.5 months best outcomes | IMM-PID-01 |
| SCID presentation age | first months of life combined T- and B-cell dysfunction | IMM-PID-01 |
| scleroderma renal crisis mortality treated | ~25% with captopril | IMM-CTD-01 |
| scleroderma renal crisis mortality untreated | ~85% without ACE inhibitor | IMM-CTD-01 |
| screening age | 35–70 y USPSTF, BMI ≥25; consider lower BMI in Asian Americans (ADA uses ≥23) | ENDO-DM-01 |
| screening start age | 21 cervical cancer screening | PREV-CERV-01 |
| screening start age men | 70 Endocrine Society/BHOF, or earlier with risk factors; USPSTF is Grade I at any age | PREV-BONE-01 |
| screening start age women | 65 universal DEXA | PREV-BONE-01 |
| screening stop age | 65 adequate prior negative screening, no CIN2+ in past 25 yr | PREV-CERV-01 |
| scurvy treatment | 300–1,000 mg vitamin C daily 1 month | NUTR-VIT-01 |
| SDH evacuation threshold | >10 mm thickness or >5 mm midline shift acute subdural hematoma | EM-TRAUMA-05 |
| second-stage-arrest-multipara | ≥2 h; individualize no descent | OB-LD-02 |
| second-stage-arrest-nullipara | ≥3 h; individualize no descent | OB-LD-02 |
| second-stage-limit-multipara | ≥2 h before diagnosing arrest; individualize if progress continues | OB-LD-01 |
| second-stage-limit-nullipara | ≥3 h before diagnosing arrest; individualize if progress continues (e.g., epidural, malposition) | OB-LD-01 |
| secondary amenorrhea duration | ≥3 mo (regular cycles) or ≥6 mo (irregular) definition | REPRO-AMEN-01 |
| Secretin stimulation positive rise | > 120 pg/mL | GI-GAST-01 |
| secretin-stimulated gastrin rise | ≥ 120 pg/mL paradoxical rise confirms gastrinoma | ENDO-ONC-01 |
| semaglutide starting dose | 0.25 mg SC weekly ×4 wk increase q≥4wk to max 2 mg weekly | ENDO-DM-02 |
| semaglutide weight loss | ~15% STEP trials | MULTI-NUTR-02 |
| semen analysis repeat interval | ≥1 month (≥2 analyses) after an abnormal result | REPRO-INFERT-01 |
| semen concentration lower limit | ≥16 million/mL WHO 2021 | REPRO-INFERT-01 |
| sentinel event analysis | ≤45 business days Joint Commission comprehensive systematic analysis and action plan | SOC-QI-01 |
| septic shock lactate | >2 mmol/L despite adequate fluid resuscitation | CV-SHOCK-01 |
| septic-arthritis-duration | 3–4 weeks non-gonococcal native joint (S. aureus), after washout | MSK-INF-01 |
| septic-synovial-WBC | >50,000/µL with PMN predominance (often >90%) — strongly suggestive, culture confirms | MSK-INF-01 |
| serum pH ceiling | ≤7.55 sodium bicarbonate infusion target | EM-TOX-04 |
| serum sickness onset | 7–21 days after first drug/biologic exposure | IMM-HYP-01 |
| severe acidosis ICU-NIV threshold | pH <7.25 warrants ICU-level NIV trial, not automatic intubation | RESP-COPD-01 |
| severe aortic stenosis mean gradient | ≥40 mmHg high-gradient severe AS criterion | PERIOP-RISK-01 |
| severe aortic stenosis peak velocity | ≥4 m/s high-gradient severe AS criterion | PERIOP-RISK-01 |
| severe AS mean gradient | ≥40 mm Hg high-gradient severe AS criterion | CV-VALV-01 |
| severe AS peak velocity | ≥4 m/s high-gradient severe AS criterion | CV-VALV-01 |
| severe CAP criteria | 1 major or ≥3 minor ATS/IDSA 2007 severity, endorsed IDSA/ATS 2019 | RESP-PNA-02 |
| severe CAP steroid | hydrocortisone 200 mg/day ICU CAP without influenza; CAPE COD 2023, SCCM 2024 | RESP-PNA-02 |
| severe feature BP | ≥160/110 mm Hg pre-eclampsia with severe features | CV-HTN-01 |
| severe hemophilia factor activity | <1% spontaneous hemarthrosis | HEME-COAG-02 |
| severe HTN threshold | ≥160/100 mmHg Category 4, combined hormonal contraceptives | REPRO-CONTRA-02 |
| severe HTN treatment window | ≤30–60 min acute severe hypertension in pregnancy | CV-PREG-01 |
| severe hypercalcemia | > 14 mg/dL symptomatic/crisis range | ENDO-CA-01 |
| severe immunosuppression steroid threshold | ≥2 mg/kg/day, or ≥20 mg/day if weight >10 kg, for ≥14 d prednisone-equivalent dose defining contraindication to live vaccines | PEDS-WELL-01 |
| severe IPSS | ≥20 medical therapy usually first; surgery for refractory symptoms, complications, or patient preference | RENAL-LUTS-01 |
| severe iron toxicity threshold | >500 µg/dL serum iron, deferoxamine indicated | HEME-MISC-01 |
| severe level | >60 mg/dL serum salicylate | EM-TOX-04 |
| severe oligospermia threshold | <5 million/mL triggers genetic/endocrine workup | REPRO-INFERT-01 |
| severe peripartum cardiomyopathy EF | <25% consider bromocriptine (off-label) plus anticoagulation | CV-CM-01 |
| severe serum iron | >500 µg/dL deferoxamine indicated | EM-TOX-07 |
| severe symptomatic bolus | 100–150 mL 3% NaCl over 10–20 min repeat up to 3x | RENAL-ELEC-02 |
| severe-feature platelets | <100,000/µL severe features | CV-PREG-01 |
| severe-feature-bp | systolic ≥160 or diastolic ≥110 mmHg two readings 4h apart; treat within 30–60 min | OB-HTN-01 |
| severe-feature-creatinine | >1.1 mg/dL or doubling severe features | OB-HTN-01 |
| severe-feature-platelets | <100,000/µL severe features | OB-HTN-01 |
| severe-feature-transaminases | >2× ULN severe features | OB-HTN-01 |
| severe-features-expectant-limit | 34 wk stable maternal/fetal status <34 wk, tertiary center | OB-HTN-01 |
| severe-range BP | ≥160/110 mmHg severe features | CV-PREG-01 |
| sexual assault evidence collection | ≤72 h ideal; 120 h+ per protocol forensic kit | SOC-LAW-01 |
| Sgarbossa concordant ST elevation | ≥1 mm LBBB/paced-rhythm STEMI | CV-ACS-01 |
| Sgarbossa discordant ST/S ratio | ≥25% modified Sgarbossa criterion (excessively discordant ST elevation) | CV-ACS-01 |
| SGLT2i hold before surgery | 3–4 d prevent euglycemic DKA | ENDO-DM-02 |
| SGLT2i hold before surgery | 3–4 d euglycemic DKA prevention | ENDO-PERI-01 |
| SH-I-followup | 5–10 days repeat exam/imaging when diagnosis is uncertain | MSK-FRAC-02 |
| shared-decision vaccination age | 27–45 y (shared decision) HPV vaccine | REPRO-CERV-01 |
| Shingrix dosing | 2 doses, 2–6 months apart adults ≥50 (1–2 months apart if immunocompromised, any age ≥19) | PREV-IMM-01 |
| shock BP (common; not required) | SBP <90 mm Hg or MAP <60 mm Hg common hypotension thresholds; shock requires tissue hypoperfusion and may be normotensive | CV-HF-02 |
| short bowel syndrome | <200 cm small bowel adults | NUTR-SUPPORT-01 |
| shoulder dystocia head-to-body interval target | ≤5 min | OB-EMER-01 |
| sick-day hydrocortisone dosing | double (>38 °C) or triple (>39 °C) oral dose sick-day rules; parenteral for surgery/trauma/vomiting | ENDO-ADR-01 |
| significant ASD shunt | Qp:Qs >1.5:1 closure indication | CV-CONG-01 |
| significant unintentional weight loss | >5% over 6–12 months triggers evaluation | NUTR-ASSESS-01 |
| significant unintentional weight loss | ≥5% over 6–12 months older adults | NUTR-GER-01 |
| simple cyst observation interval | 8–12 weeks repeat ultrasound, reproductive-age simple cyst 5–10 cm | REPRO-OVCA-01 |
| simple transfusion Hb target | ~10 g/dL ACS with Hb >1 g/dL below baseline; avoid hyperviscosity above this | HEME-SICK-02 |
| Six Sigma defect rate | <3.4 per million opportunities QI | SOC-QI-03 |
| SJS detachment | <10% BSA epidermal detachment | SKIN-DRUG-01 |
| SJS/TEN onset after drug start | 1–3 weeks causative drug exposure | SKIN-DRUG-01 |
| skeletal survey age | <2 years suspected physical abuse | SOC-LAW-01 |
| skeletal-survey-repeat-interval | 2 weeks repeat skeletal survey when the initial survey is negative but suspicion persists | MSK-FRAC-06 |
| slow gait speed | ≤0.8 m/s severe sarcopenia/frailty | NUTR-ASSESS-01 |
| SMA embolism as cause of AMI | ~50%, usually cardiac source | GI-ISCH-01 |
| smoker age contraindication | ≥35 yr combined estrogen-progestin | OB-PP-01 |
| smoking threshold | ≥15 cigarettes/day age ≥35 + ≥15/day = Cat 4; <15/day = Cat 3 | REPRO-CONTRA-02 |
| sodium in stone formers | ≤2,300 mg/day reduces urinary calcium | NUTR-MNT-02 |
| sodium target (HTN) | <1,500 mg/day reduce ≥1,000 mg/day if target not reachable | NUTR-MNT-01 |
| spironolactone onset | 3–6 months hirsutism/acne response | REPRO-PCOS-01 |
| splenectomy remission rate | ~65% chronic refractory ITP | HEME-PLT-01 |
| SPN interval CT | 6–8 mm → CT at 6–12 mo then 18–24 mo if stable | RESP-ONC-01 |
| SPN no follow-up | <6 mm low-risk patient | RESP-ONC-01 |
| SPN PET-CT threshold | >8 mm or growing CT at 3 mo, PET-CT, and/or tissue sampling by malignancy probability | RESP-ONC-01 |
| SpO2 target | 93–95% (94–98% in children) acute exacerbation | RESP-ASTHMA-01 |
| SSI fever window | POD 5–7 Wound | PERIOP-FEVER-01 |
| SSP inpatient observation threshold | <1 cm very small secondary spontaneous PTX, observe with O2 | RESP-PTX-01 |
| SSRI/SNRI discontinuation taper | ≥2–4 wk (longer for paroxetine/venlafaxine or long-term use) prevent discontinuation syndrome | PSY-MOOD-02 |
| stage 1 | 130–139/80–89 mm Hg - | CV-HTN-01 |
| stage 1 treatment threshold | PREVENT risk ≥7.5% or established CVD/diabetes/CKD | CV-HTN-01 |
| stage 2 | ≥140/90 mm Hg - | CV-HTN-01 |
| standard formula density | 20 kcal/oz term infant | NUTR-INF-01 |
| standard HbA1c target | <7% most adults | ENDO-DM-01 |
| statin initiation (diabetes) | age 40–75 yr moderate-intensity regardless of ASCVD risk; high-intensity if additional risk factors or established ASCVD | ENDO-DM-06 |
| statin start age | ≥50 non-dialysis CKD G3a–G5 | RENAL-CKD-01 |
| statin-ldl-threshold | ≥190 mg/dL automatic high-intensity statin | CV-PREV-01 |
| status epilepticus definition | ≥5 min continuous seizure or recurrent without return to baseline | NEURO-SZ-01 |
| status epilepticus definition | ≥5 min continuous seizure or recurrent without return to baseline | NEURO-SZ-02 |
| STEMI ST-elevation | ≥1 mm (V2–V3: ≥2 mm men ≥40y, ≥2.5 mm men <40y, ≥1.5 mm women) two contiguous leads, at the J point | CV-ACS-01 |
| step-down interval | ≥3 months if well controlled | RESP-ASTHMA-01 |
| step-up interval | 2–4 weeks if not controlled | RESP-ASTHMA-01 |
| steroid dose threshold | ≥20 mg prednisone/day for ≥2 weeks defines severe immunosuppression | PREV-IMM-02 |
| stone prevention urine volume | ≥2.5 L/day AUA | NUTR-MNT-02 |
| STOP-BANG risk bands | 0–2 low, 3–4 intermediate, 5–8 high general screening | RESP-OSA-01 |
| stress ulcer prophylaxis threshold | coagulopathy, shock, chronic liver disease, or ventilation >48 h stress ulcer prophylaxis | EM-CRIT-01 |
| stress-dose hydrocortisone | 50–100 mg/m² IV bolus, then 50–100 mg/m²/day q6h salt-wasting CAH adrenal crisis | PEDS-NB-03 |
| stress-dose hydrocortisone (major surgery) | 100 mg then 50 mg IV q6h (200 mg/24 h) taper over 1–3 days | ENDO-PERI-01 |
| stress-dose hydrocortisone (moderate surgery) | ~50–75 mg/day IV (e.g., 50 mg at induction, then 25 mg q8h) 1–2 days, then resume maintenance; minor surgery needs only maintenance | ENDO-PERI-01 |
| stringent HbA1c target | <6.5% young, short duration, low hypoglycemia risk | ENDO-DM-01 |
| stroke enteral feeding start | within 7 days if unable to swallow safely | NUTR-GER-01 |
| stroke transfusion delay threshold | ~2 h give simple transfusion if exchange unavailable and Hb ≤8.5 g/dL | HEME-SICK-02 |
| subacromial-impingement-painful-arc | 60-120° positive Neer/Hawkins impingement tests | MSK-JOINT-02 |
| subclinical hyperthyroidism observation range | TSH 0.1–0.4 mIU/L asymptomatic, no cardiac/bone risk factors, recheck in 3–6 months | ENDO-THY-02 |
| subclinical hyperthyroidism treatment threshold | TSH <0.1 mIU/L age ≥65 y, cardiac disease, osteoporosis, or postmenopausal without estrogen/bisphosphonate | ENDO-THY-02 |
| subclinical hypothyroidism treatment threshold | TSH ≥ 10 mIU/L or symptomatic/pregnant/anti-TPO positive; observe most adults > 70 | ENDO-THY-03 |
| subdural surgery threshold | >10 mm or midline shift >5 mm | NEURO-HEM-01 |
| submassive PE RV dysfunction | RV/LV ratio >0.9 on echo or CT | RESP-PE-01 |
| submersion observation period | 6–8h if symptomatic/resuscitated; 4–6h if asymptomatic delayed pulmonary edema/ARDS | MULTI-ENV-01 |
| subsequent BP target | 160/100 mm Hg over next 2–6 h | CV-HTN-02 |
| succinylcholine hyperkalemia risk window | avoid after ~48h post-injury burns, crush, denervation, immobilization | PERIOP-OTHER-01 |
| sudden SNHL onset window | <72 h | NEURO-ENT-02 |
| sudden SNHL steroid window | ideally ≤2 wk | NEURO-ENT-02 |
| supplemental PN trigger | EN <60% of needs after 7–10 days ICU | NUTR-SUPPORT-01 |
| surgery threshold for no improvement | 48–72 h | GI-IBD-01 |
| surgical prophylaxis duration | stop at incision closure CDC 2017; never >24 h | MULTI-ABX-01 |
| suspicious septation thickness | >3 mm adnexal mass ultrasound | REPRO-OVCA-01 |
| sweat chloride diagnostic | ≥60 mEq/L gold standard | RESP-CF-01 |
| sweat chloride diagnostic | ≥60 mEq/L cystic fibrosis confirmatory test | MULTI-GEN-02 |
| sweat chloride intermediate | 30–59 mEq/L repeat or genotype | RESP-CF-01 |
| symptomatic AS survival | 5 y angina, 3 y syncope, 2 y dyspnea without valve replacement | CV-VALV-01 |
| symptomatic CEA considered | 50–69% stenosis based on additional risk factors | CV-MISC-01 |
| symptomatic CEA threshold | 70–99% stenosis within 2 weeks of TIA/stroke | CV-MISC-01 |
| symptomatic window | 6 months defines “symptomatic” carotid stenosis | NEURO-STROKE-03 |
| synovial-WBC-noninflammatory | 200–2,000/µL non-inflammatory (e.g., osteoarthritis) | MSK-INF-01 |
| syphilis late latent/unknown duration | benzathine penicillin G 2.4 MU IM weekly ×3 CDC 2021 | REPRO-VAGIN-01 |
| syphilis primary/secondary/early latent | benzathine penicillin G 2.4 MU IM ×1 CDC 2021 | REPRO-VAGIN-01 |
| systemic alteplase dose | 100 mg IV over 2 hours massive PE | RESP-PE-01 |
| T-score osteopenia | -1.0 to -2.5 DEXA classification | MSK-BONE-01 |
| T-score osteoporosis | ≤-2.5 DEXA classification | MSK-BONE-01 |
| T2DM 2h OGTT | ≥200 mg/dL diagnosis, 75-g glucose load | ENDO-DM-01 |
| T2DM fasting glucose | ≥126 mg/dL diagnosis | ENDO-DM-01 |
| T2DM HbA1c | ≥6.5% diagnosis | ENDO-DM-01 |
| T2DM rescreen interval | q3 years if normal | PREV-CVM-01 |
| T2DM screening start age | 35 overweight or obese adults (BMI ≥23 if Asian American); USPSTF Grade B | PREV-CVM-01 |
| tachysystole definition | >5 contractions/10 min averaged over 30 min | OB-PTL-01 |
| tachysystole definition | >5 contractions/10 min averaged over 30 min | OB-FHR-01 |
| tachysystole-threshold | >5 contractions/10 min oxytocin | OB-LD-01 |
| Tagged RBC scan detection threshold | ≥ 0.1 mL/min | GI-BLEED-01 |
| Takayasu age | <40 years large-vessel vasculitis, women | IMM-VASC-01 |
| Takayasu interarm BP difference | >10 mmHg supports diagnosis | IMM-VASC-01 |
| TAM/AMKL surveillance | CBC at birth Down syndrome — transient abnormal myelopoiesis; AML-M7 risk before age 5 | MULTI-GEN-01 |
| tardive dyskinesia exposure | ≥3 months (≥1 month if age ≥60) minimum dopamine-blocker exposure for diagnosis | NEURO-MOVE-01 |
| target potassium in TdP | 4.5–5 mEq/L repletion | CV-ARR-04 |
| target serum urate | < 6 mg/dL (ACR 2020); < 5 mg/dL if tophi (EULAR) gout ULT | MSK-RHEUM-03 |
| target SpO2 | 88–92% COPD, both stable and exacerbation | RESP-COPD-01 |
| target urine output (acute hemolytic transfusion reaction) | >1 mL/kg/h acute hemolytic reaction resuscitation | HEME-TRANS-01 |
| target urine output (rhabdomyolysis) | 200–300 mL/h aggressive isotonic IV fluid resuscitation | RENAL-RHAB-01 |
| TB drug hepatotoxicity threshold | ALT >3× ULN with symptoms or >5× ULN asymptomatic stop isoniazid/rifampin/pyrazinamide | MULTI-TB-01 |
| TB meningitis therapy | 9–12 months CNS TB | RESP-TB-01 |
| TBI BP target | SBP ≥110 / MAP >80 mmHg BTF: SBP ≥100 at 50–69 y; CPP ≥60; no permissive hypotension | HEME-TRANS-02 |
| TBI perfusion target | SBP ≥100 mmHg (age 50–69) or ≥110 mmHg (age 15–49 or >70) concurrent traumatic brain injury; permissive hypotension contraindicated | EM-TRAUMA-02 |
| TCA QRS widening threshold | >100 ms IV sodium bicarbonate indicated | CV-TOX-01 |
| TCD abnormal threshold | ≥200 cm/s start chronic transfusion therapy | HEME-SICK-01 |
| TCD conditional velocity | 170–199 cm/s repeat TCD sooner | HEME-SICK-01 |
| TCD screening ages | 2–16 y annual screening | HEME-SICK-02 |
| TCD screening interval | annually, ages 2–16 stroke risk screening | HEME-SICK-01 |
| TCD stroke-risk velocity | ≥200 cm/s start chronic transfusion | HEME-SICK-02 |
| Tdap booster interval | every 10 years after one adult Tdap dose | PREV-IMM-01 |
| Tdap in pregnancy | 27–36 weeks, every pregnancy passive pertussis immunity | PREV-IMM-01 |
| Tdap in pregnancy | 27–36 weeks, every pregnancy maximizes infant antibody transfer | MULTI-VAX-01 |
| TdP QTc threshold | >500 ms high risk | CV-ARR-04 |
| temperature control | 32–37.5°C for ≥36 h adults not following commands after ROSC (any rhythm); then prevent fever while comatose (AHA 2025) | CV-ARREST-01 |
| temporal artery biopsy length | ≥1–2 cm unilateral; diagnosis | MSK-OTHER-01 |
| TEN detachment | >30% BSA epidermal detachment | SKIN-DRUG-01 |
| tenecteplase dose | 0.25 mg/kg (max 25 mg) single IV bolus, equivalent to alteplase | NEURO-STROKE-02 |
| teplizumab eligible age | ≥8 y Stage 2 T1DM | ENDO-DM-01 |
| teratogenic vitamin A dose | >10,000 IU/day pregnancy | NUTR-VIT-02 |
| teriparatide duration | typically ≤2 years longer if fracture risk remains high; boxed warning and lifetime cap removed 2020 | MSK-BONE-01 |
| testicular cancer risk after orchiopexy | 3–5× general population history of cryptorchidism | RENAL-PEDS-01 |
| therapeutic hypothermia protocol | 33.5°C × 72 h, started <6 h after birth moderate-severe HIE, ≥36 weeks | PEDS-NB-03 |
| therapeutic range | 0.6–1.2 mEq/L lithium | EM-TOX-08 |
| thionamide ANC thresholds | stop if <1,000/µL; <500/µL = agranulocytosis CBC if fever/pharyngitis; <500 → permanent stop, no switch | ENDO-THY-02 |
| third-stage-limit | <30 min retained placenta if exceeded | OB-LD-01 |
| thoracotomy threshold | >1500 mL immediate or >200 mL/h × 2–4 h hemothorax | EM-TRAUMA-04 |
| thrombectomy window | ≤24 h large-vessel occlusion with favorable imaging | NEURO-STROKE-01 |
| thrombectomy window | ≤24 h LVO with salvageable tissue | NEURO-STROKE-02 |
| Thrombosed external hemorrhoid excision window | ≤ 72 h | GI-ANOR-01 |
| thymoma prevalence in MG | 10–15% newly diagnosed MG; CT chest for all | NEURO-NM-01 |
| thyroid storm fever | ≥104°F (40°C) max Burch-Wartofsky temperature points; diagnose by total score ≥45 | ENDO-THY-02 |
| tidal volume ARDS | 6 mL/kg IBW lung-protective ventilation | RESP-VENT-01 |
| tidal volume non-ARDS | 6–8 mL/kg IBW general mechanical ventilation | RESP-VENT-01 |
| Timed Up and Go | >12 sec threshold for increased fall risk | PEDS-GER-01 |
| tinea capitis treatment duration (griseofulvin) | 6–12 wk preferred for Microsporum | SKIN-INF-02 |
| tinea capitis treatment duration (terbinafine) | 4–6 wk preferred for Trichophyton | SKIN-INF-02 |
| tinea versicolor fluconazole dose | 400 mg ×1 widespread disease | SKIN-INF-02 |
| TIPS-associated encephalopathy rate | 30–40% most common TIPS complication | GI-CIRR-02 |
| tirzepatide weight loss | up to 20–22% obesity dosing | ENDO-DM-02 |
| tirzepatide weight loss | up to 20–22% SURMOUNT trials | MULTI-NUTR-02 |
| TLS onset | 12–72 h after chemotherapy initiation in high-burden malignancy | HEME-MALIG-02 |
| tocolysis window | 24 0/7–33 6/7 wk no tocolysis ≥34 wk or with contraindications | OB-PTL-01 |
| TOF definitive repair age | 3–6 months surgical repair | CV-CONG-01 |
| tolac-success-rate | ~60–80% overall, >85% with prior vaginal delivery | OB-LD-03 |
| tolvaptan duration limit | ≤30 days limits hepatotoxicity risk | RENAL-ELEC-02 |
| tolvaptan monitoring | LFTs at baseline, 2wk, 4wk, then monthly to 18mo, then q3mo tolvaptan | RENAL-CYST-01 |
| torsades Mg dose | 2 g IV push over 1–2 min if pulseless; over 5–15 min if a pulse is present magnesium treats torsades regardless of serum Mg level | RENAL-ELEC-03 |
| torsion Doppler false-negative rate | up to 60% normal flow does not exclude torsion | REPRO-OVCYST-01 |
| torsion salvage 12h | ~50% testicular torsion | RENAL-SCROT-01 |
| torsion salvage <6h | >90% testicular torsion | RENAL-SCROT-01 |
| torsion salvage >24h | <10% testicular torsion | RENAL-SCROT-01 |
| total immunosuppression duration | ≥3–5 years lupus nephritis, induction plus maintenance | IMM-SLE-01 |
| total pulmonary TB therapy | 6 months standard regimen | RESP-TB-01 |
| toxic elemental iron dose | 20–60 mg/kg GI toxicity; >60 mg/kg systemic toxicity acute iron ingestion | EM-TOX-07 |
| toxic level | >30 mg/dL serum salicylate | EM-TOX-04 |
| toxic megacolon dilation | >6 cm transverse colon | GI-IBD-01 |
| toxic serum iron | >350 µg/dL 4–6 h post-ingestion | EM-TOX-07 |
| toxoplasmosis prophylaxis threshold | CD4 <100 TMP-SMX; requires positive Toxo IgG | MULTI-HIV-01 |
| tPA window | ≤4.5 h IV alteplase/tenecteplase from last known well | NEURO-STROKE-01 |
| tPA window | ≤4.5 h from last known well | NEURO-STROKE-02 |
| tracheostomy timing | day 7–14 repeated failed SBTs or ventilation anticipated beyond 2 weeks | RESP-VENT-02 |
| TRALI onset | within 6 h of transfusion definition | RESP-ARDS-01 |
| TRALI onset | within 6 h of transfusion TRALI | HEME-TRANS-01 |
| transferrin saturation IDA | <20% iron deficiency | HEME-ANEM-02 |
| transferrin saturation screening threshold | >45% hemochromatosis screening | GI-LIV-01 |
| transfusion goal | Hgb 7 g/dL restrictive threshold 7 g/dL; target 7–9 g/dL; avoid >9–10 | GI-BLEED-02 |
| Transplant evaluation referral MELD 3.0 | ≥ 15 (or any decompensation) | GI-CIRR-01 |
| trastuzumab cardiac monitoring interval | q3 months LVEF surveillance during therapy | REPRO-BRCA-01 |
| treatment line | ≥150 mcg/mL at 4 h Rumack-Matthew nomogram | EM-TOX-03 |
| treatment-resistant MDD threshold | ≥2 failed adequate trials definition | PSY-MOOD-01 |
| trichomoniasis regimen | metronidazole 500mg BID ×7d (women); 2g ×1 (men) 2021 CDC update from single-dose regimen in women | MULTI-GU-01 |
| triglyceride pancreatitis threshold | ≥1,000 mg/dL fat <10–15% of calories; 500–999 → fat 20–25%, no alcohol/added sugar, treat secondary causes, consider fibrate | NUTR-MNT-01 |
| Trikafta eligibility | ≥1 ΔF508 allele (~90% of patients) current age threshold ≥2 y | RESP-CF-01 |
| triple-negative share of breast cancer | ~15% receptor subtype | REPRO-BRCA-01 |
| TSH suppression target | <0.1 mIU/L high-risk differentiated thyroid cancer | ENDO-THY-01 |
| TST positive cutoffs | ≥5/≥10/≥15 mm induration thresholds | MULTI-TB-01 |
| TST positive threshold, high-risk | ≥5 mm HIV, close contact, fibrotic CXR changes, immunosuppressed | RESP-TB-01 |
| TST positive threshold, low-risk | ≥15 mm no TB risk factors | RESP-TB-01 |
| TST positive threshold, moderate-risk | ≥10 mm high-burden immigrants <5y, IVDU, congregate settings, lab workers, DM/CKD/silicosis, children <4y | RESP-TB-01 |
| TTP relapse marker | persistently low ADAMTS13 activity in remission predicts relapse; supports preemptive rituximab to prevent recurrence | HEME-MAHA-01 |
| tuberculous pleuritis ADA | >40 U/L pleural fluid adenosine deaminase supporting TB pleuritis | RESP-PLEFF-01 |
| TXA dosing, postpartum hemorrhage | 1 g IV over 10 min, repeat 1 g if bleeding persists after 30 min within 3 h of birth (WOMAN) | HEME-TRANS-02 |
| TXA dosing, trauma | 1 g IV over 10 min then 1 g IV over 8 h within 3 h of injury (CRASH-2) | HEME-TRANS-02 |
| TXA timing | within 3 h of injury class III/IV hemorrhage | CV-SHOCK-01 |
| TXA window | ≤3 h (benefit greatest <1 h); do not start after 3 h from time of injury | EM-TRAUMA-02 |
| txa-dose-window | 1 g IV over 10 min within 3 h of birth; repeat 1 g once if bleeding continues after 30 min or recurs within 24h | OB-PPH-01 |
| type 1 RTA urine pH | >5.5 distal RTA | RENAL-ABG-01 |
| type 4 RTA urine pH | <5.5 hyperkalemic RTA | RENAL-ABG-01 |
| typical acute pain opioid course | individualized; no fixed day cutoff (CDC 2022) match quantity to expected pain duration, often a few days | PSY-SUD-03 |
| UFH IV therapeutic hold before neuraxial block | 4–6h with normal aPTT ASRA guideline | PERIOP-COAG-01 |
| UFH prophylactic dose | 5000 units SQ q8–12h moderate-risk surgery alternative to LMWH, or CrCl <30 mL/min | PERIOP-VTE-01 |
| UFH resume after catheter removal | ≥1h ASRA guideline | PERIOP-COAG-01 |
| UFH SQ higher-dose hold before neuraxial block | ≥12–24h ASRA guideline | PERIOP-COAG-01 |
| UFH SQ prophylactic hold before neuraxial block | ≥4–6h ASRA guideline | PERIOP-COAG-01 |
| UGIB transfusion threshold | Hgb < 7 g/dL restrictive strategy; < 8 g/dL for cardiovascular disease/ACS | GI-BLEED-01 |
| ulipristal EC window | ≤120 h (5 days) oral emergency contraception | REPRO-CONTRA-01 |
| ulipristal EC window | ≤120 h (5 days) emergency contraception | REPRO-CONTRA-02 |
| ulipristal emergency contraception | ≤120 h after unprotected intercourse | SOC-LAW-01 |
| ULT indication threshold | ≥2 flares/year gout | MSK-RHEUM-03 |
| umbilical hernia spontaneous closure age | 4–5 years most pediatric umbilical hernias | GI-HERN-01 |
| uncomplicated CAP duration | 5 days clinical improvement | MULTI-ABX-01 |
| uncomplicated cellulitis course | 5 days extend if not improving | SKIN-INF-01 |
| uncomplicated cystitis duration | 5 days nitrofurantoin or 3 days TMP-SMX non-pregnant women | MULTI-GU-01 |
| uncomplicated S. aureus bacteremia | 2 weeks IV cultures clear ≤72h, IE excluded, no prosthetic material, no metastatic infection | MULTI-ABX-01 |
| undescended testis correction | orchiopexy by 18 mo if undescended at 6 mo cryptorchidism | PEDS-RENAL-01 |
| Unresectable arterial contact | >180° SMA/celiac contact | GI-PANC-02 |
| urine alkalinization target | pH 7.5–8.0 sodium bicarbonate infusion | EM-TOX-04 |
| urine chloride (metabolic alkalosis) | <20 mEq/L saline-responsive; >20 mEq/L saline-resistant metabolic alkalosis workup | RENAL-ABG-01 |
| urine Cl⁻, chloride-resistant | >20 mEq/L metabolic alkalosis | RESP-ABG-01 |
| urine Cl⁻, chloride-responsive | <20 mEq/L metabolic alkalosis | RESP-ABG-01 |
| UTI fever window | POD 3–5 Water | PERIOP-FEVER-01 |
| uveitis screening interval | every 3 months ANA-positive, onset <7 years, disease duration ≤4 years | MSK-PEDS-01 |
| vacuum-abandonment | 3 pop-offs or 15–20 min application limit | OB-LD-03 |
| vacuum-gestational-floor | ≥34 wk contraindicated before | OB-LD-03 |
| vaginal progesterone cutoff | ≤20 mm 16–24 wk, no prior preterm birth | OB-PTL-01 |
| valproate dose (SE) | 40 mg/kg status epilepticus second-line | NEURO-SZ-01 |
| valproic acid dose (SE) | 40 mg/kg IV established status epilepticus | NEURO-SZ-02 |
| vancomycin AUC target | 400–600 mg·h/L AUC/MIC-guided dosing, serious infections | RENAL-AKI-02 |
| vancomycin or fluoroquinolone prophylaxis timing | ≤120 min before incision surgical site infection | SOC-QI-08 |
| Vanderbilt impairment threshold | ≥1 performance item rated 4–5 functional impairment criterion | PSY-PEDS-01 |
| Vanderbilt symptom threshold | ≥6 items rated 2–3 inattention or hyperactivity subscale | PSY-PEDS-01 |
| VAP treatment duration | 7 days standard course | RESP-PNA-02 |
| varicella dosing | 2 doses, 4–8 weeks apart adults without immunity | PREV-IMM-02 |
| vasa-previa-cesarean-timing | 34–37 wk planned cesarean | OB-HEM-01 |
| vasopressin dose | fixed 0.03 units/min (up to 0.04) not titrated; add when norepinephrine 0.25–0.5 mcg/kg/min | CV-SHOCK-01 |
| vasopressor threshold for steroids | ongoing pressors (e.g., NE ≥0.25 mcg/kg/min ≥4 h) septic shock, empiric IV hydrocortisone | EM-CRIT-01 |
| very-high-risk threshold | T-score ≤-3.0 (or recent/multiple fragility fracture) anabolic agent first-line before an antiresorptive | PREV-BONE-01 |
| veteran suicide rate relative risk | ~1.5× versus general population | PSY-ANX-02 |
| Villous adenoma malignant risk | up to 40% if > 4 cm | GI-COLON-01 |
| vitamin D deficiency | 25(OH)D <20 ng/mL NAM/IOM | NUTR-VIT-02 |
| vitamin D intake | 800–1000 IU/day osteoporosis or on therapy | PREV-BONE-01 |
| vitamin D repletion | 50,000 IU weekly x 8 weeks then 1 | NUTR-VIT-02 |
| vitamin D supplementation | 400 IU/day all breastfed/partially breastfed infants, starting within days of birth | PEDS-WELL-01 |
| vitamin D toxicity | 25(OH)D >150 ng/mL with hypercalcemia | NUTR-VIT-02 |
| vosoritide age floor | any age (open epiphyses) FDA approval expanded from ≥5 y (2021) to all ages with open epiphyses (Oct 2023) | PEDS-GROW-01 |
| VTE fever window | POD 4–6 Walking | PERIOP-FEVER-01 |
| vWD type 1 share | 70–80% of von Willebrand disease | HEME-COAG-02 |
| vWD type 3 vWF level | virtually absent requires vWF concentrate | HEME-COAG-02 |
| waist circumference risk | >40 in (102 cm) men; >35 in (88 cm) women when BMI 25–34.9 | NUTR-OBES-01 |
| warfarin emergency reversal | 4-factor PCC plus IV vitamin K 10 mg surgery cannot wait | PERIOP-COAG-01 |
| warfarin hold before elective surgery | 5 days check INR before surgery | PERIOP-COAG-01 |
| warfarin hold before neuraxial block | until INR normalized ~5 days after stopping; remove catheter at INR <1.5 | PERIOP-COAG-01 |
| warfarin hold before surgery | 5 days check INR the day before surgery | PERIOP-MED-01 |
| warfarin hold before surgery | 5 days target INR <1.5 | CV-VTE-01 |
| warfarin-mechanical-valve-dose | ≤5 mg/day may continue through 1st trimester, mechanical valve | OB-MED-01 |
| warm-and-wet prevalence | ~70% most common ADHF profile | CV-HF-02 |
| weight loss target | 5–10% improves ovulation and insulin resistance | REPRO-PCOS-01 |
| Wells PE likely (two-tier) | >4 proceed to CTPA; three-tier (low <2, moderate 2–6, high >6) is a separate scheme | RESP-PE-01 |
| Wells threshold for direct CT-PA | >4 PE | CV-VTE-01 |
| Wernicke full triad prevalence | ~10–16% proportion presenting with all three features | NEURO-TOX-01 |
| Wernicke thiamine dose | 200–500 mg IV three times daily treatment | NUTR-VIT-01 |
| Wilson disease ceruloplasmin threshold | <20 mg/dL screening | GI-LIV-01 |
| Wilson disease urine copper threshold | >100 mcg/day 24-hour collection; confirmatory alongside low ceruloplasmin | GI-LIV-01 |
| Winters formula | PaCO2 = 1.5×HCO3 + 8 ± 2 metabolic acidosis compensation | RENAL-ABG-01 |
| Winter’s formula | PaCO2 = 1.5×HCO3 + 8 ± 2 metabolic acidosis compensation | RESP-ABG-01 |
| zoster vaccination age | ≥50 years COPD patients | RESP-COPD-01 |
| zoster vaccine age | ≥50 (immunocompetent) or ≥19 (immunocompromised) Shingrix, 2 doses | MULTI-VAX-01 |
| β-hCG in complete mole | >100,000 mIU/mL often | OB-GTD-01 |